

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

2/4

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/41, 31/44, 31/53, 31/445, 31/495, C07D 207/04, 211/32, 213/44, 213/46, 241/04, 251/04, 471/04, 491/048		A1	(11) International Publication Number: WO 98/00134 (43) International Publication Date: 8 January 1998 (08.01.98)
(21) International Application Number: PCT/US97/11133 (22) International Filing Date: 25 June 1997 (25.06.97) (30) Priority Data: 60/020,975 28 June 1996 (28.06.96) US 9700893.2 17 January 1997 (17.01.97) GB (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DUGGAN, Mark, E. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). EGBERTSON, Melissa, S. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). HARTMAN, George, D. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). YOUNG, Steven, D. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). IHLE, Nathan, C. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.
(54) Title: FIBRINOGEN RECEPTOR ANTAGONISTS			
(57) Abstract <p>Fibrinogen receptor antagonists having the structure X-Y-Z-A-B and pharmaceutically acceptable salts, wherein X is a 5, 6 or 7 membered aromatic or nonaromatic ring, and Y is a 5 or 6 membered aromatic ring, e.g., formula (I).</p>			
<div style="text-align: center;"></div> <div style="text-align: right;">(I)</div>			
<div style="border: 1px solid black; padding: 5px; width: fit-content; margin: auto;"><p>FP05-0115- 00EP-XX 07.7.30 SEARCH REPORT</p></div>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

TITLE OF THE INVENTION
FIBRINOGEN RECEPTOR ANTAGONISTS

BACKGROUND OF THE INVENTION

5 The invention relates generally to modulating cell adhesion and to inhibiting the binding of fibrinogen and other proteins to blood platelets, and inhibiting the aggregation of blood platelets specifically to the gp IIb/IIIa fibrinogen receptor site. Fibrinogen is a glycoprotein present in blood plasma that participates in platelet aggregation and in
10 fibrin formation. Platelets are cell-like anucleated fragments, found in the blood of all mammals, that also participate in blood coagulation. Interaction of fibrinogen with the IIb/IIIa receptor site is known to be essential for normal platelet function.

 When a blood vessel is damaged by an injury or other
15 causative factor, platelets adhere to the disrupted subendothelial surface. The adherent platelets subsequently release biologically active constituents and aggregate. Aggregation is initiated by the binding of agonists, such as thrombin, epinephrine, or ADP to specific platelet membrane receptors. Stimulation by agonists results in exposure of
20 latent fibrinogen receptors on the platelet surface, and binding of fibrinogen to the glycoprotein IIb/IIIa receptor complex.

 Attempts have been made to use natural products and synthetic peptides to determine the mechanism of adhesion and platelet aggregation. For example, Rouslahti and Pierschbacher in *Science*, 238,
25 491-497 (1987), describe adhesive proteins such as fibronectin, vitronectin, osteopontin, collagens, thrombospondin, fibrinogen, and von Willebrand factor that are present in extracellular matrices and in blood. The proteins contain the tripeptide arginine-glycine-aspartic acid (RGD) as their glycoprotein IIb/IIIa recognition site. These arginine-glycine-aspartic acid containing tripeptides are recognized by at least
30 one member of a family of structurally related receptors, integrins, which are heterodimeric proteins with two membrane-spanning subunits. The authors state that the conformation of the tripeptide

- 2 -

sequence in the individual proteins may be critical to recognition specificity.

Cheresh-in *Proc. Nat'l Acad. Sci. U.S.A.*, 84, 6471-6475, (1987), describes an Arg-Gly-Asp directed adhesion receptor expressed
5 by human endothelial cells that is structurally similar to the IIb/IIIa complex on platelets but is antigenically and functionally distinct. This receptor is directly involved in endothelial cell attachment to fibrinogen, von Willebrand factor, and vitronectin.

Pierschbacher and Rouslahti, in *J. of Biol. Chem.*, 262,
10 (36), 17294-17298 (1987) hypothesized that the Arg-Gly-Asp sequence alone would be a sufficient signal for receptor recognition and binding and that, therefore, the conformation of the tri-peptide sequence would be determinative. Various synthetic peptides were produced and the authors concluded that the stereochemical conformation of Arg-Gly-Asp
15 as influenced by enantiomeric substitutions or additions to this sequence significantly influenced receptor-ligand interaction. The authors further showed that cyclization of a decapeptide by forming a disulfide bridge between non-terminal residues Pen and Cys, rendered the peptide much less effective at inhibiting attachment to fibronectin.

20 In *Proc. Nat'l Acad. Sci. U.S.A.*, 81, 5985-5988 (1984), the same authors describe tetrapeptide variants of the cell recognition site of fibronectin that retain attachment-promoting activity. Peptides having a tetrapeptide recognition site are described in U.S. Pat. Nos. 4,589,881 and 4,614,517. A number of large polypeptide fragments in the cell-
25 binding domain of fibronectin have cell-attachment activity. For example, see U.S. Pat. Nos. 4,517,686, 4,661,111 and U.S. Pat. No. 4,578,079.

Ruggeri *et al.*, *Proc. Nat'l Acad. Sci. U.S.A.*, 83, 5708-5712 (1986) explore a series of synthetic peptides designed in lengths to
30 16 residues, that contain RGD and a valine attached to the aspartic acid residue of RGD that inhibit fibrinogen binding to platelets. See also Koczewiak *et al.*, *Biochem.* 23, 1767-1774 (1984); Ginsberg *et al.*,

- 3 -

J. Biol. Chem. 260(7), 3931-3936 (1985); and Haverstick *et al.*, *Blood* 66(4), 946-952 (1985). Other inhibitors are disclosed in Eur. Pat. App. Nos. 275,748 and 298,820.

A number of low molecular weight polypeptide factors
5 have been isolated from snake venom. These factors apparently have high affinity for the gp IIb/IIIa complex. For example, Huang *et al.*, *J. Biol Chem.*, 262, 16157-16163 (1987); Huang *et al.*, *Biochemistry*, 28, 661-666 (1989) describe the primary structure of the venom trigramin which is a 72 amino acid polypeptide that contains the RGD subunit.
10 Echistatin is another compound which has high affinity for the gp IIb/IIIa complex. This polypeptide contains 49 amino acids and has the RGD subunit and various disulfide bridges. Gan *et al.*, *J. Biol. Chem.*, 263, 19827-19832 (1988). See also, Dennis *et al.*, *Proc. Nat'l Acad. Sci. USA*, 87, 2471-2475 (1989). However, these snake venom factors also
15 have high affinity for other members of the adhesive protein receptor family including the vitronectin and fibronectin receptors so are not selective for the gp IIb/IIIa complex.

While it is known that the tripeptide sequence Arg-Gly-Asp is present in certain polypeptides that can duplicate or inhibit the cell
20 attachment-promoting effects of fibronectin and vitronectin, the tripeptide Arg-Gly-Asp has low activity. At present, there is little understanding of how other amino acids coupled to this sequence influence binding specificity. U.S. Pat. No 5,023,233 discloses small cyclic hexapeptides which contain the sequence Arg-Gly-Asp and are
25 useful platelet aggregation inhibitors. U.S. Pat. No. 5,037,808 discloses the use of indolyl platelet-aggregation inhibitors which are believed to act by antagonizing interactions between fibrinogen and/or extracellular matrix proteins and the platelet gp IIb/IIIa receptor. U.S. Pat. No. 5,037,808 discloses guanidino peptide mimetic compounds that retain an
30 Asp residue which inhibit platelet aggregation. WO9014103 describes the use of antibody-polypeptide conjugates wherein said polypeptides contain the Arg-Gly-Asp (RGD) sequence.

WO9111458 discloses the use of large cyclic peptides containing RGD flanked by proline residues which are platelet


- 4 -

aggregation inhibitors. WO9101331 discloses small cyclic platelet aggregation inhibitors which are synthetic cyclic pentapeptides containing the tripeptide sequence Arg-Gly-Asp and a thioether linkage in the cycle. U.S. Patent No. 5,051,405 also discloses the use of peptides and pseudopeptides such as N-amidino-piperidine-3-carboxylglycyl-L-aspartyl-L-valine that inhibit platelet aggregation and thrombus formation in mammalian blood. EP 445 796 discloses linear compounds which can include internal piperazinyl or piperidinyl derivatives. EP437 367 discloses linear polypeptide fibrinogen receptor antagonists. U.S. Patent No. 5,256,812 discloses compounds of the formula $R^1-A-(W)_a-X-(CH_2)_b-(Y)_c-B-Z-COOR$ wherein R^1 is a guandidino or amidino moiety and A and B are chosen from specific monosubstituted aryl or heterocyclic moieties.

While a multitude of compounds or peptide analogs believed to inhibit platelet aggregation by inhibiting binding to a blood platelet by fibrinogen are known, the present invention provides novel fibrinogen receptor antagonists that have significant binding activity and are, therefore, useful for the reasons stated herein. A number of very serious diseases and disorders involve hyperthrombotic complications which lead to intravascular thrombi and emboli. Myocardial infarction, stroke, phlebitis and a number of other serious conditions create the need for novel and effective fibrinogen receptor antagonists.

SUMMARY OF THE INVENTION

The invention includes compounds of the formula



and pharmaceutically acceptable salts,

wherein

- 5 -

X is

- 5 a 5, 6 or 7 membered aromatic or nonaromatic ring, having 1, 2 or 3 heteroatoms selected from N, O, and S, and either unsubstituted or monosubstituted on the carbon and nitrogen atoms with R^1 , or disubstituted on the carbon and nitrogen atoms with R^1 and R^2 , where R^1 and R^2 are independently selected from the group consisting of
- 10 hydrogen,
halogen,
C₁-10 alkyl,
C₃-8 cycloalkyl,
aryl,
aryl C₁-8 alkyl,
amino,
15 amino C₁-8 alkyl,
C₁-3 acylamino,
C₁-3 acylamino C₁-8 alkyl,
C₁-6 alkylamino C₁-8 alkyl,
C₁-6 alkylamino,
20 C₁-6 dialkylamino C₁-8 alkyl,
C₁-6 alkoxy,
C₁-6 alkoxy C₁-6 alkyl,
aryl C₁-6 alkyloxy,
aryl C₁-6 alkyloxy C₁-6 alkyl,
25 carboxy,
carboxy C₁-6 alkyl,
C₁-3 alkoxycarbonyl,
C₁-3 alkoxycarbonyl C₁-6 alkyl,
carboxy C₁-6 alkyloxy,
30 hydroxy, and
hydroxy C₁-6 alkyl, or

a 9 or 10 membered fused aromatic or nonaromatic ring, having 1, 2 or 3 heteroatoms selected from N, O, and S, and either

- 6 -

unsubstituted or monosubstituted on the carbon and nitrogen atoms with R^1 , or disubstituted on the carbon and nitrogen atoms with R^1 and R^2 , where R^1 and R^2 are independently selected from the group consisting of

- 5 hydrogen,
- halogen,
- C₁-10 alkyl,
- C₃-8 cycloalkyl,
- aryl,
- 10 aryl C₁-8 alkyl,
- amino,
- amino C₁-8 alkyl,
- C₁-3 acylamino,
- C₁-3 acylamino C₁-8 alkyl,
- 15 C₁-6 alkylamino C₁-8 alkyl,
- C₁-6 alkylamino,
- C₁-6 dialkylamino C₁-8 alkyl,
- C₁-6 alkoxy,
- C₁-6 alkoxy C₁-6 alkyl,
- 20 aryl C₁-6 alkyloxy,
- aryl C₁-6 alkyloxy C₁-6 alkyl,
- carboxy,
- carboxy C₁-6 alkyl,
- C₁-3 alkoxycarbonyl,
- 25 C₁-3 alkoxycarbonyl C₁-6 alkyl,
- carboxy C₁-6 alkyloxy,
- hydroxy, and
- hydroxy C₁-6 alkyl;

30 Y is


a 5 or 6 membered aromatic or nonaromatic ring, having 0, 1, 2 or 3 heteroatoms selected from N, O, and S, and either unsubstituted or substituted on carbon and nitrogen atoms with R^3 selected from the group consisting of

- 7 -


hydrogen,
 halogen,
 C₁-10 alkyl,
 C₃-8 cycloalkyl,
 5 aryl,
 aryl C₁-8 alkyl,
 amino,
 amino C₁-8 alkyl,
 C₁-3 acylamino,
 10 C₁-3 acylamino C₁-8 alkyl,
 C₁-6 alkylamino,
 C₁-6 alkylamino C₁-8 alkyl,
 C₁-6 dialkylamino,
 C₁-6 dialkylamino C₁-8 alkyl,
 15 C₁-6 alkoxy,
 C₁-6 alkoxy C₁-6 alkyl,
 aryl C₁-6 alkyloxy,
 aryl C₁-6 alkyloxy C₁-6 alkyl,
 carboxy,
 20 carboxy C₁-6 alkyl,
 C₁-3 alkoxycarbonyl,
 C₁-3 alkoxycarbonyl C₁-6 alkyl,
 carboxy C₁-6 alkyloxy,
 hydroxy, and
 25 hydroxy C₁-6 alkyl;

or


X and Y combined together form the structures



- 8 -



Z is



- 9 -

Z represents a bond;

R⁴ is

5 hydrogen,
 C₁-4 alkyl, or
 C₃-6 cycloalkyl;

A is

10 a 5 or 6 membered aromatic ring, having 0, 1, 2 or 3 heteroatoms
 selected from N, O, and S, and either unsubstituted or
 monosubstituted on carbon and nitrogen atoms with R⁵,
 disubstituted on carbon and nitrogen atoms with R⁵ and R⁶, or
 trisubstituted on carbon and nitrogen atoms with R⁵, R⁶ and R⁷,
 where R⁵, R⁶ and R⁷ are each independently selected from the
 group consisting of

15 hydrogen,
 halogen,
 C₁-10 alkyl,
 C₃-8 cycloalkyl,
 aryl,
20 aryl C₁-8 alkyl,
 arylsulfonylamino,
 amino,
 amino C₁-8 alkyl,
 nitro,
25 C₁-3 acylamino,
 C₁-3 acylamino C₁-8 alkyl,
 C₁-6 alkylamino,
 C₁-3 alkylsulfonylamino,
 C₁-6 alkylamino C₁-8 alkyl,
30 C₁-6 dialkylamino,
 C₁-6 dialkylamino C₁-8 alkyl,
 C₁-6 alkoxy,
 C₁-6 alkoxy C₁-6 alkyl,
 trihaloalkyl,

- 10 -

aryl C₁-6 alkyloxy,
aryl C₁-6 alkyloxy C₁-6 alkyl,
carboxy,
carboxy C₁-6 alkyl,
5 C₁-3 alkoxy carbonyl,
C₁-3 alkoxy carbonyl C₁-6 alkyl,
carboxy C₁-6 alkyloxy,
hydroxy, and
hydroxy C₁-6 alkyl, or

10

A is

a 9 or 10 membered fused aromatic ring, having 0, 1, 2 or 3
heteroatoms selected from N, O, and S, and either unsubstituted
or monosubstituted on carbon and nitrogen atoms with R⁵,
15 disubstituted on carbon and nitrogen atoms with R⁵ and R⁶, or
trisubstituted on carbon and nitrogen atoms with R⁵, R⁶ and R⁷,
where R⁵, R⁶ and R⁷ are each independently selected from the
group consisting of


hydrogen,
20 halogen,
C₁-10 alkyl,
C₃-8 cycloalkyl,
aryl,
aryl C₁-8 alkyl,
25 amino,
amino C₁-8 alkyl,
C₁-3 acylamino,
C₁-3 acylamino C₁-8 alkyl,
C₁-6 alkylamino,
30 C₁-6 alkylamino C₁-8 alkyl,
C₁-6 dialkylamino,
C₁-6 dialkylamino C₁-8 alkyl,
C₁-6 alkoxy,
C₁-6 alkoxy C₁-6 alkyl,

- 11 -

5 aryl C₁-6 alkyloxy,
 aryl C₁-6 alkyloxy C₁-6 alkyl,
 carboxy,
 carboxy C₁-6 alkyl,
 C₁-3 alkoxy carbonyl,
 C₁-3 alkoxy carbonyl C₁-6 alkyl,
 carboxy C₁-6 alkyloxy,
 hydroxy, and
 hydroxy C₁-6 alkyl;

10

B is



wherein

15 m is 1, 2, or 3,
 n is 0, 1, 2, or 3, and
 p is 0, 1, 2, or 3;

20 R⁸ is selected from the group consisting of
 hydrogen,
 C₁-10 alkyl,
 C₃-8 cycloalkyl,
 aryl,
 aryl C₁-8 alkyl,
 amino,
 25 amino C₁-8 alkyl,
 C₁-3 acylamino,
 C₁-3 acylamino C₁-8 alkyl,
 C₁-6 alkylamino,

- 12 -

- 5 C1-6 alkylamino C1-8 alkyl,
C1-6 dialkylamino,
C1-6 dialkylamino C1-8 alkyl,
C1-6 alkoxy,
C1-6 alkoxy C1-6 alkyl,
aryl C1-6 alkyloxy,
aryl C1-6 alkyloxy C1-6 alkyl,
carboxy,
carboxy C1-6 alkyl,
10 C1-3 alkoxycarbonyl,
C1-3 alkoxycarbonyl C1-6 alkyl,
carboxy C1-6 alkyloxy,
hydroxy,
hydroxy C1-6 alkyl; and
15 R⁹ is
hydrogen,
C1-8 alkyl,
aryl,
20 aryl C1-6 alkyl,
C1-8 alkylcarbonyloxy C1-6 alkyl
aryl carbonyloxy C1-6 alkyl,
aryl C1-6 alkylcarbonyloxy C1-6 alkyl,
C1-8 alkylaminocarbonyl C1-6 alkyl, or
25 C1-8 dialkylamino carbonyl C1-6 alkyl.

The invention also includes the use of a compound of the invention, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting the aggregation of blood
30 platelets, preventing platelet thrombosis, preventing thromboembolism or preventing reocclusion, in a mammal.

- 13 -

DETAILED DESCRIPTION OF THE INVENTION

The invention includes compounds of the formula

X-Y-Z-A-B

5 and pharmaceutically acceptable salts,

wherein

X is

- 10 a 5, 6 or 7 membered aromatic or nonaromatic ring, having 1, 2
or 3 heteroatoms selected from N, O, and S, and either
unsubstituted or monosubstituted on the carbon and nitrogen
atoms with R¹, or disubstituted on the carbon and nitrogen atoms
with R¹ and R², where R¹ and R² are independently selected
from the group consisting of
- 15 hydrogen,
halogen,
C₁-10 alkyl,
C₃-8 cycloalkyl,
aryl,
- 20 aryl C₁-8 alkyl,
amino,
amino C₁-8 alkyl,
C₁-3 acylamino,
C₁-3 acylamino C₁-8 alkyl,
- 25 C₁-6 alkylamino C₁-8 alkyl,
C₁-6 alkylamino,
C₁-6 dialkylamino C₁-8 alkyl,
C₁-6 alkoxy,
C₁-6 alkoxy C₁-6 alkyl,
- 30 aryl C₁-6 alkyloxy,
aryl C₁-6 alkyloxy C₁-6 alkyl,
carboxy,
carboxy C₁-6 alkyl,
C₁-3 alkoxycarbonyl,

- 14 -

C₁-3 alkoxycarbonyl C₁-6 alkyl,
carboxy C₁-6 alkyloxy,
hydroxy, and
hydroxy C₁-6 alkyl, or

5

a 9 or 10 membered fused aromatic or nonaromatic ring, having
1, 2 or 3 heteroatoms selected from N, O, and S, and either
unsubstituted or monosubstituted on the carbon and nitrogen
atoms with R¹, or disubstituted on the carbon and nitrogen atoms
with R¹ and R², where R¹ and R² are independently selected
from the group consisting of

10

hydrogen,
halogen,
C₁-10 alkyl,
C₃-8 cycloalkyl,
aryl,
aryl C₁-8 alkyl,
amino,
amino C₁-8 alkyl,

15

20

C₁-3 acylamino,
C₁-3 acylamino C₁-8 alkyl,
C₁-6 alkylamino C₁-8 alkyl,
C₁-6 alkylamino,
C₁-6 dialkylamino C₁-8 alkyl,

25

C₁-6 alkoxy,
C₁-6 alkoxy C₁-6 alkyl,
aryl C₁-6 alkyloxy,
aryl C₁-6 alkyloxy C₁-6 alkyl,
carboxy,

30

carboxy C₁-6 alkyl,
C₁-3 alkoxycarbonyl,
C₁-3 alkoxycarbonyl C₁-6 alkyl,
carboxy C₁-6 alkyloxy,
hydroxy, and

- 15 -


hydroxy C₁₋₆ alkyl;

Y is





- 5 a 5 or 6 membered aromatic ring or non-aromatic ring, having 0, 1, 2 or 3 heteroatoms selected from N, O, and S, and either unsubstituted or substituted on the carbons and nitrogens with R³ selected from the group consisting of
- 10 hydrogen,
halogen,
C₁₋₁₀ alkyl,
C₃₋₈ cycloalkyl,
aryl,
aryl C₁₋₈ alkyl,
amino,
15 amino C₁₋₈ alkyl,
C₁₋₃ acylamino,
C₁₋₃ acylamino C₁₋₈ alkyl,
C₁₋₆ alkylamino,
C₁₋₆ alkylamino C₁₋₈ alkyl,
20 C₁₋₆ dialkylamino,
C₁₋₆ dialkylamino C₁₋₈ alkyl,
C₁₋₆ alkoxy,
C₁₋₆ alkoxy C₁₋₆ alkyl,
aryl C₁₋₆ alkyloxy,
25 aryl C₁₋₆ alkyloxy C₁₋₆ alkyl,
carboxy,
carboxy C₁₋₆ alkyl,
C₁₋₃ alkoxycarbonyl,
C₁₋₃ alkoxycarbonyl C₁₋₆ alkyl,
30 carboxy C₁₋₆ alkyloxy,
hydroxy, and
hydroxy C₁₋₆ alkyl;

- 16 -





X and Y combined together form the structures



5 Z is



- 17 -



Z represents a bond;

5 R^4 is

hydrogen,
C₁₋₄ alkyl, or
C₃₋₆ cycloalkyl;

A is

10 a 5 or 6 membered aromatic ring, having 0, 1, 2 or 3 heteroatoms selected from N, O, and S, and either unsubstituted or monosubstituted on the carbons or nitrogen with R^5 , disubstituted with R^5 and R^6 , or trisubstituted with R^5 , R^6 and R^7 , where R^5 , R^6 and R^7 are independently selected from the group consisting of

15 hydrogen,
halogen,
C₁₋₁₀ alkyl,
C₃₋₈ cycloalkyl,
20 aryl,

- 18 -

- 5 aryl C₁-8 alkyl,
arylsulfonylamino,
amino,
amino C₁-8 alkyl,
nitro,
C₁-3 acylamino,
C₁-3 acylamino C₁-8 alkyl,
C₁-6 alkylamino,
C₁-3 alkylsulfonylamino,
10 C₁-6 alkylamino C₁-8 alkyl,
C₁-6 dialkylamino,
C₁-6 dialkylamino C₁-8 alkyl,
C₁-6 alkoxy,
C₁-6 alkoxy C₁-6 alkyl,
15 trihaloalkyl,
aryl C₁-6 alkyloxy,
aryl C₁-6 alkyloxy C₁-6 alkyl,
carboxy,
carboxy C₁-6 alkyl,
20 C₁-3 alkoxycarbonyl,
C₁-3 alkoxycarbonyl C₁-6 alkyl,
carboxy C₁-6 alkyloxy,
hydroxy, and
hydroxy C₁-6 alkyl, or
25
- 30 a 9 or 10 membered fused aromatic ring, having 0, 1, 2 or 3 heteroatoms selected from N, O, and S, and either unsubstituted or monosubstituted on the carbons or nitrogen with R⁵, disubstituted with R⁵ and R⁶, or trisubstituted with R⁵, R⁶ and R⁷, where R⁵, R⁶ and R⁷ are independently selected from the group consisting of
hydrogen,
halogen,
C₁-10 alkyl,

- 19 -

C3-8 cycloalkyl,
 aryl,
 aryl C1-8 alkyl,
 amino,
 5 amino C1-8 alkyl,
 C1-3 acylamino,
 C1-3 acylamino C1-8 alkyl,
 C1-6 alkylamino,
 C1-6 alkylamino C1-8 alkyl,
 10 C1-6 dialkylamino,
 C1-6 dialkylamino C1-8 alkyl,
 C1-6 alkoxy,
 C1-6 alkoxy C1-6 alkyl,
 aryl C1-6 alkyloxy,
 15 aryl C1-6 alkyloxy C1-6 alkyl,
 carboxy,
 carboxy C1-6 alkyl,
 C1-3 alkoxycarbonyl,
 C1-3 alkoxycarbonyl C1-6 alkyl,
 20 carboxy C1-6 alkyloxy,
 hydroxy, and
 hydroxy C1-6 alkyl;

B is

$-\text{O}(\text{CH}_2)_m\text{CO}_2\text{R}^9,$
 $-(\text{CH}_2)_n\text{CO}_2\text{R}^9,$ or
 $-\underset{\text{R}^8}{\text{CH}}(\text{CH}_2)_p\text{CO}_2\text{R}^9,$
 25 $-\text{OCH}(\text{R}^8)(\text{CH}_2)_p\text{CO}_2\text{R}^9$

wherein

m is 1, 2, or 3,

n is 0, 1, 2, or 3, and

- 20 -

p is 0, 1, 2, or 3;

R⁸ is selected from the group consisting of

5 hydrogen,
 C₁-10 alkyl,
 C₃-8 cycloalkyl,
 aryl,
 aryl C₁-8 alkyl,
 amino,
10 amino C₁-8 alkyl,
 C₁-3 acylamino,
 C₁-3 acylamino C₁-8 alkyl,
 C₁-6 alkylamino,
 C₁-6 alkylamino C₁-8 alkyl,
15 C₁-6 dialkylamino,
 C₁-6 dialkylamino C₁-8 alkyl,
 C₁-6 alkoxy,
 C₁-6 alkoxy C₁-6 alkyl,
 aryl C₁-6 alkyloxy,
20 aryl C₁-6 alkyloxy C₁-6 alkyl,
 carboxy,
 carboxy C₁-6 alkyl,
 C₁-3 alkoxycarbonyl,
 C₁-3 alkoxycarbonyl C₁-6 alkyl,
25 carboxy C₁-6 alkyloxy,
 hydroxy,
 hydroxy C₁-6 alkyl; and

R⁹ is

30 hydrogen,
 C₁-8 alkyl,
 aryl,
 aryl C₁-6 alkyl,
 C₁-8 alkylcarbonyloxy C₁-6 alkyl

- 21 -

aryl carbonyloxy C₁-6 alkyl,
 aryl C₁-6 alkylcarbonyloxy C₁-6 alkyl,
 C₁-8 alkylaminocarbonyl C₁-6 alkyl, or
 C₁-8 dialkylamino carbonyl C₁-6 alkyl.

5

In one class, the compounds have the structure





X-Y-Z-A-B

10 and pharmaceutically acceptable salts,

wherein

15 X is a 5, 6 or 7 membered aromatic or nonaromatic ring
 having 1, 2 or 3 nitrogen atoms and unsubstituted or
 substituted with NH₂;

20 Y is a 5 or 6 membered aromatic or nonaromatic ring having 0,
 1, 2 or 3 nitrogen atoms and unsubstituted or substituted
 with C₁-3alkyl;
 or X and Y together form the fused ring systems:




or

;

- 22 -

Z is



Z represents a bond;

- 5 A is a 5 or 6 membered aromatic ring, having 0, 1, 2, or 3
 nitrogen atoms and unsubstituted or monosubstituted on
 the carbons or nitrogen with R^5 , disubstituted with R^5 and
 R^6 , same or different, or trisubstituted with R^5 , R^6 and
 R^7 , same or different, wherein R^5 , R^6 and R^7 are selected
 10 from the group consisting of
 arylsulfonylamino,
 C_{1-3} alkylsulfonylamino,
 C_{1-3} alkyl,
 $-\text{CF}_3$,
 15 C_{1-3} alkyloxy,
 halogen,
 nitro,
- or
- 20 A is a 9 membered fused aromatic ring system having 0, 1, 2 or
 3 nitrogen atoms,
- or
- A is isoindolinone or indolinone;
- 25 B is $-\text{OCH}(\text{R}^8)(\text{CH}_2)_p\text{CO}_2\text{R}^9$,
 $(\text{CH}_2)_n\text{CO}_2\text{R}^9$,

- 23 -

$n = 0, 1, 2, 3,$

$p = 0, 1, 2, 3,$

wherein

R^8 is hydrogen or C_{1-3} alkyl and

5 R^9 is hydrogen or $-(CH_2)_{1-3}C(O)NH(CH_2)_{0-2}CH_3$
or $-(CH_2)_{1-3}C(O)N((CH_2)_{0-2}CH_3)_2$.

In a subclass of the class, the compounds have the structure

10 $X-Y-Z-A-B$





and pharmaceutically acceptable salts,

wherein

15

X is a 5 or 6 membered aromatic or nonaromatic ring having 1 or 2 nitrogen atoms and unsubstituted or substituted with NH_2 ;


20 Y is a 6 membered aromatic or nonaromatic ring having 0 or 1 nitrogen atoms and unsubstituted or substituted with CH_3 ;
or X and Y form the fused ring systems:



25

- 24 -

Z is




Z represents a bond;


- 5 A is phenyl unsubstituted, monosubstituted with R⁵,
disubstituted with R⁵ and R⁶, or trisubstituted with R⁵, R⁶,
or R⁷, where R⁵, R⁶, or R⁷ are selected from



10



15



or

20

A is a 9 membered fused aromatic ring system having 1
nitrogen atom,

or

A is isoindolinone or indolinone;

25

B is $-\text{OCH}(\text{R}^8)\text{CO}_2\text{R}^9,$


- 25 -

wherein $n = 1$ or 2 R^8 is hydrogen or C_{1-3} alkyl and R^9 is hydrogen, $-(\text{CH}_2)_{1-3}\text{C}(\text{O})\text{NH}(\text{CH}_2)_{0-2}\text{CH}_3$, or $-(\text{CH}_2)_{1-3}\text{C}(\text{O})\text{N}((\text{CH}_2)_{0-2}\text{CH}_3)_2$.

5

In a group of the subclass, the compounds have the structure

10




and pharmaceutically acceptable salts,


wherein

15

X is






Y is





20

- 26 -

or X and Y form the fused ring systems:




5 Z is



Z represents a bond;

- 27 -

A is



and

5

B is

10

-OCH₂CO₂H,
 -OCH₂CO₂CH₂C(O)NHCH₃,
 -OCH₂CO₂CH₂C(O)N(CH₂CH₃)₂,
 -OCH₂CO₂CH₂CH₃,
 -CH₂CH₂CO₂H,

- 28 -

-CH₂COOH,
-OCH(CH₃)CO₂H, or
-OCH(CH₃)CO₂CH₂CH₃.

5 Exemplary compounds of the group include

3-(4-(4-piperazin-1-ylphenylcarbonylamino)phenyl)
propanoic acid,

10 2-(4-(4-Piperazinyl-1-yl)phenylcarbonylamino)phenoxy)
acetic acid,

Ethyl 2-(4-(4-(1-piperazinyl)phenylcarbonylamino)phenoxy)acetate,
hydrochloride,

15 2-(5-(4-(1-Piperazinyl)phenylcarbonylamino)indol-1-yl)
acetic acid,

20 3-(3-(4-Piperazin-1-ylphenyl)carbonylamino)phenyl)
propanoic acid,

Ethyl 2-(4-(4-(piperazin-1-yl)phenylcarbonylamino)
phenoxy)propanoate

25 2-(4-(4-(Piperazin-1-yl)phenylcarbonylamino)phenoxy)
propionic acid,

2-(4-(((2-Piperazin-1-yl)pyridin-5-yl)carbonylamino)phenoxy)acetic
acid,

30 3-Methyl-4-((1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol-7-
yl)carbonylamino)phenoxyacetic acid,

- 29 -

2-(4-(5-(4-(1,1-Dimethylethoxycarbonyl)-piperazin-1-yl)-2-thienylcarbonylamino)-3-methylphenoxy)-acetic acid,

4-(2-(1,1-dimethylethoxycarbonyl)-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]benzofuran-7-yl)carbonylamino)-3-methylphenoxy acetic acid,

4-((2,3,4,5-tetrahydropyrazino-[1,2-a]indole-8-yl)carbonylamino)-3-methylphenoxyacetic acid, and

(+ /-) 4-((3-(1,1-Dimethylethoxycarbonyl)-1,1a,2,3,4,5-hexahydropyrazino-[1,2-a]indole-8-yl)carbonylamino)-3-methylphenoxyacetic acid.

One test which is used to evaluate fibrinogen receptor antagonist activity is based on evaluation of inhibition of ADP-stimulated platelets. Aggregation requires that fibrinogen bind to and occupy the platelet fibrinogen receptor site. Inhibitors of fibrinogen binding inhibit aggregation. In the ADP-stimulated platelet aggregation assay used to determine inhibition associated with the compounds claimed in the instant invention, human platelets are isolated from fresh blood, collected into acid citrate/dextrose by differential centrifugation followed by gel filtration on Sepharose 2B in divalent ion-free Tyrode's buffer (pH 7.4) containing 2% bovine serum albumin.

Platelet aggregation is measured at 37°C in a Chronolog aggregometer. The reaction mixture contains gel-filtered human platelets (2×10^8 per ml), fibrinogen (100 micrograms per ml (ug/ml)), Ca^{2+} (1 mM), and the compound to be tested. The aggregation is initiated by adding 10 mM ADP 1 minute after the other components are added. The reaction is then allowed to proceed for at least 2 minutes. The extent of inhibition of aggregation is expressed as the percentage of the rate of aggregation observed in the absence of inhibitor. The IC_{50} is the dose of a particular compound inhibiting aggregation by 50% relative to a control lacking the compound.

- 30 -

The following compounds were tested and found to have IC₅₀ values in the range between 10 nM and 50 mM:

- 5 3-(4-(4-piperazin-1-ylphenylcarbonylamino)phenyl)
propanoic acid,
- 2-(4-(4-Piperazinyl-1-yl)phenylcarbonylamino)phenoxy)
acetic acid,
- 10 Ethyl 2-(4-(4-(1-piperazinyl)phenylcarbonylamino)phenoxy)acetate,
hydrochloride,
- 2-(5-(4-(1-Piperazinyl)phenylcarbonylamino)indol-1-yl)
acetic acid,
- 15 3-(3-(4-Piperazin-1-ylphenyl)carbonylamino)phenyl)
propanoic acid,
- Ethyl 2-(4-(4-(piperazin-1-yl)phenylcarbonylamino)
20 phenoxy)propanoate
- 2-(4-(4-(Piperazin-1-yl)phenylcarbonylamino)phenoxy)
propionic acid,
- 25 2-(4-(((2-Piperazin-1-yl)pyridin-5-yl)carbonylamino)phenoxy)acetic
acid,
- 3-Methyl-4-((1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol-7-
yl)carbonylamino)phenoxyacetic acid,
- 30 2-(4-(5-(4-(1,1-Dimethylethoxycarbonyl)-piperazin-1-yl)-2-
thienylcarbonylamino)-3-methylphenoxy)-acetic acid

- 31 -

4-(2-(1,1-dimethylethoxycarbonyl)-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]benzofuran-7-yl)carbonylamino)-3-methylphenoxy acetic acid,

5 4-((2,3,4,5-tetrahydropyrazino-[1,2-a]indole-8-yl)carbonylamino)-3-methylphenoxyacetic acid, and

(+ /-) 4-((3-(1,1-Dimethylethoxycarbonyl)-1,1a,2,3,4,5-hexahydropyrazino-[1,2-a]indole-8-yl)carbonylamino)-3-methylphenoxyacetic acid.

10

Additionally, these compounds are useful for treating mammals suffering from a bone condition caused or mediated by increased bone resorption, who are in need of such therapy.

15 Pharmacologically effective amounts of the compounds, including pharmaceutically acceptable salts thereof, are administered to the mammal, to inhibit the activity of mammalian osteoclasts.

20 Additionally, these compounds are useful for treating angiogenesis (formation of new blood vessels). It has been postulated that the growth of tumors depends on an adequate blood supply, which in turn is dependent on the growth of new vessels into the tumor. Inhibition of angiogenesis can cause tumor regression in animal models. (See, Harrison's Principles of Internal Medicine, 12th ed., 1991). These compounds are therefore useful in the treatment of cancer by inhibiting tumor growth. (See e.g., Brooks et al., *Cell*, 79:1157-1164 (1994)).

25 The term "pharmaceutically acceptable salts" shall mean non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid. Representative salts include the following salts:

30 acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynapthoate, iodide, isothionate, lactate, lactobionate, laurate,

- 32 -

malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, oleate, oxalate, pamaote, palmitate, panthothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, tannate, tartrate, teoclate,
5 tosylate, triethiodide, valerate.

Compounds of the present invention may be chiral; included within the scope of the present invention are racemic mixtures and separated enantiomers of the general formula. Furthermore, all diastereomers, including E, Z isomers, of the general formula are
10 included in the present scope. Furthermore, hydrates as well as anhydrous compositions and polymorphs of the general formula are within the present invention.

Prodrugs, such as ester derivatives of described compounds, are compound derivatives which, when absorbed into the
15 bloodstream of a warm-blooded animal, cleave in such a manner as to release the drug form and permit the drug to afford improved therapeutic efficacy.

The term "pharmaceutically effective amount" shall mean that amount of a drug or pharmaceutical agent that will elicit the
20 biological or medical response of a tissue, system or animal that is being sought by a researcher or clinician. The term "anti-coagulant" shall include heparin, and warfarin. The term "thrombolytic agent" shall include agents such as streptokinase and tissue plasminogen activator. The term "platelet anti-aggregation agent" shall include agents such as
25 aspirin and dipyridamole.

The term "alkyl" means straight or branched alkane containing 1 to about 10 carbon atoms, e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl radicals and the like; the term alkenyl means straight or
30 branched alkene containing 2 to about 10 carbon atoms, e.g., propylenyl, buten-1-yl, isobutenyl, pentenylen-1-yl, 2,2-methylbuten-1-yl, 3-methylbuten-1-yl, hexen-1-yl, hepten-1-yl, and octen-1-yl radicals and the like; alkynyl means straight or branched alkyne containing 2 to about 10 carbon atoms, e.g., ethynyl, propynyl, butyn-1-yl, butyn-2-yl,

- 33 -

pentyn-1-yl, pentyn-2-yl, 3-methylbutyn-1-yl, hexyn-1-yl, hexyn-2-yl, hexyn-3-yl, 3,3-dimethylbutyn-1-yl radicals and the like.


The term "aryl" means a 5- or 6-membered aromatic ring containing 0, 1, or 2 heteroatoms selected from O, N, and S, e.g. phenyl, pyridine, pyrimidine, imidazole, thiophene, oxazole, isoxazole, thiazole, and amino- and halogen- substituted derivatives thereof.

The terms "alkyloxy" or "alkoxy" include an alkyl portion where alkyl is as defined above, e.g., methyloxy, propyloxy, and butyloxy.

The terms "arylalkyl" and "alkylaryl" include an alkyl portion where alkyl is as defined above and to include an aryl portion where aryl is as defined above. The C_{0-n} or C_{1-n} designation where n may be an integer from 1-10 or 2-10 respectively refers to the alkyl component of the arylalkyl or alkylaryl unit. Examples of arylalkyl include benzyl, fluorobenzyl, chlorobenzyl, phenylethyl, phenylpropyl, fluorophenylethyl, chlorophenylethyl, thienylmethyl, thienylethyl, and thienylpropyl. Examples of alkylaryl include toluene, ethylbenzene, propylbenzene, methylpyridine, ethylpyridine, propylpyridine, butylpyridine, butenylpyridine, and pentenylpyridine.

The term "halogen" includes fluorine, chlorine, iodine and bromine.

The term "oxy" means an oxygen (O) atom. The term "thio" means a sulfur (S) atom. Under standard nomenclature used throughout this disclosure, the terminal portion of the designated side chain is described first followed by the adjacent functionality toward the point of attachment. For example, a C₁₋₆ alkyl substituted with C₁₋₅ alkyl-carbonylamino is equivalent to



In the schemes and examples below, various reagent symbols have the following meanings:

- 34 -

	BOC	
	(or Boc):	t-butyloxycarbonyl
	Pd-C:	palladium on activated carbon catalyst
	DMF:	dimethylformamide
5	DMSO:	dimethylsulfoxide
	CBZ:	carbobenzyloxy
	CH ₂ Cl ₂ :	methylene chloride
	CHCl ₃ :	chloroform
	EtOH:	ethanol
10	MeOH:	methanol
	EtOAc:	ethyl acetate
	HOAc:	acetic acid
	BOP:	benzotriazol-1-yloxytris(dimethylamino)phosphonium, hexafluorophosphate
15	EDC:	1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
	Oxone:	potassium peroxymonosulfate
	LDA:	lithium diisopropylamide
	PYCLU:	Chloro-N,N,N',N'-bis(pentamethylene)formamidinium hexafluorophosphate
20	NMM:	N-methylmorpholine

The compounds of the present invention can be administered in such oral forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. Likewise, they may be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed as an anti-aggregation agent.

Compounds of the invention may be administered to patients where prevention of thrombosis by inhibiting binding of fibrinogen to the platelet membrane glycoprotein complex IIb/IIIa receptor is desired. They are useful in surgery on peripheral arteries

- 35 -

(arterial grafts, carotid endarterectomy) and in cardiovascular surgery where manipulation of arteries and organs, and/or the interaction of platelets with artificial surfaces, leads to platelet aggregation and consumption. The aggregated platelets may form thrombi and thromboemboli. Compounds of this invention may be administered to these surgical patients to prevent the formation of thrombi and thromboemboli.

Extracorporeal circulation is routinely used for cardiovascular surgery in order to oxygenate blood. Platelets adhere to surfaces of the extracorporeal circuit. Adhesion is dependent on the interaction between gp IIb/IIIa on the platelet membranes and fibrinogen adsorbed to the surface of the circuit. (Gluszko *et al.*, *Amer. J. Physiol.*, 252(H), 615-621 (1987)). Platelets released from artificial surfaces show impaired hemostatic function. Compounds of the invention may be administered to prevent adhesion.

Other applications of these compounds include prevention of platelet thrombosis, thromboembolism and reocclusion during and after thrombolytic therapy and prevention of platelet thrombosis, thromboembolism and reocclusion after angioplasty or coronary artery bypass procedures. They may also be used to prevent myocardial infarction.

The dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.

Oral dosages of the present invention, when used for the indicated effects, will range between about 0.01 mg per kg of body weight per day (mg/kg/day) to about 100 mg/kg/day and preferably

- 36 -

0.01-100 mg/kg/day and most preferably 0.01-20 mg/kg/day. For example, a typical 90 kg patient would receive oral dosages ranging between about 0.9 mg/day and about 9 g/day, most preferably between about 0.9 mg/day and 1.8 g/day. Suitable pharmaceutical oral

5 compositions such as tablets or capsules may contain between 10-500 mg of active drug, for example, 10 mg, 100 mg, 200 mg and 500 mg. Intravenously, the most preferred doses will range from about 1 to about 10 mg/kg/minute during a constant rate infusion.

Advantageously, compounds of the present invention may
10 be administered in divided doses of two, three, or four times daily. Furthermore, preferred compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be
15 administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regime.


In the methods of the present invention, the compounds herein described in detail can form the active ingredient, and are
20 typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier" materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with convention pharmaceutical practices.

25 For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for
30 oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable


- 37 -

binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn-sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms
5 include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch methyl cellulose, agar, bentonite, xanthan gum and the like.


- 38 -

SCHEME 1

- 39 -

SCHEME 1, CONTINUED


- 40 -



Methyl 4-(1-piperazinyl)benzoate (1-3)

5 A solution of amine 1-1 (20.0 g, 132 mmol), amine 1-2 (23.6 g, 132 mmol) and n-butanol (500 ml) was refluxed for 168 h. The solution was allowed to cool to ambient temperature. The crystals were collected, washed with Et₂O and dried *in vacuo* to give ester 1-3 as a white solid.

10 ¹H NMR (CD₃OD): δ 7.86 (d, J=9Hz, 2H), 7.98 (d, J=9Hz, 2H), 3.78 (s, 3H), 3.53 (m, 4H), 3.31 (m, 4H).




Methyl 4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)benzoate (1-4)

15 To a stirred solution of amine 1-3 (15.0 g, 61.1 mmol), NEt₃ (7.42 g, 73.4 mmol) and DMF (150 ml) was added Boc₂O (14.7 g, 67.2 mmol). After 1.0 h, the solution was diluted with EtOAc and then washed with H₂O, 10% KHSO₄, brine, dried (MgSO₄) and concentrated to furnish ester 1-4 as a yellow solid.

20 TLC R_f = 0.63 (silica, 40% EtOAc/hexanes)

¹H NMR (CD₃OD): δ 7.91 (d, J=9Hz, 2H), 7.01 (d, J=9Hz, 2H), 3.88 (s, 3H), 3.59 (m, 4H), 3.38 (m, 4H).

- 41 -




4-(4-(1,1-Dimethylethoxycarbonyl)piperazin-1-yl)benzoic acid (1-5)

5 A solution of ester 1-4 (21.1 g, 61.1 mmol) 1 N NaOH (100 ml, 100 mmol) and EtOH (200 ml) was heated to 60°C for 2.0 h. The solution was acidified with 10% KHSO₄ and then extracted with EtOAc. The EtOAc phase was washed with brine, dried (MgSO₄) and concentrated to furnish acid 1-5 as a white solid.

¹H NMR (CD₃OD): δ 7.81 (d, J=9Hz, 2H), 6.88 (d, J=9Hz, 2H), 3.49 (m, 4H), 3.24 (m, 4H), 1.40 (s, 9H).

10



N-(4-bromophenyl)-4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)benzamide (1-7)


15 A solution of acid 1-5 (400 mg, 1.31 mmol), amine 1-6 (248 mg, 1.44 mmol), BOP reagent (867 mg, 1.97 mmol), NMM (575 μl, 5.24 mmol) and DMF was heated at 60°C for 72 h. The solution was diluted with EtOAc and then washed with H₂O, sat. NaHCO₃, 10% KHSO₄ brine, dried (MgSO₄) and concentrated. Flash chromatography

20 (silica, 20% EtOAc/hexanes) furnished amide 1-7 as a yellow solid. TLC R_f = 0.36 (silica, 20% EtOAc/hexanes)

¹H NMR (CDCl₃): δ 7.78 (d, J=9Hz, 2H), 7.70 (s, 1H), 7.54 (d, J=9Hz, 2H), 7.46 (d, J=9Hz, 2H), 6.92 (d, J=9Hz, 2H), 3.58 (m, 4H), 3.30 (m, 4H), 1.49 (s, 9H).


25

- 42 -



(E)-Methyl 3-(4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenyl)carbonylamino)phenyl)prop-3-enoate (1-8)

- 5 A solution of amide 1-7 (300 mg, 0.6519 mmol), methyl acrylate (587 μ l, 6.52 mmol), O(tolyl)₃P (120 mg, 0.311 mmol), NEt₃ (184 μ l, 1.30 mmol), Pd (OAc)₂ (15 mg, 0.0512 mmol) and CH₃CN (5 ml) was heated to 100°C in a sealed tube for 18 h. The solution was diluted with EtOAc and then washed with H₂O, sat. NaHCO₃, 10% KHSO₄, brine, dried (MgSO₄) and concentrated. Flash chromatography (silica, 25% → 40% EtOAc/hexanes) furnished olefin 1-8 as a yellow solid.
- 10 TLC R_f = 0.36 (silica, 50% EtOAc/hexanes)
- ¹H NMR (CDCl₃): δ 7.87 (s, 1H), 7.81 (d, J=9Hz, 2H), 7.68 (m, 3H), 7.53 (d, J=9Hz, 2H), 6.94 (d, J=9Hz, 2H), 6.39 (d, J=16Hz, 1H), 3.81 (s, 3H), 3.61 (m, 4H), 3.30 (m, 4H), 1.50 (s, 9H).
- 15




- 20 Methyl 3-(4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenyl)carbonylamino)phenyl)propanoate (1-9)

- A mixture of ester 1-8 (260 mg, 0.56 mmol), 10% Pd/C (100 mg) and EtOH (10 ml) was stirred under 1 atm H₂ for 18 h. The reaction mixture was filtered through a celite pad and concentrated to furnish ester 1-9 as a brown solid.
- 25 ¹H NMR (CDCl₃): δ 7.79 (d, J=9Hz, 2H), 7.67 (s, 1H), 7.54 (d, J=8Hz, 2H), 7.19 (d, J=8Hz, 2H), 6.92 (d, J=9Hz, 2H), 3.67 (s, 3H), 3.60 (m,

- 43 -

4H), 3.29 (m, 4H), 2.94 (t, J=8Hz, 2H), 2.63 (t, J=8Hz, 2H), 1.49 (s, 9H).




5 3-(4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenyl)carbamoyl)phenylpropanoic acid (1-10)

A solution of ester 1-9 (250 mg, 0.53 mmol), 1 N NaOH (1 ml, 1.00 mmol) and EtOH (3 ml) was stirred at ambient temperature for 1.5 h. The solution was acidified with 10% KHSO₄ and then extracted with EtOAc. The EtOAc phase was washed with brine, dried (MgSO₄) and concentrated to furnish acid 1-10 as a tan solid.

TLC R_f = 0.11 (silica, 10:0.2:0.2 CH₂Cl₂/MeOH/AcOH)

¹H NMR (CD₃OD): δ 7.86 (d, J=9Hz, 2H), 7.55 (d, J=8Hz, 2H), 7.20 (d, J=9Hz, 2H), 7.08 (d, J=8Hz, 2H), 3.60 (bs, 4H) 3.45 (m, 4H), 2.89 (t, J=8Hz, 2H), 2.59 (t, J=8Hz, 2H), 1.48 (s, 9H).



20 3-(4-(4-piperazin-1-yl)phenyl)carbamoyl)phenylpropanoic acid (1-11)


To a solution of acid 1-10 (215 mg, 0.4743 mmol), TFA (3.0 ml) and CH₂Cl₂ (3.0 ml) was stirred at ambient temperature for 1.5 h. The solution was concentrated and then azeotroped with toluene. The residue was triturated with 10:0.2:0.2 EtOH/NH₄OH/H₂O, filtered, washed with Et₂O and dried *in vacuo* to furnish acid 1-11 as a tan solid.

- 44 -


TLC R_f = 0.55 (silica, 10:1:1 EtOH/NH₄OH/H₂O)

¹H NMR (D₂O): δ 7.83 (d, J=9Hz, 2H), 7.42 (d, J=8Hz, 2H), 7.31 (d, J=8Hz, 2H), 7.16 (d, J=9Hz, 2H), 3.25 (m, 4H), 2.96 (m, 4H), 2.89 (t, J=8Hz, 2H), 2.49 (t, J=8Hz, 2H).

- 45 -


SCHEME 2

- 46 -



N-(4-Hydroxyphenyl)-4-(4-(1,1-dimethylethoxycarbonyl)piperazinyl-1-yl)benzamide (2-3)

- 5 A solution of carboxylic acid 2-1 (400 mg, 1.31 mmole), 4-aminophenyl 2-2 (210 mg, 1.44 mmol), BOP reagent (867 mg, 1.97 mmole), NMM (575 μ l, 5.24 mmol) and DMF (10 ml) was heated to 60°C for 72 h. The reaction mixture was diluted with EtOAc and then washed with H₂O, sat NaHCO₃, 10% KHSO₄, dried (MgSO₄) and then
- 10 concentrated. Flash chromatography (silica, 50% EtOAc/hexanes) furnished the amide 2-3 as a white solid.
- TLC R_f = 0.25 (silica, 50% EtOAc/hexanes)
- ¹H NMR (CD₃OD): δ 7.82 (d, J=9Hz, 2H), 7.40 (d, J=9Hz, 2H), 7.0 (d, J=9Hz, 2H), 6.75 (d, J=9Hz, 2H), 3.57 (bs, 4H), 3.30 (bs, 4S), 1.47 (s,
- 15 9H).



- 20 tert-Butyl 2-(4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazinyl-1-yl)phenyl)carbonylamino)phenoxy)acetate (2-5)

To a stirred solution of amide 2-3 (400 mg, 1.01 mmol) and DMF (5 ml) was added cesium carbonate (820 mg, 2.53 mmole) followed by t-butyl bromoacetate (195 μ l, 1.21 mmol). After 20 h, the reaction mixture was diluted with EtOAc and then washed with H₂O,


25 10% KHSO₄, brine, dried (MgSO₄) and concentrated. Flash chromatography (silica, 25% EtOAc/hexanes) furnished ester 2-5 as a white solid.

- 47 -

TLC R_f = 0.40 (silica, 50% EtOAc/hexanes)

¹H NMR (CDCl₃): δ 7.79 (d, J=9Hz, 2H), 7.63 (s, 1H), 7.54 (d, J=9Hz, 2H), 6.92 (m, 4H), 4.51 (s, 2H), 3.60 (m, 4H), 3.30 (m, 4H), 1.50 (s, 18H).

5



2-(4-(4-Piperazinyl-1-yl)phenylcarbonylamino)phenoxy)
acetic acid (2-6)


10 A solution of ester 2-5 (275 mg, 0.5378 mmol), TFA (5 ml) and CH₂Cl₂ (5 ml) was stirred at ambient temperature for 2.0 h. The solution was concentrated and then azeotroped with toluene. The residue was triturated with 10:0.5:0.5 EtOH/NH₄OH/H₂O, filtered, washed with EtOH and then washed with EtOH to furnish acid 2-6 as a
15 white solid.

TLC R_f = 0.34 (silica, 10:0.5:0.5 EtOH/NH₄OH/H₂O)


¹H NMR (CD₃OD): δ 7.83 (d, J=9Hz, 2H), 7.50 (d, J=9Hz, 2H), 7.00 (d, J=9Hz, 2H), 6.92 (d, J=9Hz, 2H), 4.36 (s, 2H), 3.30 (m, 4H), 2.96 (m, 4H).

20

- 48 -

SCHEME 3

- 49 -



tert-Butyl 2-(4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenylcarbonyl(N-methyl)amino)phenoxy)acetate (3-1)


5 To a stirred solution of ester 2-5 (200 mg, 0.3911 mmol) was added cesium carbonate (318 mg, 0.9778 mmole) followed by CH₃I (29 μ l, 0.47 mmol). After heating at 60° for 2.0 h, the reaction mixture was diluted with EtOAc and then washed with H₂O, 10% KHSO₄, brine, dried (MgSO₄) and concentrated. Flash chromatography (silica, 40%

10 EtOAc/hexanes) furnished ester 3-1 as a yellow solid.

TLC R_f = 0.45 (silica, 50% EtOAc/hexanes)

¹H NMR (CDCl₃): δ 7.21 (d, J=9Hz, 2H), 6.97 (d, J=9Hz, 2H), 6.75 (d, J=9Hz, 2H), 6.63 (d, J=9Hz, 2H), 4.45 (s, 2H), 3.52 (bt, 4H), 3.43 (s, 3H), 3.13 (bt, 4H), 1.47 (s, 18H).

15



2-(4-(4-(1-Piperazinyl)phenylcarbonyl(N-methyl)amino)phenoxy)-acetic acid (3-2)


20 A solution of ester 3-1 (190 mg, 0.3617 mmole), TFA (3 ml) and CH₂Cl₂ (3 ml) was stirred at ambient temperature for 30 minutes. The solution was concentrated and then azeotroped with toluene. Flash chromatography (silica, 10:0.2:0.2 EtOH/NH₄OH/H₂O) furnished acid 3-2 as a white solid.

25 TLC R_f = 0.42 (silica, 10:0.2:0.2 EtOH/NH₄OH/H₂O)

- 50 -

^1H NMR (CD_3OD): δ 7.25 (d, $J=9\text{Hz}$, 2H), 7.06 (d, $J=9\text{Hz}$, 2H), 6.91 (d, $J=9\text{Hz}$, 2H), 6.82 (d, $J=9\text{Hz}$, 2H), 4.66 (s, 2H), 3.50 (m, 4H), 3.41 (s, 3H), 3.35 (m, 4H).

5


SCHEME 4

10 Ethyl 2-(4-(4-(1-piperazinyl)phenylcarbamoylphenoxy)acetate hydrochloride (4-1)


To a stirred solution of acid 2-6 (40 mg, 0.1125 mmol) and EtOH (2 ml) at 0°C was bubbled HCl gas for 3 minutes. After 24 h at ambient temperature, the solution was concentrated to give ethyl ester 4-1 as a white solid.

15 ^1H NMR (D_2O): δ 7.87 (d, $J=9\text{Hz}$, 2H), 7.44 (d, $J=9\text{Hz}$, 2H), 7.19 (d, $J=9\text{Hz}$, 2H), 7.05 (d, $J=9\text{Hz}$, 2H), 4.80 (s, 2H), 4.31 (q, $J=7\text{Hz}$, 2H) 3.62 (m, 4H), 3.43 (m, 4H), 1.30 (t, $J=7\text{Hz}$, 3H).

- 51 -


SCHEME 5

- 52 -



N-(5-Indolyl)-4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)benzamide (5-2)

- 5 To a stirred solution of acid 2-1 (500 mg, 1.63 mmol), NMM (715 μ l, 6.52 mmol) and DMF (5 ml) was added BOP reagent (1.08 g, 2.45 mmol). After 30 minutes, amine 5-1 (Aldrich 260 mg, 1.96 mmole) was added. After 18 h at 60°C, the solution was diluted with EtOAc and then washed with H₂O, brine, dried (MgSO₄) and
- 10 concentrated. Flash chromatography (silica, 20% EtOAc/CHCl₃) afforded amide 5-2 as a yellow solid.
- TLC R_f = 0.13 (silica, 20% EtOAc/CHCl₃)
- ¹H NMR (10% CD₃OD/CDCl₃): δ 7.90 (s, 1H), 7.83 (d, J=9Hz, 2H), 7.63 (m, 2H), 7.22 (9s, 1H), 6.94 (d, J=9Hz, 2H), 6.52 (d, J=3Hz, 1H),
- 15 3.59 (m, 4H), 3.28 (m, 4H), 1.49 (s, 9H).



- 20 tert-Butyl 2-(5-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenylcarbonylamino)indol-1-yl)acetate (5-4)

To a stirred solution of amide 5-2 (300 mg, 0.71 mmol) and THF (5 ml) was added NaH (60% dispersion in mineral oil; 29 mg, 0.7137 mmol). After 10 minutes, bromide 5-3 (115 μ l, 0.71 mmol) was added. After 30 minutes, the solution was diluted with EtOAc and then


25 washed with H₂O, brine, dried (MgSO₄) and concentrated. Flash

- 53 -

chromatography (silica, 40% EtOAc/hexanes) afforded ester 5-4 as a yellow solid.

TLC R_f = 0.18 (silica, 40% EtOAc/hexanes)

^1H NMR: δ 7.92 (s, 1H), 7.83 (d, $J=9\text{Hz}$, 2H), 7.77 (s, 1H), 7.39 (dd, $J=9\text{Hz}$, 2H, 1H), 6.93 (d, $J=9\text{Hz}$, 2H), 6.52 (d, $J=3\text{Hz}$, 1H), 4.72 (s, 2H), 3.60 (m, 4H), 3.28 (m, 4H), 1.49 (s, 9H), 1.43 (s, 9H).




10 2-(5-(4-(1-piperazinyl)phenylcarbonylamino)indol-1-yl)
acetic acid (5-5)

To a stirred solution of ester 5-2 (250 mg, 0.4678 mmol), anisole (203 μl , 1.87 mmol) and CH_2Cl_2 (3 ml) at 0°C was added TFA. After 30 min., the solution was concentrated and then azeotroped with toluene. Flash chromatography (silica, 10:0.1:0.1 EtOH/ NH_4OH / H_2O) afforded crude acid. The crude material was purified by prep HPLC to furnish acid 5-5.


TLC R_f = 0.31 (silica, 10:0.5:0.5 EtOH/ NH_4OH / H_2O)

^1H NMR (50:50 d_6 - DMSO/ D_2O , 2 drops 1N NaOD): δ 7.87 (d, $J=9\text{Hz}$, 2H), 7.71 (s, 1H), 7.24 (m, 3H), 7.07 (d, $J=9\text{Hz}$, 2H), 6.47 (d, $J=3\text{Hz}$, 1H), 4.63 (s, 2H), 3.25 (m, 4H), 2.89 (m, 4H).

- 54 -

SCHEME 6

- 55 -


SCHEME 6 CONTINUED

5

N-(3-bromophenyl)-4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)benzamide (6-2)

- 10 A solution of acid 1-5 (400 mg, 1.31 mmol), amine 6-1 (248 mg, 1.44 mmol), BOP reagent (867 mg, 1.97 mmol), NMM (575 μ l, 5.24 mmol) and DMF (10 ml) was heated to 60°C for 72 h. The solution was diluted with EtOAc and then washed with H₂O, sat. NaHCO₃, 10% KHSO₄, brine, dried (MgSO₄) and concentrated. Flash chromatography (silica, 25% EtOAc/hexanes) furnished amide 6-2 as a
- 15 yellow solid.
 TLC R_f = 0.31 (silica, 25% EtOAc/hexanes)
¹H NMR (CD₃OD): δ 7.99 (s, 1H), 7.84 (d, J=9Hz, 2H), 7.60 (m, 1H), 7.25 (m, 2H), 7.02 (d, J=9Hz, 2H), 3.57 (m, 4H), 3.31 (m, 4H), 1.47 (s, 9H).

- 56 -




5 (E)-Methyl (3-(3-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl))phenyl)carbonylaminophenyl)prop-3-enoate (6-3)

A solution of amide 6-2 (400 mg, 0.86 mmol), methyl acrylate (783 μ l, 8.69 mmole), O(tolyl)₃P (159 mg, 0.415 mmol), NEt₃ (245 μ l, 1.74 mmole), Pd(OAc)₂ (20 mg, 0.069 mmole) and CH₃CN (5 ml) was heated to 100°C in a sealed tube for 18 h. The solution was
 10 diluted with EtOAc and then washed with H₂O, sat. NaHCO₃, 10% KHSO₄, brine, dried (MgSO₄) and concentrated. Flash chromatography (silica, 20% \rightarrow 30% EtOAc/hexanes) furnished olefin 6-3 as a yellow solid.

TLC R_f = 0.47 (silica, 50% EtOAc/hexanes)

15 ¹H NMR (CD₃OD): δ 7.94 (s, 1H), 7.87 (dd, J=2Hz, 9Hz, 2H), 7.71 (m, 2H), 7.36 (m, 2H), 7.03 (dd, J=2Hz, 9Hz, 2H), 6.52 (d, J=16Hz, 1H), 3.78 (s, 3H), 3.57 (m, 4H), 3.29 (m, 4H), 1.47 (s, 9H).



20


Methyl (3-(3-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl))phenyl)carbonylaminophenyl)propanoate (6-4)

A mixture of ester 6-3 (300 mg, 0.64 mmol), 10% Pd/C (100 mg) and EtOH (10 ml) was stirred under 1 atm H₂ for 18 h. The

- 57 -

reaction mixture was filtered through a celite pad and concentrated to furnish ester 6-4 as a yellow oil.

¹H NMR (CDCl₃): δ 7.80 (m, 3H), 7.54 (s, 1H), 7.47 (d, J=8Hz, 1H), 7.27 (m, 1H), 6.96 (d, 8Hz, 1H), 6.92 (d, J=9Hz, 2H), 3.68 (s, 3H), 3.60 (m, 4H), 3.29 (m, 4H), 2.96 (t, J=8Hz, 2H), 2.66 (t, J=8Hz, 2H), 1.50 (s, 9H).




10 3-(3-(4-(4-(1,1-Dimethylethoxycarbonyl)piperazin-1-yl))phenyl)-
carbonylaminophenyl)propanoic acid (6-5)

A solution of ester 6-4 (260 mg, 0.5563 mmol), 1 N NaOH (1 ml, 1 mmol) and EtOH (3 ml) was stirred at ambient temperature for 1.0 h. The solution was acidified with 10% KHSO₄ and then extracted with EtOAc. The EtOAc phase was washed with brine, dried (MgSO₄) and concentrated to furnish acid 6-5 as a white solid.

15 TLC R_f = 0.08 (silica, 10:0.2:0.2 CH₂Cl₂/MeOH/AcOH)
¹H NMR (CD₃OD): δ 7.84 (d, J=9Hz, 2H), 7.51 (m, 2H), 7.25 (t, J=8Hz, 1H), 7.03 (m, 3H), 3.57 (m, 4H), 3.29 (m, 4H), 2.91 (t, J=8Hz, 2H), 2.60 (t, J=8Hz, 2H), 1.47 (s, 9H).


- 58 -




3-(3-(4-Piperazin-1-ylphenyl)carbonylamino)phenyl)
propanoic acid (6-6)

- 5 A solution of acid 6-5 (210 mg, 0.4633 mmol), TFA (3 ml) and CH₂Cl₂ (3 ml) was stirred at ambient temperature for 1.0 h. The solution was concentrated and then azeotroped with toluene. Flash chromatography (silica, 10:0.1:0.1 → 10:0.5:0.5 EtOH/NH₄OH/H₂O) furnished acid 6-6 as a tan solid.
- 10 TLC R_f = 0.59 (silica, 10:1:1 EtOH/NH₄OH/H₂O)
 ¹H NMR (D₂O): δ 7.82 (d, J=9Hz, 2H), 7.38 (m, 2H), 7.34 (s, 1H), 7.15 (d, J=9Hz, 3H), 3.25 (m, 4H), 2.96 (m, 4H), 2.90 (t, J=8Hz, 2H), 2.50 (t, J=8Hz, 2H).

- 59 -


SCHEME 7

- 60 -



Ethyl 2-[4-(4-(4-(1,1-Dimethylethoxycarbonyl)piperazin-1-yl)phenylcarbonylamino)phenoxypropanoate (7-2)

- 5 Phenol 2-3 (381 mg, 0.993 mmol), ethyl 2-bromopropionate (7-1, 129 μ L, 0.99 mmol), and Cs_2CO_3 (807 mg, 2.5 mmol) were combined in 5 mL DMF. After stirring overnight the reaction was diluted with EtOAc, washed with water (3x), 10% KHSO_4 (3x) and brine, dried (MgSO_4), filtered and concentrated. Flash chromatography (silica, 40% EtOAc/hexane) provided 7-2 as a white solid.
- 10 TLC R_f = 0.41 (silica, 50% EtOAc/hexane)
 ^1H NMR (400 MHz, CDCl_3): δ 7.78 (d, $J=9\text{Hz}$, 2H), 7.60 (s, 1H), 7.52 (d, $J=9\text{Hz}$, 2H), 6.92 (d, $J=9\text{Hz}$, 2H), 6.89 (d, $J=9\text{Hz}$, 2H), 4.72 (q, $J=7\text{Hz}$, 1H), 4.22 (q, $J=7\text{Hz}$, 2H), 3.59 (m, 4H), 3.28 (m, 4H), 1.61 (d, $J=7\text{Hz}$, 3H), 1.49 (s, 9H), 1.26 (t, $J=7\text{Hz}$, 3H).
- 15




- 20 Ethyl 2-(4-(4-(piperazin-1-yl)phenylcarbonylamino)phenoxy)propanoate(7-3)

- A solution of 7-2 (266 mg, 0.53 mmol) and anisole (200 μ L, 1.8 mmol) in 5 mL 1:1 $\text{CH}_2\text{Cl}_2/\text{TFA}$ was stirred for 20 min. After concentration and azeotroping with toluene, flash chromatography (silica, 33:1:1 EtOH/ $\text{H}_2\text{O}/\text{NH}_4\text{OH}$) provided 7-3 as a white solid.
- 25 TLC R_f = 0.37 (silica, 20:1:1 EtOH/ $\text{H}_2\text{O}/\text{NH}_4\text{OH}$)

- 61 -

^1H NMR (400 MHz, CD_3OD): δ 7.84 (d, $J=9\text{Hz}$, 2H), 7.54 (d, $J=9\text{Hz}$, 2H), 7.01 (d, $J=9\text{Hz}$, 2H), 6.88 (d, $J=9\text{Hz}$, 2H), 4.21 (q, $J=7\text{Hz}$, 2H), 3.31 (m, 4H), 2.98 (m, 4H), 1.57 (d, $J=7\text{Hz}$, 3H), 1.26 (t, $J=\text{Hz}$, 3H).




5


2-(4-(4-(Piperazin-1-yl)phenyl)carbamoyl)phenoxy)
propionic acid (7-4)

- Ester 7-3 (44 mg, 0.11 mmol) was dissolved in 1 mL
- 10 EtOH, then 1 M NaOH (122 μL , 0.12 mmol) was added. After 3 h the reaction was neutralized with 1 N HCl, concentrated, then purified by flash chromatography (silica, 50:1:1 EtOH/ H_2O / NH_4OH) providing 7-4 as a white solid.
- TLC R_f = 0.15 (silica, 50:1:1 EtOH/ H_2O / NH_4OH)
- 15 ^1H NMR (400 MHz, D_2O): δ 7.69 (d, $J=9\text{Hz}$, 2H), 7.22 (d, $J=9\text{Hz}$, 2H), 7.01 (d, $J=9\text{Hz}$, 2H), 6.80 (d, $J=9\text{Hz}$, 2H), 4.48 (q, $J=7\text{Hz}$, 1H), 3.10 (m, 4H), 2.82 (m, 4H), 1.40 (d, $J=7\text{Hz}$, 3H).

- 62 -


SCHEME 8

- 63 -



Ethyl 6-[4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl]nicotinate (8-2)


- Ethyl 6-chloronicotinate (8-1, Maybridge Chemical Co.,
 2.0 g, 10.8 mmol) and piperazine (1.4 g, 15 mmol) were combined in
 54 mL NMP and heated at 50°C overnight. After cooling, Boc₂O (2.6
 g, 11.9 mmol) was added. The reaction mixture was stirred overnight
 then diluted with EtOAc, washed with water, sat NaHCO₃ and brine,
 dried (MgSO₄), filtered and concentrated. Flash chromatography
 (silica, 25% EtOAc/hexane) provided 8-2 as a white solid.
 TLC R_f = 0.63 (silica, 40% EtOAc/hexane)
¹H NMR (400 MHz, CDCl₃): δ 8.80 (d, J=2Hz, 1H), 8.04 (dd, J=9,
 2Hz, 1H), 6.58 (d, J=9Hz, 1H), 4.34 (q, J=7Hz, 2H), 3.68 (m, 4H), 3.54
 (m, 4H), 1.49 (s, 9H), 1.37 (t, J=7Hz, 3H).



6-[4-(1,1-Dimethylethoxycarbonyl)piperazin-1-yl]nicotinic acid (8-3)


- Ester 8-2 (3.0 g, 9.3 mmol) was dissolved in 93 mL EtOH,
 1 M NaOH (23 mL, 23 mmol) was added, and the reaction mixture was
 stirred overnight. After concentrating, the residue was dissolved in
 water, washed with EtOAc, and the aqueous layer was acidified with
 10% KHSO₄. After extracting with EtOAc, the organic layer was
 washed with brine, dried (MgSO₄), filtered and concentrated providing
8-3 as a white solid.
¹H NMR (400 MHz, CD₃OD): δ 8.71 (d, J=2Hz, 1H), 8.08 (dd, J=9,
 2Hz, 1H), 6.77 (d, J=9Hz, 1H), 3.61 (m, 4H), 3.53 (m, 4H), 1.49 (s,
 9H).

- 64 -



N-(4-Hydroxyphenyl)-6-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)nicotinamide (8-4)

- 5 Acid 8-3 (500 mg, 1.6 mmol), NMM (720 μ L, 6.5 mmol) and BOP reagent (793 mg, 1.8 mmol) were combined in 8 mL DMF. After 1.5 h, 4-aminophenol (260 mg, 1.8 mmol) was added and the reaction was heated to 60°C overnight. The reaction mixture was diluted with EtOAc, washed with water (5x), sat. NaHCO₃ and brine, dried (MgSO₄), filtered and concentrated. Flash chromatography (silica, 50-60% EtOAc/hexane) provided 8-4 as a brown solid. TLC R_f = 0.40 (silica, 70% EtOAc/hexane) ¹H NMR (400 MHz, CDCl₃): δ 8.66 (d, J=2Hz, 1H), 7.98-7.95 (m, 2H), 7.33 (d, J=9Hz, 2H), 6.75 (d, J=9Hz, 2H), 6.58 (d, J=9Hz, 1H), 3.61 (m, 4H), 3.52 (m, 4H), 1.48 (m, 9H).
- 10
- 15



- 20 tert-Butyl 2-((4-(2-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)pyridin-5-yl)carbonylamino)phenoxy)acetate (8-5)


Phenol 8-4 (374 mg, 0.94 mmol), t-butyl bromoacetate (151 μ L, 0.94 mmol) and Cs₂CO₃ (761 mg, 2.3 mmol) were combined in 5 mL DMF. After 90 min. the reaction mixture was diluted with EtOAc, washed with water (4x) and brine, dried (MgSO₄), filtered and concentrated. Flash chromatography (silica, 50% EtOAc/hexane) provided 8-5 as a brown solid. TLC R_f = 0.53 (silica, 70% EtOAc/hexane)

25

- 65 -

¹H NMR (400 MHz, CDCl₃): δ 8.66 (d, J=2Hz, 1H), 7.99 (dd, J=9, 2Hz, 1H), 7.56 (s, 1H), 7.52 (d, J=8Hz, 2H), 6.90 (d, J=8Hz, 2H), 6.65 (d, J=9Hz, 1H), 4.51 (s, 2H), 3.68 (m, 4H), 3.56 (m, 4H), 1.49 (s, 18H).


5








2-(4-(((2-Piperazin-1-yl)pyridin-5-yl)carbonylamino)phenoxy)acetic acid (8-6)

Ester 8-5 (290 mg, 0.57 mmol) was dissolved in 5 mL 1:1
10 TFA/CH₂Cl₂. After 1 h the reaction was concentrated and azeotroped
with toluene. Flash chromatography (silica, 10:1:1 EtOH/H₂O/NH₄OH)
and trituration with Et₂O provided 8-6 as a light brown solid.
¹H NMR (400 MHz, D₂O): δ 8.42 (d, J=2Hz, 1H), 7.89 (dd, J=9, 2Hz,
1H), 7.04 (d, J=8 Hz, 2H), 6.78 (d, J=9Hz, 2H), 6.76 (d, J=10 Hz, 1H),
15 4.32 (s, 2H), 3.37 (m, 4H), 2.74 (m, 4H).


- 66 -

SCHEME 9


- 67 -

SCHEME 9 (CONT'D)9-4BOC₂O / TEA9-5Pd(OAc)₂ / dppp/ DMF
CO(g) CH₃OH9-6LiOH
THF/H₂O/MeOH9-710-4PYCLU/*i*-Pr₂NEt


- 68 -

SCHEME 9 (CONT'D)


- 69 -

SCHEME 9 (CONT'D)9-6NaBH₃CN / EtOAc


(+/-)

9-10LiOH / MeOH / H₂O/THF


(+/-)

9-11

- 70 -

SCHEME 9 (CONT'D)

- 71 -




Ethyl 2-(4-bromo-1-hydrazinimine)propanoate 9-1

A mixture of 4-bromophenylhydrazine (Aldrich, 0.5 g, 2.2 mmol) and ethyl acetoacetate (Aldrich, 0.24 mL, 2.2 mmol) in pyridine (0.6 mL) was heated to reflux overnight. The reaction was cooled, diluted with water and the precipitate that resulted was collected and washed with water, dried under vacuum to give 9-1.

R_f(10% MeOH/CHCl₃ saturated with NH₃)=0.86

¹H NMR (400 MHz, CDCl₃) δ 7.64 (s, 1H), 7.41 (d, 2H), 7.39 (d, 2H), 4.30-4.34 (q, 2H), 2.10 (s, 3H), 1.36 (t, 3H).




5-Bromo-2-ethoxycarbonyl indole 9-2

A mixture of 9-1 (0.54 g, 1.9 mmol) and polyphosphoric acid (1.6 mL) was heated to 115°C for 10 minutes, then diluted with cold water and extracted with EtOAc. The layers were separated and the aqueous layer extracted with EtOAc. The organic layers were combined, washed with brine, dried with MgSO₄, filtered and concentrated to give 9-2 as a brown solid.

R_f(30% EtOAc/hexanes)=0.45

¹H NMR (400 MHz, CDCl₃) δ 8.95(bs, 1H), 7.82 (s, 1H), 7.41 (d, 1H), 7.30 (d, 1H), 7.15 (s, 1H), 4.44 (q, 2H), 1.40 (t, 3H).

- 72 -


9-31-(Cyanomethyl)-2-ethoxycarbonyl-5-bromo-indole 9-3

5 A solution of 9-2 (11.2 g, 44.4 mmol) in DMF (400 mL) was treated with NaH (3.2 g of 60% dispersion in oil, 66.6 mmol) for 0.5 hour and then chloroacetonitrile (Aldrich, 5.6 mL, 88.8 mmol) was added and the reaction was stirred overnight. The solvent was removed *in vacuo* and the residue was partitioned between water and EtOAc. The water layer was extracted with EtOAc, the organic layers were
10 combined, washed with water, brine, dried with MgSO₄, filtered and evaporated to give 9-3 as a brown solid.

R_f(30% EtOAc/hexanes)=0.46

¹H NMR (400 MHz, CDCl₃) δ 7.82-7.83 (bs, 1H), 7.51-7.54 (dd, 1H), 7.30-7.32 (bd, 2H), 5.60 (s, 2H), 4.41-4.43 (q, 2H), 1.41-1.43 (t, 3H).

15

9-48-Bromo-2,3,4,5-tetrahydropyrazino-[1,2-a]indole 9-4


20 A slurry of 9-3 (12.2 g, 39.7 mmol) in diethyl ether (400 mL) was added via dropping funnel to a solution of LAH in ether (79.4 mL, 1 M in ether, 79.4 mmol) and stirred at room temperature overnight. The slurry was diluted with saturated sodium potassium tartrate (Rochelle's salt) and stirred for 15 minutes, then transferred to a separatory funnel containing EtOAc and the layers separated. The
25 aqueous layer was extracted with EtOAc, the organic layers were combined, washed with water, brine, dried with MgSO₄, filtered and evaporated to give 9-4 as a brown solid.

- 73 -

Rf(10% MeOH/CHCl₃ saturated with NH₃)=0.42

¹H NMR (400 MHz, CDCl₃) δ 8.38-8.41 (bs, 1H), 7.66 (s, 1H), 7.21-7.22 (dd, 2H), 7.14 (d, 2H), 6.14 (s, 1H), 4.22 (s, 2H), 3.99 (t, 2H), 3.36-3.37 (t, 2H).

5




8-Bromo-3-(1,1-dimethylethoxycarbonyl)-2,3,4,5-tetrahydropyrazino-[1,2-a]indole 9-5

10 A solution of 9-4 (10 g, 40 mmol) in CH₂Cl₂ (200 mL) was cooled to 0°C and treated with di-tertbutyldicarbonate (8.7 g, 40 mmol) and triethylamine (5.6 mL, 40 mmol). The solution was allowed to warm slowly and after 48 hours was concentrated and the residue dissolved in EtOAc, washed with water and brine, dried over Na₂SO₄,
15 filtered and evaporated. The residue was chromatographed (30% EtOAc/hexanes) to give 9-5 as a solid.

Rf(30% EtOAc/hexanes)=0.22

¹H NMR (400 MHz, CDCl₃) δ 7.67 (d, 1H), 7.23 (d, 1H), 7.13 (d, 1H), 6.21 (s, 1H), 4.80 (s, 2H), 4.04 (t, 2H), 3.93 (t, 2H), 1.50 (s, 9H).

20



8-Methoxycarbonyl-3-(1,1-dimethylethoxycarbonyl)-2,3,4,5-tetrahydropyrazino-[1,2-a]indole 9-6


25 A solution of 9-5 (3.0 g, 8.5 mmol) in MeOH (60 mL) and DMSO (20 mL) was treated with triethylamine (3.55 mL, 25.5 mmol), 1,3-Bis(diphenylphosphino)propane (1.75 g, 4.25 mmol) and palladium (II) acetate (0.952 g, 4.25 mmol). Carbon monoxide was bubbled

- 74 -

through the solution while it was heated to reflux for 2 hours. The reaction was heated at reflux overnight under a balloon atmosphere of carbon monoxide. Additional 1,3-Bis(diphenylphosphino)propane (0.8 g, 2.12 mmol) and palladium acetate (0.476 g, 2.12 mmol) were added and the reaction was heated at reflux for 48 hours under a balloon atmosphere of carbon monoxide. The reaction was cooled to room temperature, the residue was partitioned between water and EtOAc. The water layer was extracted with EtOAc, the organic layers were combined, washed with water, brine, dried with MgSO₄, filtered and evaporated. The residue was chromatographed (25% EtOAc/hexanes) to give 9-6 as a yellow solid.

R_f(30% EtOAc/hexanes)=0.21

¹H NMR (400 MHz, CDCl₃) δ 8.32 (s, 1H), 7.90 (d, 1H), 7.26 (d, 1H), 6.38 (s, 1H), 4.83 (s, 2H), 4.12 (t, 2H), 3.96-3.93 (m, 5H), 1.50 (s, 9H).


9-7

3-(1,1-dimethylethoxycarbonyl)-2,3,4,5-tetrahydropyrazino-[1,2-a]indole-8-carboxylic acid 9-7

A slurry of 9-6 (150 mg, 0.454 mmol) in THF/H₂O/MeOH was treated with LiOH (38.2 mg, 0.91 mmol) and stirred for 1 hour. TLC indicated no reaction. LiOH (38.2 mg.) was added and the reaction mixture (still a slurry) was stirred for an additional hour with no reaction. The reaction mixture was concentrated to dryness and dissolved in MeOH and H₂O. LiOH (114 mg) was added and the reaction mixture was stirred and heated to 75° for 3 hours and stirred at RT for 16 hours resulting in a complete reaction. The reaction mixture is diluted with EtOAc and 10% citric acid. The layers are separated and the organic layer is washed with water and brine, dried, filtered and concentrated to give 9-7 as a white solid.

- 75 -

^1H NMR (400 MHz; CDCl_3) δ 8.40 (s, 1H), 7.95(d, 1H), 7.32 (d, 1H), 6.41 (s, 1H), 4.84 (s, 2H), 4.14-4.11 (m, 2H), 3.96 (m, 2H), 1.50 (s, 9H).



5


Ethyl 4-((3-(1,1-dimethylethoxycarbonyl)-2,3,4,5-tetrahydropyrazino-[1,2-a]indole-8-yl)carbonylamino)-3-methylphenoxyacetate 9-8

A solution of 9-7 (110 mg, 0.35 mmol) and 10-4 (85.7 mg, 0.35 mmol) in CH_2Cl_2 were treated with diisopropylethylamine and PYCLU as described for 23-5 to give 9-8 as a white solid after chromatography in 50% EtOAc/Hexane.

R_f (50% EtOAc/Hexane) 0.34

^1H NMR (400 MHz, CDCl_3) δ 8.12 (s, 1H), 7.8-7.65 (m, 2H), 7.59 (s, 1H), 7.36 (d, 1H), 6.84 (m, 2H), 6.39 (s, 1H), 4.85 (s, 2H), 4.62 (s, 2H), 4.29-4.27 (q, 2H), 4.15-4.13 (t, 2H), 3.96 (t, 2H), 2.33 (s, 3H), 1.50 (s, 9H), 1.33-1.31 (t, 3H).

15



20

4-((2,3,4,5-tetrahydropyrazino-[1,2-a]indole-8-yl)carbonylamino)-3-methylphenoxyacetic acid 9-9


A slurry of 9-8 (0.15 mmol, 75 mg) and THF/ H_2O /MeOH was treated with LiOH (13 mg, 0.30 mmol) and stirred for 1 hour. The reaction mixture was diluted with EtOAc and 10% citric acid. The

25

- 76 -

layers were separated and the organic layer was washed with H₂O and brine. The organic layer was dried, filtered and concentrated to give desired acid as a white solid. This solid is slurried in EtOAc, cooled to -78° and saturated with HCl. The reaction mixture is warmed to 0° and stirred for 15 min. The reaction mixture was concentrated to yield a white solid which was taken up in a EtOAc/hexane/ether mixture and filtered. The solids were washed with ether to give 9-9 as a white solid. R_f 10/1/1 EtOH/NH₄OH/H₂O) 0.16

¹H NMR (400 MHz; D₂O) δ 8.09 (s, 1H), 7.62-7.60 (d, 1H), 7.45 (d, 1H), 7.14-7.12 (d, 1H), 6.84 (d, 1H), 6.79-6.76 (dd, 1H), 6.35 (s, 1H), 4.40 (s, 2H), 4.07-4.02 (m, 4H), 3.23-3.22 (t, 2H), 2.15 (s, 3H).

9-10


15 (+ /-) 8-Methoxycarbonyl-3-(1,1-dimethylethoxycarbonyl)-1,1a,2,3,4,5-hexahydropyrazino-[1,2-a]indole 9-10

9-6 (0.091 mmol, 30 mg) was dissolved in EtOAc and cooled to 0°C. NaBH₃CN (0.45 mmol, 28 mg) was added portion-wise and the reaction was warmed to room temperature for 15 min. The reaction mixture was basified with saturated NaHCO₃ and extracted into EtOAc. The organic layer was washed with brine, dried (MgSO₄), filtered and concentrated to yield 9-10 as a colorless oil.

R_f (2:1 hexane/ EtOAc)=0.4


¹H NMR (400 MHz; CDCl₃) δ 7.83-7.82 (d, 1H), 7.73 (s, 1H), 6.40-6.38 (d, 1H), 4.15-4.0 (bs, 2H), 3.85 (s, 3H), 3.60-3.56 (m, 2H), 3.05-2.65 (m, 4H), 2.60-2.58 (dd, 1H), 1.50 (s, 9H).

- 77 -

9-11

(+ /-) 3-(1,1-Dimethylethoxycarbonyl)-1,1a,2,3,4,5-hexahydro-pyrazino-[1,2-a]indole-8-carboxylic acid 9-11

- 5 9-10 (0.90 mmol, 300 mg) was slurried in THF/H₂O/MeOH (2mL/2/2). LiOH (1.8 mmol, 76 mg) was added and the reaction mixture was heated to 50°C. After 0.5 hours, the reaction mixture became homogeneous, and was then stirred at room temperature for an additional 2 hours. The reaction mixture was diluted with 10% citric acid and EtOAc. The layers were separated, and the organic layer was washed with H₂O and brine. Drying (MgSO₄), filtering and concentrating gave 9-11 as a yellow solid.
- 10 R_f (97/3/1 CHCl₃/MeOH/HOAc)=0.70
- 15 ¹H NMR (400 MHz; CDCl₃) δ 7.90 (d, 1H), 7.87 (s, 1H), 6.41-6.39 (d, 1H), 4.25-4.0 (bs, 2H), 3.65-3.57 (m, 2H), 3.10-3.0 (dd, 1H), 3.02-2.98 d, 1H), 2.98-2.91 (bs, 1H), 2.69-2.66 (bs, 1H), 2.62-2.60 (dd, 1H), 1.50 (s, 9H).

9-12

20

(+ /-) Ethyl 4-((3-(1,1-Dimethylethoxycarbonyl)-1,1a,2,3,4,5-hexahydro-pyrazino-[1,2-a]indole-8-yl)carbonylamino)-3-methylphenoxyacetate 9-12


- 25 A solution of 9-11 (250 mg, 0.79 mmol) and 10-4 (193 mg, 0.79 mmol) in CH₂Cl₂ were treated with diisopropylethylamine and

- 78 -

PYCLU as described for 23-5 to give 9-12 as a white solid after chromatography in 50% EtOAc/Hexane.

Rf (50% EtOAc/Hexane) 0.35

¹H NMR (400 MHz, CDCl₃) δ 7.70-7.63 (m, 3H), 7.36 (s, 1H), 6.82-6.76 (m, 2H), 6.45-6.43 (d, 1H), 4.60 (s, 2H), 4.30-4.25 (q, 2H), 4.21-4.09 (bs, 2H), 3.59-3.57 (m, 2H), 3.10-3.09 (m, 1H), 3.05-2.51 (m, 3H), 2.78-2.60 (m, 1H), 2.29 (s, 3H), 1.50 (s, 9H), 1.32-1.29 (t, 3H).



10


(+/-) 4-((3-(1,1-Dimethylethoxycarbonyl)-1,1a,2,3,4,5-hexahydro-pyrazino-[1,2-a]indole-8-yl)carbonylamino)-3-methylphenoxyacetic acid 9-13

A slurry of 9-12 (0.25 mmol, 125 mg) and THF/H₂O/MeOH was treated with LiOH (21 mg, 0.50 mmol) and heated to 80° for 1 hour. The reaction mixture was diluted with EtOAc and 10% citric acid. The layers were separated and the organic layer was washed with H₂O and brine. The organic layer was dried, filtered and concentrated to give desired acid as a white solid. This solid is slurried in EtOAc, cooled to -78° and saturated with HCl. The reaction mixture is warmed to 0° and stirred for 15 min. The reaction mixture was concentrated and the white solid triturated with ether to give 9-13 as a white solid.


Rf 10/1/1 EtOH/NH₄OH/H₂O) 0.3

¹H NMR (400 MHz, D₂O) δ 7.70-7.67 (d, 1H), 7.63 (s, 1H), 7.11-7.09 (d, 1H), 6.86 (d, 1H), 6.78-6.76 (dd, 1H), 6.69-6.68 (d, 1H), 4.57 (s, 2H), 3.93-3.90 (bd, 2H), 3.39-3.31 (m, 3H), 3.19-3.07 (m, 3H), 2.74-2.68 (dd, 1H).

- 79 -

SCHEME 10

- 80 -

SCHEME 10 CONTINUED

5 4-(1,1-Dimethylethoxycarbonyl)amino-3-methylphenol (10-2)

To a 1 L round bottomed flask with a stirring bar, reflux condenser and an argon inlet was added 4-amino-3-methylphenol (15.00 g, 121.79 mmol), di-*tert*-butylpyrocarbonate (27.25 g, 124.84 mmol) and CHCl₃ (300 mL). This heterogeneous mixture was heated at reflux
 10 for 24 h during which time all of the solids dissolved. The mixture was cooled to room temperature and the solid product was collected by filtration. The material was triturated with a mixture of Et₂O-hexanes (1:1), collected on a frit and dried *in vacuo* to give 21.25 g (92%) of 4-

- 81 -

(1,1-dimethylethoxycarbonyl)amino-3-methylphenol (10-2), mp: 143-144°C.

¹H NMR (CDCl₃): δ 1.51 (s, 9H), 2.14 (s, 3H), 6.08 (br s, 1H), 6.48 (m, 2H), 6.60 (br s, 1H), 7.20 (d, j=8.5Hz, 1H).

5

Ethyl 4-(1,1-Dimethylethoxycarbonyl)amino-3-methylphenoxyacetate (10-3)

To a 200 mL round bottomed flask with a stirring bar, and an argon inlet was added 4-(1,1-dimethylethoxycarbonyl)amino-3-methylphenol (5.00 g, 22.39 mmol), Cs₂CO₃ (14.59 g, 44.78 mmol), DMF (50 mL), and ethyl bromoacetate (2.61 mL, 23.51 mmol). This mixture was stirred vigorously at ambient temperature for 24 h. The mixture was filtered through a frit and the DMF was removed under high vacuum. The residue was dissolved in EtOAc (300 mL) and washed with H₂O (2x) and brine (1x). Drying (MgSO₄), filtration, and removal of the solvent *in vacuo* gave a solid. This material was triturated with 5% Et₂O-hexane, the solid was collected by filtration and dried *in vacuo* to give 5.40 g (78%) of ethyl 4-(1,1-dimethylethoxycarbonyl)amino-3-methylphenoxyacetate as a white, crystalline solid.

20

¹H NMR (CDCl₃): δ 1.29 (t, j=7.2Hz, 3H), 1.51 (s, 9H), 2.22 (s, 3H), 4.26 (q, j=7.2Hz, 2H), 4.57 (s, 2H), 6.08 (br s, 1H), 6.72 (m, 2H), 7.56 (s, 1H).

25 Ethyl 4-amino-3-methylphenoxyacetate, hydrochloride (10-4)

To a 500 mL round bottomed flask with a gas dispersion tube was added a solution of ethyl 4-(1,1-dimethylethoxycarbonyl)amino-3-methylphenoxyacetate (5.31 g, 17.13 mmol) in EtOAc (200 mL). This solution was cooled in an ice bath and dry HCl gas was sparged through the solution, vigorously, for 10 min. The resulting mixture was aged for 15 min. at 0°C. The excess HCl gas was removed with a stream of argon and the solvent was removed *in vacuo*. The product was triturated with 50 mL of EtOAc and collected on a frit. The crystals were washed with additional EtOAc and dried *in vacuo* to

30

- 82 -

give 4.21 g (100%) of ethyl 4-amino-3-methylphenoxyacetate, hydrochloride as white crystals, mp: 198-200°C.

¹H NMR (DMSO-d₆): δ 1.21 (t, j=7.1Hz, 3H), 2.33 (s, 3H), 4.17 (q, j=7.1Hz, 2H), 4.78 (s, 2H), 6.82 (dd, j=3,9Hz, 1H), 6.92 (d, j=3Hz, 1H),
5 7.39 (d, j=9Hz, 1H), 10.21 (br s, 3H).

Ethyl 2-(4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenylcarbonylamino)-3-methylphenoxy)acetate (10-5)

To a 100 mL round bottomed flask with a stirring bar and
10 an argon inlet was added 4-(4-(1,1-dimethylethoxycarbonyl)piperazinyl)benzoic acid (0.75 g, 2.45 mmol), ethyl 4-amino-3-methylphenoxyacetate hydrochloride (0.60 g, 2.45 mmol), chloro-N,N,N',N'-bis(pentamethylene)formamidinium hexafluorophosphate (0.97 g, 2.69 mmol), and CH₂Cl₂ (30 mL). This mixture was cooled in
15 an ice bath and diisopropylethylamine (1.74 mL, 10.0 mmol) was added. The ice bath was allowed to expire and the solution was stirred at ambient temperature for 48 h. The solution was diluted with CHCl₃ and washed with 10% aqueous citric acid, saturated aqueous NaHCO₃, and brine. Drying (MgSO₄), filtration and removal of the solvent *in vacuo*
20 gave an oil. This material was chromatographed on 75 g of silica gel using 50% EtOAc-hexane as eluant. There was obtained 1.22 g (100%) of ethyl 2-(4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenylcarbonylamino)-3-methylphenoxy)acetate as a crystalline solid.
¹H NMR (CDCl₃): δ 1.30 (t, j=7.1Hz, 3H), 1.49 (s, 9H), 2.27 (s, 3H),
25 3.27 (m, 4H), 3.59 (m, 4H), 4.26 (q, j=7.1Hz, 2H), 4.59 (s, 2H), 6.75 (m, 2H), 6.90 (d, j=8.8Hz, 2H), 7.54 (br s, 1H), 7.65 (m, 1H), 7.79 (d, j=8.8Hz, 2H).

30 2-(4-(4-(4-(1,1-Dimethylethoxycarbonyl)piperazin-1-yl)phenylcarbonylamino)-3-methylphenoxy)acetic acid (10-6)

To a 100 mL round bottomed flask with a stirring bar and an argon inlet was added ethyl 2-(4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenylcarbonylamino)-3-methylphenoxy)acetate (1.22 g, 2.45 mmol) and 20 mL of CH₃OH. To this solution was

- 83 -

added aqueous NaOH (10 mL of a 1N solution). The mixture was stirred at ambient temperature for 18 h. The mixture was neutralized with 10 mL of 1N HCl and diluted with H₂O. The product was collected on a frit and washed with a little H₂O. This material was

5 dried *in vacuo* to give 0.953 g (83%) of 2-(4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenylcarbonylamino)-3-methylphenoxy)acetic acid as a white solid.

¹H NMR (CDCl₃): δ 1.49 (s, 9H), 2.26 (s, 3H), 3.27 (m, 4H), 3.58 (m, 4H), 4.57 (s, 2H), 6.74 (m, 2H), 6.90 (d, j=8.5 Hz, 2H), 7.60 (m, 1H),

10 7.65 (m, 1H), 7.79 (d, j=8.5 Hz, 2H).

2-(4-(4-(1-Piperazinyl)phenylcarbonylamino)-3-methylphenoxy)acetic acid, dihydrochloride (10-7)


To a 200 mL round bottomed flask equipped with a stirring

15 bar and a gas dispersion tube was added 2-(4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenylcarbonylamino)-3-methylphenoxy)acetic acid (0.95 g, 2.03 mmol) and 100 mL of dry EtOAc. This well stirred suspension was cooled in an ice bath and HCl gas was sparged through the solution for 15 min. This mixture was aged 30

20 min. at 0°C then the excess HCl was removed with a stream of argon and the EtOAc was removed *in vacuo*. The product was triturated with EtOAc, collected on a frit and dried *in vacuo* to give 895 mg of 2-(4-(4-(1-piperazinyl)phenylcarbonylamino)-3-methylphenoxy)acetic acid, dihydrochloride, mp: >250°C.

25 ¹H NMR (DMSO-d₆): δ 2.16 (s, 3H), 3.20 (m, 4H), 3.54 (m, 4H), 4.66 (s, 2H), 6.72 (d, j=3Hz, 1H), 6.75 (s, 1H), 7.06 (d, j=9.0Hz, 2H), 7.15 (d, j=3.0Hz, 1H), 7.90 (d, j=9.0Hz, 2H), 9.43 (br s, 1H), 9.56 (s, 1H).


- 84 -

SCHEME 11


R.A. Glennon.; et. al.
J. Med. Chem. 1992 35 734.

11-1


SOCl₂ / MeOH

11-2









ClCH₂CO₂Et KI
K₂CO₃
Acetone

11-3



NaH / Toluene

11-4


- 85 -

SCHEME 11 (CONT'D)11-511-611-711-8


- 86 -

SCHEME 11 (CONT'D)11-811-9


1. NaBH₄
2. BOC₂O / TEA

11-10

Pd(OAc)₂
1,3 bis diphenyl phosphino propane
TEA / DMSO / MeOH

11-11

LiOH




11-12

- 87 -


SCHEME 11 (CONT'D)

1. oxalyl chloride / DMF cat.

2.


1. LiOH
2. HCl

- 88 -



Methyl 4-bromo-2-hydroxy benzoate 11-2

- 200 mL of MeOH was cooled to 0°C and treated dropwise with thionyl chloride (30 mL, 0.4 mole) so that the reaction temperature was kept below 15°C throughout the addition. A solution of **11-1** (12.7g, prepared by the method of R. Glannon *et al.*, *J. Med. Chem.* **1992** 35, 734, 0.0585 mol) in 50 mL MeOH was added to the reaction and the mixture was warmed to room temperature and stirred for 48 hours, then heated to 60°C for 7 hours. The volatile components were removed under high vacuum and the residue chromatographed (silica, gradient straight hexanes to 10% EtOAc/Hexanes) to give **11-2** as a bright yellow oil that solidified on standing.
- R_f (5% EtOAc/Hexanes) 0.6
- ¹H NMR (400 MHz, CDCl₃) δ 10.8 (s, 1H), 7.68 (d, 1H), 7.19 (s, 1H), 7.03 (d, 1H), 3.95 (s, 3H).




Methyl 4-Bromo-2-(ethyl acet-2-yloxy)-benzoate 11-3

- A solution of **11-2** (26.6 g, 0.115 mole) in acetone (80 mL) was treated with chloroethylacetate (14 g, 0.115 mole), potassium iodide (3 g, 0.018 mole), and potassium carbonate (31.7 g, 0.23 mole) and heated to 50°C with vigorous stirring for 2 hours. The suspension was filtered, evaporated to dryness, resuspended in ether, re-filtered and concentrated to give **11-3** as a golden-brown oil.

- 89 -

Rf (10% EtOAc/Hexanes) 0.11

¹H NMR (400 MHz, CDCl₃) δ 7.7 (d, 1H), 7.2 (d, 1H), 7.04 (s, 1H), 4.7 (s, 2H), 4.3 (q, 2H), 3.9 (s, 3H), 1.3 (t, 3H).




6-Bromo-benzofuran-3-one 11-5

Sodium hydride (5.52 g, 60% dispersion in oil, 0.138 mole) was placed in a 3L vessel equipped with an overhead stirrer, argon line, reflux condenser and addition funnel. Toluene (215 mL) was added and the solution heated to reflux. A solution of 11-3 (36.3 g, 0.115 mole) in 100 mL toluene was added dropwise over 1.5 hours to give an orange suspension. The reaction was heated for an additional 3 hours, then cooled to room temperature and filtered through a glass-fiber filter. The cake was washed with 500 mL Et₂O and dried under vacuum to give 11-4 as a sandy orange solid (streaks from baseline in 30% EtOAc/Hexanes). A suspension of 11-4 (5 g, 0.016 mol) in EtOH (20 mL) was added to a solution of NaOH (4 g, 0.1 mole) in H₂O (35 mL). The reaction was heated to reflux for 1.25 hours, then cooled and the volatile components removed under vacuum. The residue was suspended in 200 mL 6N HCl and 200 mL CHCl₃ and stirred vigorously for 0.5 hours. The layers were separated and the aqueous layer was washed with CHCl₃. The organic layers were combined, dried with MgSO₄, filtered and evaporated to give 11-5 as a deep red solid.

Rf (20% EtOAc/Hexanes) 0.61


¹H NMR (400 MHz, CDCl₃) δ 7.53 (d, 1H), 7.35 (s, 1H), 7.24 (d, 1H), 4.64 (s, 2H).

- 90 -



(6-Bromo-benzofuran-3-yl)-acetonitrile 11-6

- Sodium hydride (0.7 g, 0.0173 mol) was washed with
5 hexanes then suspended in THF (8 mL). Diethyl
cyanomethylphosphonate (3.07 g, 0.0173 mol) was added dropwise and
stirred 10 minutes to give clear yellow solution. A solution of 11-5
(3.38 g, 0.0158 mol) in THF (20 mL) was added dropwise, the solution
stirred for 0.5 hour, then heated to reflux for 0.5 hour. A solution of
10 6N HCL (3.4 mL) was added and the THF was removed under vacuum.
The concentrated solution was diluted with Et₂O and washed with 4 X
30 mL 6N HCl, the ether layer was dried (MgSO₄), filtered and
evaporated. The residue was chromatographed (20% EtOAc/Hexanes)
to give 11-6 as an orange solid.
15 R_f (20% EtOAc/Hexanes) 0.45
¹H NMR (400 MHz, CDCl₃) δ 7.7 (s, 1H), 7.65 (s, 1H), 7.45 (s, 2H),
3.75 (s, 2H).



20

2-(6-Bromo-benzofuran-3-yl)-ethylamine 11-7


- A solution of 11-6 (10.9 g, 0.0462 mol) in THF (100 mL)
was cooled to 0°C and treated dropwise with BH₃/THF solution
(1Molar, 110.8 mL, 0.11 mol). The cold bath was removed and the
25 reaction stirred overnight. MeOH was carefully added (20 mL) and the
solvent removed under vacuum.. The residue was dissolved in 50 mL

- 91 -

MeOH and 400 mL MeOH saturated with HCl and heated to reflux for 3 hours. The volatile components were removed under vacuum and the residue was suspended in Et₂O. A bright yellow solid precipitated and was collected and washed five times with Et₂O, then dried under vacuum to give 11-7 as a tan solid.

R_f (5% MeOH/ CHCl₃ saturated with NH₃) 0.23

¹H NMR (400 MHz, CD₃OD) δ 7.72 (s, 2H), 7.6 (d, 1H), 7.45 (d, 1H), 3.25 (m, 2H), 3.06 (m, 2H).



7-bromo-2-(1,1-dimethylethoxycarbonyl)-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]benzofuran 11-10

A solution of 11-7 (11.8 g, 0.043 mol) in MeOH (150 mL) was diluted with CHCl₃ (400 mL) and washed with 75 mL 1N NaOH. The aqueous layer was backwashed with CHCl₃, the organic layers were combined, evaporated, and the residue azeotroped with toluene to remove residual water. The resulting brown oil was treated with 200 mL ethyl formate and brought to reflux for 1.5 hours until the solution was homogenous. The solvent was removed, the residue was dissolved in 200 mL CHCl₃, washed with 30 mL 1N HCl, brine, dried over MgSO₄, filtered and evaporated to give 11-8 as a solid that was used without further purification. R_f (5% MeOH/ CHCl₃ saturated with NH₃) 0.47


¹H NMR (400 MHz, CD₃OD) δ 8.04 (s, 1H), 7.67 (s, 1H), 7.63 (s, 1H), 7.55 (d, 1H), 7.4 (d, 1H), 3.53 (m, 2H), 2.4 (m, 2H). Solid 11-8 was crushed and placed in a flask equipped with an overhead stirrer. Polyphosphoric acid (20 mL) and CHCl₃ (5 mL) was added and the reaction heated to 80°C for 1.5 hours. The reaction was removed from the oil bath and 250 mL H₂O, 30 mL NH₄OH, and 200 mL CHCl₃ was added and stirred vigorously. The resulting opaque mixture was

- 92 -

transferred to a separatory funnel, the layers separated, and the aqueous layer was extracted repeatedly with CHCl_3 . The organic layers were combined, filtered through a pad of SolkaFloc, dried over Na_2SO_4 , filtered and evaporated to give the intermediate cyclic imine (11-9) as a pale yellow foam. A 5g sample of this material (0.02 mol) was dissolved in 200 mL MeOH and 20 mL 1N HCl. Sodium borohydride (1.5g, 0.04 mol) was added in portions. After 0.5 hours the solvent was removed and the residue was partitioned between saturated NaHCO_3 and CHCl_3 . The aqueous layer was extracted with CHCl_3 , the organic layers were combined, dried (Na_2SO_3) and filtered to give a clear yellow solution. (Rf amine (5% MeOH/ CHCl_3 saturated with NH_3) 0.45). Di-tert-butyl dicarbonate (4.5 g, 0.02 mol) and TEA (2.8 mL, 0.02 mol) were added and the solution stirred overnight, then washed with 10% KHSO_4 . The organic layer was evaporated and the residue was chromatographed in 10% EtOAc/Hexanes to give 11-10 as a white solid.

Rf (20% EtOAc/Hexanes) 0.60

^1H NMR (400 MHz, CDCl_3) δ 7.6 (s, 1H), 7.35 (d, 1H), 7.3 (d, 1H), 4.56 (bs, 2H), 3.75 (bs, 2H), 2.7 (bs, 2H), 1.5 (s, 9H).



Methyl 2-(1,1-dimethylethoxycarbonyl)-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]benzofuran-7-yl carboxylate 11-11

A solution of 11-10 (1g, 2.84 mmol), 1,3 di-phenyl phosphino propane (0.35 g, 0.852 mmol) in DMSO/MeOH (1:1, 15 mL) was treated with TEA (1.5 mL, 10.7 mmol) and thoroughly purged with carbon monoxide, then treated with $\text{Pd}(\text{OAc})_2$ (0.191g, 0.852 mmol) and warmed to 80°C. After heating overnight, the reaction was cooled, treated with an additional amount of 1,3 di-phenyl phosphino


- 93 -

propane (0.35g, 0.852 mmol), re-purged with carbon monoxide and treated with an additional amount of Pd(OAc)₂ (0.191 g, 0.852 mmol). After heating for three days the reaction was evaporated, partitioned between water and CHCl₃, and the water layer washed with CHCl₃.

- 5 The organic layers were combined, dried over MgSO₄, filtered through a sintered glass filter and concentrated. The residue was chromatographed (silica, gradient 5% EtOAc/Hexanes to 10% EtOAc/Hexanes) to give 11-11 as a yellow oil.

R_f (20% EtOAc/Hexanes) 0.5

- 10 ¹H NMR (400 MHz, CDCl₃) δ 8.13 (s, 1H), 7.96 (d, 1H), 7.48 (d, 1H), 4.6 (bs, 2H), 3.95 (s, 3H), 3.75 (bs, 2H), 2.75 (bs, 2H), 1.5 (s, 9H).




- 15 2-(1,1-dimethylethoxycarbonyl)-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]benzofuran-7-yl carboxylic acid 11-12

A solution of 11-11 (0.79 g, 2.38 mmol) in 1:1 THF/MeOH (30 mL) was treated with LiOH (0.95 g, 23.8 mmol) in 10 mL of H₂O and heated to 30°C overnight. The solvents were removed under vacuum and the residue was dissolved in H₂O and acidified with 10% KHSO₄ and extracted with EtOAc. The organic layer was dried over MgSO₄, filtered and evaporated to give 11-12 as an off-white solid.

R_f (97:3:1 CHCl₃/MeOH/HOAc) 0.27

- 20 ¹H NMR (400 MHz, CDCl₃) δ 8.2 (s, 1H), 8.0 (d, 1H), 7.50 (d, 1H),
25 4.65 (bs, 2H), 3.8 (bs, 2H), 2.75 (bs, 2H), 1.52 (s, 9H).

- 94 -




5 Ethyl 4-(2-(1,1-dimethylethoxycarbonyl)-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]benzofuran-7-yl)carbonylamino)-3-methylphenoxy-acetate 11-13

A solution of 11-12 (0.1 g, 0.321 mmol) in CH₂Cl₂ (10 mL) was treated with oxalyl chloride (0.06 mL, 0.7 mmol) and two drops of DMF. After stirring at room temperature for 0.5 hours, the reaction was diluted with benzene and evaporated. The resulting acid chloride was dissolved in CHCl₃ (5 mL) and treated with 10-4 (0.075 g, 0.26 mmol), then cooled to 0°C and treated with diisopropylethylamine (0.167 mL, 0.3 mmol). The reaction was warmed to room temperature and stirred overnight, then evaporated, partitioned between EtOAc and 10% KHSO₄, and the EtOAc layer was washed again with 10% KHSO₄.
 15 The EtOAc layer was washed with brine, dried over MgSO₄, filtered and evaporated to give 11-13.

R_f (60% EtOAc/Hexanes) 0.64

¹H NMR (400 MHz, CDCl₃) δ 8.0 (s, 1H), 7.73 (m, 2H), 7.62 (s, 1H), 7.53 (d, 1H), 6.85 (s, 1H), 6.8 (m, 1H), 4.62 (d, 2H), 4.61 (s, 2H), 4.29 (q, 2H), 3.68 (bs, 2H), 2.75 (bs, 2H), 2.30 (s, 3H), 1.5 (s, 9H), 1.3 (t, 3H).
 20

- 95 -



5 4-(2-(1,1-dimethylethoxycarbonyl)-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]benzofuran-7-yl)carbonylamino-3-methylphenoxy acetic acid 11-14




A solution of 11-13 (0.145 g, 0.285 mmol) in 1:1 THF/MeOH (6 mL) was treated with LiOH (0.114 g, 28.5 mmol) dissolved in 6 mL of H₂O. After stirring for 1 hour at room temperature the solvents were removed, the residue dissolved in
10 H₂O/EtOAc/10% KHSO₄ and the layers separated. The water layer was washed with EtOAc, the organic layers were combined, dried, and filtered to give the intermediate acid as a yellow oil. This material was dissolved in EtOAc (10 mL), cooled to -78°C, the solution saturated with HCl gas and warmed to 0°C for 0.5 hours, then concentrated and
15 dried under vacuum to give 11-14 as fluffy solid.

R_f (9:1:1 EtOH/H₂O/NH₄OH) 0.78





¹H NMR (400 MHz, D₂O) δ 7.84 (s, 1H), 7.65 (d, 1H), 7.5 (d, 1H), 7.1 (d, 1H), 6.81 (s, 1H), 6.72 (d, 1H), 4.28 (s, 2H), 3.8 (bs, 2H), 2.96 (m, 2H), 2.6 (bs, 2H), 2.13 (s, 3H).

20

- 96 -

SCHEME 12

- 97 -

SCHEME 12 CONTINUED

- 98 -

2-Methyl-3-aminophenol (12-2)

To a 500 mL erlenmeyer flask was added sulfanilic acid (14.38 g, 83 mmol), sodium carbonate (4.29 g, 40.5 mmol) and distilled H₂O (83 mL), when all of the sulfanilic acid dissolved, the solution was
5 cooled in an ice bath to 0°C and a solution of sodium nitrite (6.16 g, 89.3 mmol) in H₂O (15 mL) was added in one portion. The ice bath was allowed to warm to +15°C and the mixture was stirred at this temperature 1 h. The reaction mixture was poured onto a mixture of ice (100 g) and 12N HCl (17.4 mL). The ice was allowed to melt and
10 the solid diazonium salt was collected by suction filtration on a scintered glass frit. *O*-cresol (9.10 g, 84.1 mmol) was dissolved in a solution of NaOH (1.21 g, 30.25 mmol) in H₂O (100 mL). This solution was cooled to 0°C and the solid diazonium salt was added in one portion. This well stirred mixture was maintained at +15°C for 4 h. The
15 temperature of the mixture was raised to +60°C and sodium dithionite (35 g, 1.03 mol) was added portionwise. The reaction was allowed to proceed at +60°C for 15 min. The mixture was cooled to room temperature, diluted with saturated aqueous NaHCO₃ and extracted with EtOAc. The EtOAc extract was dried (MgSO₄), filtered, concentrated
20 *in vacuo* and chromatographed on 100 g of silica gel using 1:3 EtOAc-hexane as eluant. There was obtained 2-methyl-3-amino-phenol as a tan solid.
¹H NMR (CDCl₃) δ 2.18 (s, 3H), 3.35 (br s, 2H), 4.24 (br s, 1H), 6.42 (m, 1H), 6.50 (m, 1H), 6.61 (d, *j*=9Hz, 1H).

4-(1,1-Dimethylethoxycarbonyl)amino-2-methylphenol (12-4)

Using a method similar to that described for compound
10-2, 4-(1,1-dimethylethoxycarbonyl)amino-2-methylphenol was prepared.
30 ¹H NMR (CDCl₃): δ 1.51 (s, 9H), 2.21 (s, 3H), 4.62 (br s, 1H), 6.22 (br s, 1H), 6.62 (m, 1H), 6.98 (m, 1H), 7.08 (br s, 1H).

- 99 -

Ethyl 4-(1,1-dimethylethoxycarbonyl)amino-2-methylphenoxyacetate (12-4)

Using a method similar to that described for compound 10-3, ethyl 4-(1,1-dimethylethoxycarbonyl)amino-2-methylphenoxyacetate was prepared.

¹H NMR (CDCl₃): δ 1.29 (t, j=7.2Hz, 3H), 1.52 (s, 9H), 2.28 (s, 3H), 4.25 (q, j=7.2Hz, 2H), 4.58 (s, 2H), 6.25 (br s, 1H), 6.65 (d, j=8.5Hz, 1H), 7.08 (br d, j=8.5Hz, 1H), 7.17 (br s, 1H).

10 Ethyl 4-amino-2-methylphenoxyacetate, hydrochloride (12-5)

Using a method similar to that described for compound 10-4, ethyl 4-amino-2-methylphenoxyacetate, hydrochloride was prepared.

15 ¹H NMR (CD₃OD): δ 1.21 (t, j=7.1Hz, 3H), 2.35 (s, 3H), 4.25 (q, j=7.1Hz, 2H), 4.81 (s, 2H), 6.95 (d, j=9Hz, 1H), 7.21 (m, 2H).

Ethyl 2-(4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenylcarbonylamino)-2-methylphenoxy)acetate (12-6)

Using a method similar to that described for compound 20 10-5, ethyl 2-(4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenylcarbonylamino)-2-methylphenoxy)acetate was prepared.

¹H NMR (DMSO-d₆): δ 1.41 (t, j=7Hz, 3H), 1.42 (s, 9H), 2.20 (s, 3H), 2.50 (m, 4H), 3.29 (m, 4H), 4.29 (q, j=7Hz, 2H), 4.78 (s, 2H), 6.80 (d, j=8.5 Hz, 1H), 7.01 (d, j=8.8Hz, 2H), 7.50 (m, 2H), 7.86 (d, j=8.8Hz, 2H), 9.68 (s, 1H).

2-(4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenylcarbonylamino)-2-methylphenoxy)acetic acid (12-7)


Using a method similar to that described for compound 30 10-6, 2-(4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenylcarbonylamino)-2-methylphenoxy)acetic acid was prepared and used in the next step without purification.

- 100 -


2-(4-(4-(1-Piperazinyl)phenylcarbonylamino)-2-methylphenoxy)acetic acid, dihydrochloride (12-8)

Using a method similar to that described for compound 10-7, 2-(4-(4-(1-piperazinyl)phenylcarbonylamino)-2-methyl-
5 phenoxy)acetic acid, dihydrochloride was prepared, mp: >250°C.
¹H NMR (D₂O): δ 2.15 (s, 3H), 3.29 (m, 4H), 3.48 (m, 4H), 4.65 (s, 2H), 6.76 (d, j=8.5Hz, 1H), 7.04 (d, j=8.6, 2H), 7.17 (m, 2H), 7.69 (d, j=8.6Hz, 2H).


- 101 -

SCHEME 13

- 102 -

SCHEME 13 CONTINUED

- 103 -



Methyl 3-methyl-4-aminobenzoate (13-2)

To a 500 mL round bottomed flask equipped with a stirring bar, reflux condenser and a drying tube was added 3-methyl-4-aminobenzoic acid (8.00 g, 52.92 mmol) and anhydrous methanol (300 mL). This solution was saturated with anhydrous HCl gas and the mixture was stirred at ambient temperature for 26 h. The methanol and HCl were removed *in vacuo* and the solid product was suspended in 400 mL of EtOAc. This mixture was made basic by careful addition of aqueous NaHCO₃ solution. The layers were separated and the organic phase was washed with brine, dried (MgSO₄), filtered and concentrated *in vacuo* to give methyl 3-methyl-4-aminobenzoate as a yellow solid.

¹H NMR (CDCl₃): δ 2.18 (s, 3H), 3.85 (s, 3H), 3.99 (br s, 2H), 6.63 (d, *j*=8.3 Hz, 1H), 7.75 (m, 3H).

- 104 -

Methyl and n-Butyl 3-methyl-4-(1-piperazinyl)benzoate (13-3)

To a 1L round bottomed flask with a stirring bar, reflux condenser, and an argon inlet was added methyl 3-methyl-4-aminobenzoate (8.74 g, 52.74 mmol), bis 2-chloroethylamine hydrochloride (9.81 g, 55.0 mmol) and n-BuOH (175 mL). This mixture was heated at reflux for 8 days. The n-BuOH was removed *in vacuo* and the residue was partitioned between EtOAc (200 mL) and 0.2N HCl (300 mL). The layers were separated and the organic phase was extracted with another 100 mL portion of 0.2 N HCl. The aqueous phases were combined and made basic with solid NaHCO₃. This mixture was extracted with EtOAc (2 x 200 mL) and the combined EtOAc extracts were washed with brine, dried (Na₂SO₄), filtered and concentrated *in vacuo* to give 10.39 g of a mixture of ethyl and n-butyl 3-methyl-4-(1-piperazinyl)benzoates. This material was used in the next step without further purification.

Methyl and n-Butyl 3-methyl-4-(1-(4-(1,1-dimethylethoxy)carbonyl)-piperazinyl)benzoates (13-4)

To a 1L round bottomed flask equipped with a stirring bar and an argon inlet was added a mixture of ethyl and n-butyl 3-methyl-4-(1-piperazinyl)benzoates (10.39 g, 44.35 mmol based on the mw of the methyl ester only; *vide supra*), di-*tert*-butyldicarbonate (14.67 g, 67.22 mmol) and dry CHCl₃ (100 mL). This solution was heated at reflux for 19 h. The cooled reaction mixture was concentrated *in vacuo* and the residue was chromatographed on silica gel (300 g) using 40% EtOAc-hexane as eluant to give 5.0 g of a mixture of methyl and n-butyl 3-methyl-4-(1-(4-(1,1-dimethylethoxy)carbonyl)piperazinyl)benzoates. This material was used in the next step without further purification.

3-Methyl-4-(1-(4-(1,1-dimethylethoxy)carbonyl)piperazinyl)benzoic acid (13-5)

The product from the preceding step, a mixture of methyl and n-butyl 3-methyl-4-(1-(4-(1,1-dimethylethoxy)carbonyl)piperazinyl)benzoates (5.00 g) was dissolved in 95% EtOH (100 mL) and

- 105 -

NaOH (10 g, 250 mmol) was added. This solution was heated at reflux for 2 h. The mixture was cooled to room temperature and the EtOH was removed *in vacuo*. The residue was dissolved in 300 mL of H₂O. This solution was washed with Et₂O (200 mL) then acidified with 10% aqueous citric acid. This mixture was extracted with EtOAc (2 x 250 mL). The combined EtOAc extracts were washed with H₂O and brine. Drying (MgSO₄), filtration and removal of the solvent *in vacuo* gave an oil. This material was chromatographed on 75 g of silica gel using 40% EtOAc-hexane as eluant. The chromatographed product was recrystallized from 15 mL of 20% EtOAc-hexane to give 228 mg of 3-methyl-4-(1-(4-(1,1-dimethylethoxy)carbonyl)piperazinyl)benzoic acid as white crystals.

¹H NMR (CDCl₃): δ 1.49 (s, 9H), 2.35 (s, 3H), 2.94 (m, 4H), 3.59 (m, 4H), 6.99 (d, *j*=8Hz, 1H), 7.92 (m, 2H), 11.65 (br s, 1H).

15

4-(1,1-Dimethylethoxycarbonylamino)phenol (13-7)

To a 500 mL round bottomed flask with a stirring bar, reflux condenser and an argon inlet was added 4-aminophenol (10.00 g, 91.63 mmol), di-*tert*-butyldicarbonate (20.00 g, 91.63 mmol) and dry CHCl₃ (250 mL). This solution was heated at reflux for 6 h. The mixture was cooled in an ice bath and the product was collected by filtration. The product was washed with a little cold CHCl₃ and dried *in vacuo* to give 16.43 (86%) of 4-(1,1-dimethylethoxycarbonylamino)phenol as white crystals, mp: 142-143°C.

¹H NMR (CDCl₃): δ 1.51 (s, 9H), 5.27 (br s, 1H), 6.34 (br s, 1H), 6.72 (d, *j*=8Hz, 2H), 7.16 (d, *j*=8Hz, 2H).

25

Ethyl (4-(1,1-dimethylethoxycarbonylamino)phenoxy)acetate (13-8)

To a 500 mL round bottomed flask with a stirring bar and an argon inlet was added 4-(1,1-dimethylethoxycarbonylamino)phenol (8.20 g, 39.19 mmol), Cs₂CO₃ (25.54 g, 78.38 mmol), DMF (75 mL), and ethyl bromoacetate (4.78 mL, 43.11 mmol). This heterogeneous mixture was stirred at ambient temperature for 3.5 h. The mixture was diluted with a little CHCl₃ and filtered through a frit to remove the

30

- 106 -

salts. The DMF was removed under high vacuum and the residue was suspended in 500 mL of EtOAc. This mixture was washed with H₂O (3x), and brine. Drying (MgSO₄), filtration and removal of the solvent *in vacuo*, gave an oil. This material was chromatographed on 400g of silica gel using 20% EtOAc-hexane as eluant. There was obtained 11.9 g (100%) of ethyl (4-(1,1-dimethylethoxycarbonyl-amino)phenoxy)acetate as an oil.

¹H NMR (CDCl₃): δ 1.29 (t, j=6.4Hz, 3H), 1.50 (s, 9H), 4.25 (q, j=6.4Hz, 2H), 4.57 (s, 2H), 6.36 (br s, 1H), 6.84 (d, j=8Hz, 2H), 7.26 (d, j=8Hz, 2H).

Ethyl 4-aminophenoxyacetate, hydrochloride (13-9)

To a 500 mL round bottomed flask with a stirring bar and a gas dispersion tube was added ethyl (4-(1,1-dimethylethoxycarbonyl-amino)phenoxy)acetate (11.9 g, 40.29 mmol) and dry EtOAc. This solution was cooled in an ice bath and saturated with anhydrous HCl gas over 15 min. The resulting suspension was aged 30 min. at 0°C. The excess HCl was removed with a stream of argon and the EtOAc was removed *in vacuo*. The solid product was triturated with EtOAc, collected on a frit, and dried *in vacuo* at room temperature to give 7.33 g (78%) of ethyl 4-aminophenoxyacetate, hydrochloride as a white crystalline solid.

¹H NMR (DMSO-d₆): δ 1.211 (t, j=6.4Hz, 3H), 4.16 (q, j=6.4Hz, 2H), 4.82 (s, 2H), 7.05 (d, j=8Hz, 2H), 7.34 (d, j=8Hz, 2H), 10.27 (br s, 3H).
Ethyl 2-(4-(4-(3-methyl-4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenylcarbonylamino)phenoxy)acetate (13-10)

In a manner similar to that described for compound 10-5, using acid 13-5 and aniline 13-8, ethyl 2-(4-(4-(3-methyl-4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenyl-carbonylamino)-phenoxy)acetate was prepared.


¹H NMR (CDCl₃): δ 1.29 (t, j=7.0Hz, 3H), 1.48 (s, 9H), 2.37 (s, 3H), 2.95 (m, 4H), 3.59 (m, 4H), 4.25 (q, j= 7.Hz, 2H), 4.61 (s, 2H), 6.95 (d, j=8.5Hz, 2H), 7.03 (d, j=8.5Hz, 1H), 7.55 (d, j=8.5Hz, 2H), 7.62 (m, 2H).

- 107 -

2-(4-(4-(3-Methyl-4-(1-piperazinyl)phenylcarbonylamino)phenoxy)acetic acid (13-11)

To a 100 mL round bottomed flask with a stirring bar was added ethyl 2-(4-(4-(3-methyl-4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenylcarbonylamino)phenoxy)acetate (311 mg, 0.63 mmol),
5 MeOH (5 mL), THF (20 mL), and 1N LiOH (20 mL). This solution was stirred at ambient temperature for 24 h. The solvents were removed *in vacuo* and the residue was acidified with 10% aqueous citric acid. This mixture was extracted with EtOAc. The EtOAc extract was
10 dried (MgSO₄), filtered and cooled to 0°C in an ice bath. This solution was saturated with dry HCl gas and aged 30 min. at 0°C. The excess HCl was removed with a stream of argon and the solvent was removed *in vacuo*. The product was purified by preparative reverse phase HPLC using a H₂O-CH₃CN gradient on a Waters C-18 column. Obtained 105
15 mg of 2-(4-(4-(3-methyl-4-(1-piperazinyl)phenylcarbonylamino)phenoxy)acetic acid as a white solid.
¹H NMR (D₂O): δ 2.28 (s, 3H), 3.17 (m, 4H), 3.35 (m, 4H), 4.55 (s, 2H), 6.94 (d, j=7.5Hz, 2H), 7.12 (d, j=8.2Hz, 1H), 7.33 (d, j=7.5Hz, 2H), 7.63 (m, 2H).

- 108 -

SCHEME 14

- 109 -

1-Nitrophenyl-4-(1,1-dimethylethoxycarbonyl)piperazine (14-2)

To a 200 mL round bottomed flask was added 1-nitrophenylpiperazine (5.01 g, 24.2 mmol), di-*tert*-butyldicarbonate (5.85 g, 26.8 mmol), triethylamine (3.87 mL, 27.8 mmol), and dry THF (100 mL). This solution was heated at reflux for 18 h. The mixture was cooled to room temperature and the solvents were removed *in vacuo*. The residue was dissolved in EtOAc and washed with 10% aqueous citric acid, H₂O, and brine. Drying (MgSO₄), filtration, and removal of the solvent *in vacuo* gave 7.7 g of 1-nitrophenyl-4-(1,1-dimethylethoxycarbonyl)piperazine as a yellow solid.

¹H NMR (CDCl₃): δ 1.42 (s, 9H), 3.41 (m, 4H), 3.62 (m, 4H), 6.81 (d, j=8.5Hz, 2H), 8.16 (d, j=8.5Hz, 2H).

4-(4-(1,1-Dimethylethoxycarbonyl)piperazin-1-yl)aniline (14-3)

To a 250 mL Parr hydrogenation bottle was added 1-nitrophenyl-4-(1,1-dimethylethoxycarbonyl)piperazine (4.5 g, 16.34 mmol), EtOAc (81 mL), MeOH (27 mL), and 5% Pd-C (0.18 g). This mixture was hydrogenated under 45 psig H₂ at ambient temperature for 24 h. The mixture was filtered through a celite pad and the solvents were removed *in vacuo*. The residue was chromatographed on 250 g of silica gel using 70% EtOAc-hexane as eluant. There was obtained 3.43 g of 4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)aniline as a yellow solid.

¹H NMR (CDCl₃): δ 1.49 (s, 9H), 2.98 (m, 4H), 3.49 (br s, 2H), 3.57 (m, 4H), 6.66 (d, j=9Hz, 2H), 6.82 (d, j=9Hz, 2H).

N-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenyl)-4-hydroxybenzamide (14-4)

To a 100 mL round bottomed flask with a stirring bar and an argon inlet was added 4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)aniline (0.868 g, 3.13 mmol), 4-hydroxybenzoic acid (0.525 g, 3.80 mmol), chloro-N,N,N',N'-bis(pentamethylene)formamidinium hexafluorophosphate (1.35 g, 3.74 mmol), and CH₂Cl₂ (45 mL). This mixture was cooled in an ice bath and diisopropylethylamine (0.96 mL,

- 110 -

5.52 mmol) was added. The ice bath was allowed to expire and the mixture was stirred at ambient temperature 18 h. The mixture was diluted with EtOAc and washed with 10% aqueous citric acid, water and brine. Drying (MgSO₄), filtration and removal of the solvent *in vacuo* gave an oil. This material was chromatographed on 100 g of silica gel using 70% EtOAc-hexane as eluant to give 0.57 g of N-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenyl)-4-hydroxybenzamide as a grey solid.

¹H NMR (CDCl₃): δ 1.48 (s, 9H), 3.01 (m, 4H), 3.48 (m, 4H), 6.82 (d, J=9Hz, 2H), 6.85 (d, j=9Hz, 2H), 7.58 (d, j=8Hz, 2H), 7.81 (d, j=8Hz, 2H), 9.80 (br s, 1H), 10.01 (br s, 1H).

tert-Butyl 4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenylaminocarbonyl)phenoxyacetate (14-5)

To a 100 mL round bottomed flask with a stirring bar and an argon inlet was added N-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenyl)-4-hydroxybenzamide (0.56 g, 1.41 mmol) DMF (35 mL), Cs₂CO₃ (0.49 g, 1.51 mmol) and *tert*-butyl bromoacetate (0.28 mL, 1.75 mmol). This mixture was stirred at ambient temperature for 18 h. The mixture was diluted with EtOAc and washed with H₂O and brine. Drying (MgSO₄), filtration and removal of the solvent *in vacuo* gave 0.78 g of *tert*-butyl 4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenylaminocarbonyl)phenoxyacetate which was used in the next step without purification.

¹H NMR (DMSO-d₆): δ 1.48 (s, 9H), 1.49 (s, 9H), 3.02 (m, 4H), 3.39 (m, 4H), 4.78 (s, 2H), 6.88 (d, j=9Hz, 2H), 7.02 (d, j=9Hz, 2H), 7.62 (d, j=8Hz, 2H), 7.82 (d, j=8Hz, 2H), 9.82 (br s, 1H).

4-(4-(Piperazin-1-yl)phenylaminocarbonyl)phenoxyacetic acid (14-6)





To a 100 mL round bottomed flask with a stirring bar and a gas dispersion tube was added *tert*-butyl 4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenylaminocarbonyl)phenoxyacetate (0.78 g, 1.52 mmol) and EtOAc (40 mL). This solution was cooled in an ice bath and HCl gas was sparged through the solution for 15 min. The

- 111 -


resulting mixture was aged 90 min. The excess HCl and EtOAc were removed *in vacuo* and the crude product was purified by preparative reverse phase HPLC. There was obtained 0.218 g of 4-(4-(piperazin-1-yl)phenylaminocarbonyl)phenoxyacetic acid as a crystalline solid.

- 5 ^1H NMR (0.1N NaOD-D₂O): δ 2.99 (m, 4H), 3.15 (m, 4H), 4.59 (s, 2H), 7.03 (d, $j=9\text{Hz}$, 2H), 7.16 (d, $j=9\text{Hz}$, 2H), 7.737 (d, $j=8\text{Hz}$, 2H), 7.88 (d, $j=8\text{Hz}$, 2H).

- 112 -

SCHEME 1515-115-215-315-415-5

- 113 -

SCHEME 15 CONTINUED





- 114 -

2-(4-(4-(1-Piperazinyl)phenylcarbonylamino)-3,5-dimethyl-
phenoxy)acetic acid, dihydrochloride (15-8)


Using a -sequence essentially the same as described for
compound 12-8, but starting with 3,5-dimethylphenol (15-1), 2-(4-(4-
5 (1-piperazinyl)phenylcarbonylamino)-3,5-dimethylphenoxy)acetic acid,
dihydrochloride was prepared, mp: >250°C.

¹H NMR (D₂O): δ 2.15 (s, 6H), 3.32 (m, 4H), 3.54 (m, 4H), 4.64 (s,
2H), 6.72 (s, 2H), 7.12 (d, j=8.6, 2H), 7.17 (m, 2H), 7.83 (d, j=8.6Hz,
2H).


- 116 -



- 117 -

16-24-(4-Pyridinyl)benzoic acid (16-2)

- A slurry of 16-1 (5 g, 29.6 mmol, prepared as described in Chambron, J.C; Sauvage, J.P., *Tetrahedron*, 1987, 895 and Comins, D.L.; Abdullah, A.H., *J. Org. Chem.*, 1982, 47, 4315 method B) in 200 mL H₂O was treated with 10% HCl until the solids dissolved. The solution was treated with solid KMnO₄ in portions (11.2 g, 888 mmol), stirred until the KMnO₄ had dissolved and heated to 90°C for 18hr.
- 10 An additional 2 g of KMnO₄ was added and the reaction was again heated to 90°C for 2 hr. The reaction was cooled to ~60°C, filtered and the solids were washed with warm water. The filtrate was evaporated and the residue chromatographed (Silica gel, 10:1:1 EtOH/H₂O/NH₄OH) to give 16-2 as an off-white solid.
- 15 ¹H NMR (400 MHz, DMSO) δ 8.61 (m, 2H), 8.0 (m, 2H), 7.72 (m, 4H).

16-34-(1-(1,1-Dimethylethoxycarbonyl)piperidin-4-yl)benzoic acid (16-3)

- 20 A solution of 16-2 (0.5 g, 2.5 mmol) in 20 mL 20% HOAc/MeOH was treated with 250 mg PtO₂ and hydrogenated at 50 psi for 4 hr. The solution was filtered through Solka Floc, evaporated and azeotroped with heptane to remove excess HOAc. The intermediate amino acid acetic acid salt was obtained as a white solid.
- 25 R_f (10:1:1 EtOH/H₂O/NH₄OH) 0.3.


- 118 -

¹H NMR (400 MHz, CD₃OD) δ 8.96 (m, 2H), 7.35 (m, 2H), 3.5 (bd, 2h), 3.4 (m, 2H), 3.2 (m, 2H), 3.0 (m, 2H).

A slurry of the amino acid (0.5 g, 1.9 mmol) in 30% H₂O/dioxane (12 mL) was treated with 1 N NaOH (4.8 mL) and
 5 ditertbutyldicarbonate (0.564 g, 2.58 mmol) at room temperature for 6 hr. The reaction was acidified to pH 5 with 10% KHSO₄ and extracted several times with EtOAc. The EtOAc layers were combined and evaporated to give 16-3 as a white solid.

R_f (97:3:1 CHCl₃/MeOH/HOAc) 0.39.

10 ¹H NMR (400 MHz, CD₃OD) δ 7.95 (d, 2H), 7.33 (d, 2H), 4.2 (bd, 2H), 2.85 (b, 3H), 1.8 (bd, 2H), 1.6 (m, 2H), 1.48 (s, 9H).




15 Ethyl 2-(4-(4-(1-(1,1-Dimethylethoxycarbonyl)piperidin-4-yl)phenylcarbonyl amino)-3-methylphenoxy)acetate (16-4)

A slurry of 16-3 (0.15g, 0.49 mmol) and 10-4 (0.12g, 0.49 mmol) in CH₂Cl₂ was treated with chloro-N,N,N',N',-bis(pentamethylene)formamidinium hexafluorophosphate (0.194g, 0.54 mmol) and diisopropylethyl amine (0.34 mL, 1.96 mmol) and stirred at
 20 room temperature for 24 hours. The solution was diluted with EtOAc and washed with H₂O, 10% citric acid, saturated NaHCO₃ and brine, dried over MgSO₄, filtered and evaporated. The residue was
 25 chromatographed (silica gel 50% EtOAc/Hexanes) then triturated with ether/hexanes to give 16-4.

R_f(50% EtOAc/Hexanes) 0.33.

¹H NMR (400 MHz, CDCl₃) δ 7.81 (2s, 2H), 7.70 (d, 1H), 7.50 (s, 1H), 7.31 (2s, 2H), 6.8 (m, 2H), 4.6 (s, 2H), 4.28 (q, 2H), 2.8 (m, 2H), 2.72 (m, 1H), 2.30 (s, 3H), 1.85 (bd, 2H), 1.75 (m, 2H), 1.48 (s, 9H) 1.3 (t, 3H).
 30


- 119 -



2-(4-(4-(Piperidin-4-yl)phenyl)carbonylamino)-3-methylphenoxy)
acetate (16-5)


- 5 A solution of 16-4 (0.1g, 0.2 mmol) in 1:1:1 THF/MeOH/H₂O was treated with LiOH (0.084g, 2 mmol) at room temperature. After 1 hour the reaction was diluted with EtOAc and 10% KHSO₄ and the layers were separated. The organic layer was washed with H₂O, brine, dried with MgSO₄, filtered and evaporated to
- 10 give the acid as a clear oil.
R_f(9:1:1 CH₂Cl₂/MeOH/HOAc) 0.57.
¹H NMR (400 MHz, CD₃OD) δ 7.94 (2s, 2H), 7.44(2s, 2H), 7.2 (d, 1H), 6.90 (m, 1H), 6.8 (m, 1H), 4.62 (s, 2H), 4.24 (bd, 2H), 2.9 (b, 2H), 2.83 (m, 1H), 2.28 (s, 3H), 1.86 (bd, 2H), 1.7-1.6 (m, 2H), 1.5 (s, 9H).
- 15 A slurry of the intermediate acid (0.9 g, 1.19 mmol) was cooled to -78°C and saturated with HCl gas. The reaction was warmed to 0°C, then concentrated *in vacuo* to give 16-5 as the HCl salt.
R_f (10:1:1 EtOH/H₂O/NH₄OH) 0.81.
¹H NMR (400 MHz, CD₃OD) δ 7.94 (2s, 2H), 7.44 (2s, 2H), 7.2 (d,
- 20 1H), 6.90 (m, 1H), 6.8 (m, 1H), 4.65 (s, 2H), 3.52 (bd, 2h), 3.15 (bt, 2H), 3.05 (m, 1H), 2.12 (bd, 2H), 1.97 (m, 2H).

- 120 -




Ethyl 2-(4-(4-(Pyridin-4-yl)phenylcarbamoyl)-3-methylphenoxy)acetate (16-6)

- 5 16-2 (0.5 g, 2.5 mmol) and Ethyl 2-acetoxy-4-amino benzene hydrochloride (13-9) (0.579 g, 2.5 mmol) were coupled as described for 16-4 to give 16-6 after chromatography (silica gel, 5% MeOH/EtOAc) followed by reverse phase preparative HPLC.
- 10 ¹H NMR (400 MHz, CD₃OD) δ 8.82 (d, 2H), 8.30 (d, 2H), 8.15 (d, 2H), 8.05 (d, 2H), 7.60 (d, 2H), 6.98 (d, 2H), 4.70 (s, 2H), 4.23 (q, 2H), 1.30 (t, 3H).




- 15 2-(4-(4-(Pyridin-4-yl)phenylcarbamoyl)phenoxy)acetic acid (16-7)
- 16-6 was treated with LiOH as described for 16-5 to give 16-7 after chromatography (silica gel, 10:1:1 EtOH/H₂O/NH₄OH) followed by preparative reverse phase HPLC.
- R_f (10:1:1 EtOH/H₂O/NH₄OH) 0.76.
- 20 ¹H NMR (400 MHz, DMSO) δ 8.65 (d, 2H), 8.10 (d, 2H), 7.96 (d, 2H), 7.8 (d, 2H), 7.65 (d, 2H), 6.90 (d, 2H), 4.58 (bs, 2H).


- 121 -

SCHEME 17


- 122 -

SCHEME 17 (CONT'D)

- 124 -

17-12-Amino-4-(4-methylphenyl)pyridine (17-1)


NaNH₂ (142 mmol) was prepared *in situ* as described in Leffler, M.T. *Organic Reactions* 1942 Vol. I. Dimethylaniline (20 ml) was added dropwise to the freshly prepared NaNH₂. 16-1 (8.0 g, 47.3 mmol) was dissolved in a small amount of dimethylaniline and added to the mixture. The slurry was heated to 160° for 2 hours. The reaction mixture is cooled and diluted with 10% KHSO₄ and water. The layers are separated, and the dimethylaniline layer is washed with 10% KHSO₄. The aqueous layers are combined, basified with saturated NaHCO₃, and extracted with EtOAc (3x). The combined organic layers are washed w/brine and concentrated to yield an oily solid. This oily solid was purified by flash chromatography (5% MeOH/EtOAc) to give 17-1 as a tan solid. R_f (5% MeOH/EtOAc) 0.36. ¹H NMR (400 MHz, DMSO-d₆) δ 7.9 (d, 1H), 7.5 (d, 2H), 7.3 (d, 2H), 6.7 (d, 1H), 6.6 (s, 1H), 5.9 (d, 1H), 2.3 (s, 3H).

17-22-(1,1-Dimethylethoxycarbonylamino)-4-(4-methylphenyl)pyridine (17-2)

17-1 is dissolved in dichloroethane (30 mL) and added dropwise, rapidly to a refluxing solution of Boc₂O in dichloroethane (10 mL). After the addition, the reaction is refluxed for 30 min, then stirred at RT overnight. The reaction mixture is cooled and

- 125 -


concentrated to yield a yellow solid, which is purified by chromatography (silica, 30% EtOAc/Hexane) to give 17-2 as a white solid. R_f (50% EtOAc/Hex) 0.73. ^1H NMR (400 MHz, CDCl_3) δ 8.3 (d, 1H), 8.2 (s, 1H), 7.5-7.6 (m, 4H), 7.3 (bs, 1H), 7.1 (d, 1H), 2.3 (s, 3H), 1.5 (s, 9H)



2-(1,1-Dimethylethoxycarbonylamino-4-(4-dibromomethylphenyl)pyridine (17-3)

- 10 17-2 (1.0 g, 3.5 mmol) is dissolved in CCl_4 . NBS (1.3 g; 7.3 mmol) is added, followed by AIBN (28.7 mg, 0.18 mmol). The reaction is heated to reflux while shining a white light directly on the flask. After 2 hours, AIBN (28.7 mg) is added, the light is turned off, and the reaction is stirred overnight to effect completion to product.
- 15 The reaction mixture is cooled and the succinimide is filtered off, washing the solids with CCl_4 . The filtrate is concentrated to give 17-3 as a brown solid which is used in the next step without further purification. R_f (50% EtOAc/Hex) 0.70. ^1H NMR (400 MHz, CDCl_3) δ 8.3 (d, 1H), 8.2 (s, 1H), 7.7 (m, 3H), 7.2 (bs, 1H), 7.1 (d, 1H), 6.7 (s, 1H), 1.5 (s, 9H).
- 20

- 126 -




4-(2-(1,1-Dimethylethoxycarbonylamino)pyrid-4-yl)
benzaldehyde (17-4)

5 17-3 (1.5 g, 34 mmol) is dissolved in water/THF (15 mL/45 mL). AgNO₃ (1.1 g, 6.8 mmol) is added and stirred for 1/2 hour. The reaction mixture is diluted w/EtOAc and water. The layers are separated and the organic layer is filtered to remove the solids. The filtrate is washed w/brine, dried (MgSO₄), filtered and concentrated to

10 yield a brown solid. The solid is purified on a "plug" of silica, eluting first w/50% EtOAc/hexane, then 100% EtOAc to elute all of the product. The fractions are concentrated to give 17-4 as a brown solid. R_f (50% EtOAc/Hexane)0.62. ¹H NMR (400 MHz, CDCl₃) δ 10.1 (s, 1H), 8.29 (d,1H), 8.26 (s,1H), 8.0 (d,2H), 7.8 (d, 2H), 7.5 (bs, 1H), 7.2

15 (d,1H), 1.5 (s, 9H).



20 4-(2-(1,1-Dimethylethoxycarbonylamino)pyrid-4-yl)
benzoic acid (17-5)


17-4 (1.0 g, 3.4 mmol) is slurried in CH₃CN (40 mL). 10% KHSO₄ (1.3 mL) and 30% H₂O₂ (0.957 mL) are added and the solution is cooled in an ice bath. NaClO₂ (8.5 mmol, 770 mg) is added dropwise in 50 mL water over 20 min. The reaction is stirred for 16

25 hrs. The reaction mixture is diluted w/EtOAc and washed with saturated NaHCO₃ (2x). The aqueous layers are combined, acidified

- 127 -

with 10% KHSO₄, and extracted w/CH₂Cl₂ (2x) and EtOAc (2x) to give 17-5 as a yellow solid. ¹H NMR (400MHz, DMSO-d₆) δ 12.6-12.8 (bs, 1H), 9.9 (s, 1H), 8.3 (d, 1H), 8.0-8.1 (m, 3H), 7.9 (d, 2H), 7.3 (d, 1H), 1.5 (s, 9H).


5



Ethyl 2-(4-(4-(2-(1,1-Dimethylethoxycarbonylamino)pyrid-4-yl)carbonylamino)phenoxy)acetate (17-6)


- 10 A mixture of 17-5 (300 mg, 0.956 mmol), 13-9 (0.956 mmol, 236 mg), diisopropylethylamine (3.8 mmol, 0.66 mL), PYCLU (1.05 mmol, 378 mg), and CH₂Cl₂ (10 ml) is stirred at RT for 16 hours. The reaction mixture is diluted with EtOAc and washed with saturated NaHCO₃ and Brine. The Organic layer is dried (MgSO₄),
- 15 filtered and concentrated to yield a pink solid. Triturations with hexanes followed by flash chromatography (silica, 30% EtOAc/Hex) afforded 17-6 as a white solid. R_f (30% EtOAc/Hexanes) 0.24. ¹H NMR (400 MHz, CDCl₃) δ 8.3 (d, 1H), 8.2 (s, 1H), 7.9 (d, 2H), 7.8 (2d, 3H), 7.4 (bs, 1H), 7.6 (bs, 1H), 7.2 (d, 1H), 6.8 (s, 1H), 6.7 (d, 1H), 4.6 (s,
- 20 2H), 4.3 (q, 2H), 2.3 (s, 3H), 1.5 (s, 9H), 0.9 (t, 3H).

- 128 -




2-(4-(4-(2-(1,1-Dimethylethoxycarbonylamino)pyrid-4-yl)carbonylamino)phenoxy)acetic acid (17-7)

- 5 A mixture of 17-6 (0.17 mmol, 90 mg), LiOH (0.60 mmol, 25 mg), and THF/H₂O/MeOH/ (1 mL/1 mL/1 mL) is stirred for 2 hours. The reaction mixture is diluted with EtOAc and 10% KHSO₄. The aqueous layer is back-extracted with EtOAc. The organic layers are combined, washed with brine, dried (MgSO₄), filtered and
- 10 concentrated to yield 17-7 as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 8.3 (d, 1H), 8.1 (bd, 3H), 7.9 (d, 2H), 7.5 (bs, 1H), 7.2 (s, 1H), 6.9 (s, 1H), 6.8 (d, 1H), 4.7 (s, 2H), 2.3 (s, 3H), 1.5 (s, 9H).




- 15 2-(4-(4-(2-Aminopyrid-4-yl)carbonylamino)phenoxy)acetic acid (17-8)
- 17-7 (0.14 mmol, 70 mg) is dissolved in EtOAc (3 mL) and cooled to -78°. HCl (g) is bubbled through until the solution is saturated. The reaction is stirred at 0° for 3 hours, then at 35° for 16
- 20 hours. The reaction mixture is concentrated to yield a tan solid, which is purified by flash chromatography (10/0.25/0.25 EtOH/NH₄OH/H₂O) to yield 17-8 as an off white solid. R_f (10/0.5/0.5/0.5 EtOH/NH₄OH/H₂O) 0.86. ¹H NMR (400MHz, DMSO-d₆) δ 9.8 (s, 1H), 8.0 (d, 2H), 7.9 (d, 1H), 7.7 (d, 2H), 7.2 (d, 1H), 6.9 (m, 2H), 6.8
- 25 (m, 2H), 6.0 (d, 1H), 2.2 (s, 3H).


- 129 -

SCHEME 18

- 130 -


SCHEME 18 (CONT'D)

- 131 -



4-(3(R)-((N-benzyl)pyrrolidinyl)amino)phenyl nitrile (18-1)

5 A solution of N-benzyl-3-(R)-aminopyrrolidine (TCI, 0.45 g, 2.27 mmol) in 1 mL acetonitrile was treated with 4-fluorophenylcyanide (Aldrich, 3 g, 25.5 mmol) and heated to 100°C. The acetonitrile was allowed to evaporate and the slurry was heated for 18 hours. Additional 4-fluorophenylcyanide (1 g) was added and the reaction heated for 18 hours. The oily mixture was absorbed onto silica
10 gel and eluted first with 20% EtOAc/Hexanes, then with 5% MeOH/CHCl₃ saturated with NH₃ to give 18-1.
R_f (5% MeOH/CHCl₃ saturated with NH₃) 0.55.
¹H NMR (400 MHz, CDCl₃) δ 7.4 (d, 2H), 7.3 (m, 5H), 6.5 (d, 2H), 4.45 (bd, 1H), 4.0 (m, 1H), 3.64 (s, 2H), 2.83 (m, 1H), 2.75 (dd, 1H),
15 2.6 (dd, 1H), 2.43 (m, 1H), 2.34 (m, 1H), 1.6 (m, 1H).



Methyl 4-(3(R)-((N-benzyl)pyrrolidinyl)amino)benzoate (18-2)

20 A solution of 18-1 (0.52 g, 1.87 mmol) in dioxane (10 mL) and 1:1 H₂O/concentrated H₂SO₄ (10 mL) was heated to 100°C for 18 hours. The solvent was removed *in vacuo* and the residue dissolved in MeOH (30 mL) and stirred for 4 days. The solvent was removed and


- 132 -

the residue taken up in saturated NaHCO_3 and 1N NaOH to give a pH of 10, then extracted with chloroform. The organic extracts were combined, evaporated and the residue chromatographed in a gradient of 20-30% EtOAc/Hexanes to give 18-2 as a clear oil.

5 $R_f = (50\% \text{ EtOAc/Hexanes})$ 0.31.

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.45 (d, 2H), 7.30 (m, 5H), 4.35 (bd, 1H), 4.05 (m, 1H), 3.34 (s, 3H), 3.63 (s, 2H), 2.8 (m, 2H), 2.58 (dd, 1H), 2.45 (dd, 1H), 2.84 (m, 1H), 1.65 (m, 1H).

10




Methyl 4-(3-(R)-(1-(1,1-dimethylethoxycarbonyl)pyrrolidinyl)amino)benzoate (18-3)

15 A suspension of 18-2 (0.29 g, 0.93 mmol) and 10% Pd/C (0.068 g, 23% by weight) in CH_3OH (7 ml) was stirred under hydrogen atmosphere for 48 hours. The mixture was filtered through Solka Floc, and solvent removed. The residue was dissolved in CH_2Cl_2 (5 ml) and treated with Et_3N (0.65 ml, 4.7 mmol) and BOC_2O (0.45 g, 2.1 mmol). The reaction mixture was stirred 1 h at room temperature, then diluted
20 with EtOAc and washed with 10% KHSO_4 and brine, dried (Na_2SO_4), and the solvent removed. The residue was purified by flash chromatography on silica gel, eluting with EtOAc (1)/hexane (1) to provide 18-3 as an oil.

$R_f = 0.3$ (silica gel, EtOAc (3)/hexane (2)).

25 $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 1.47 (9H, s), 1.92 (1H, s), 2.20 (1H, q), 3.25 (3H, s), 4.11 (1H, m), 4.19 (1H, m), 6.55 (2H, d), 7.87 (2H, d).


- 133 -



Ethyl 2-(3-methyl-4-(4-(3-(R)-((1-(1,1-dimethylethoxycarbonyl)pyrrolidinyl)amino)phenylcarbonylamino)phenoxy)acetic acid (18-4)

- 5 A solution of 18-3 (0.245 g, 0.76 mmol) in dioxane (4 ml) was treated with 1N NaOH (3.0 ml, 3.0 mmol) at room temperature for 1 h. A second portion of 1N NaOH (3.0 ml, 3.0 mmol) was then added, and the reaction mixture was stirred for 15 h. The solution was then adjusted to pH 7 with 1N HCl and the solvent removed. The residue was
- 10 suspended in CH₂Cl₂ (6 ml) and treated with 10-4 (0.19 g, 0.77 mmol), diisopropylethylamine (0.53 mmol, 3.0 mmol), and PYCLU (Fluka, 0.30 g, 0.83 mmol). The reaction mixture was stirred for 48 h at room temperature, then solvent was removed and the residue was purified by flash chromatography on silica gel, eluting with EtOAc (3)/hexane (2)
- 15 to give 18-4 as an oil.
 R_f=0.2 (silica gel, EtOAc (3)/hexane (2)).
 ¹H NMR (400 MHz, CDCl₃) δ 1.30 (3H, t), 1.47 (9H, s), 1.93 (1H, s), 2.24 (1H, m), 2.28 (3H, s), 3.27 (1H, m), 3.49 (2H, m), 3.73 (1H, m), 4.11 (2H, m), 4.16 (1H, m), 4.29 (2H, q), 4.60 (2H, s), 6.62 (2H, d),
- 20 6.77 (1H, d), 6.81 (1H, s), 7.41 (1H, s), 7.68 (1H, d), 7.73 (2H, d).

- 134 -




5 2-(3-Methyl-4-(4-(3(R)-(pyrrolidinyl)amino)phenylcarbonylamino)phenoxy)acetic acid (18-5)

A solution of 18-4 (0.216 g, 0.434 mmol) in EtOAc (10 ml) was cooled to -78°C and treated with HCl (g) for 1.5 min. The reaction mixture was stirred at 0°C for 1 h and then solvent was removed. The residue taken up in THF (1)/CH₃OH (1)/H₂O (1) (6 ml) and treated with LiOH·H₂O (0.11g, 2.6 mmol) at room temperature for 2.5 h. The solvent was removed and the residue was purified by flash chromatography on silical gel eluting with EtOH (18)/H₂O (1)/NH₄OH (1) to afford 18-5 as a white solid.


R_f=0.2 (silica gel, EtOH (18)/H₂O (1)/NH₄OH (1)).

15 ¹H NMR (400 MHz, D₂O) δ 1.57 (1H, m), 2.06 (1H, m), 2.08 (3H, s), 2.60 (1H, m), 2.76 (1H, m), 2.86 (1H, m), 3.03 (1H, m), 3.93 (1H, m), 4.38 (2H, s), 6.71 (3H, m), 6.80 (1H, s), 7.05 (1H, d), 7.66 (2H, d).


- 135 -

SCHEME 19

- 136 -

SCHEME 19 (CONT'D)

- 137 -




N-benzyl-3-(R)-((1,1-dimethylethoxycarbonyl)amino)pyrrolidine (19-1)

5 A solution of N-benzyl-3-(R)-aminopyrrolidine (TCI, 5.00 g, 28.4 mmol) in CH₂Cl₂ (100 ml) was treated with Boc₂O (6.80 g, 31.2 mmol) and Et₃N (7.9 ml, 57 mmol). The reaction was stirred at room temperature for 15 h, then solvent was removed. The residue was purified by flash chromatography on silica gel eluting with EtOAc

10 R_f=0.4 (silica gel, EtOAc (1)/ hexane (1)).

¹H NMR (400 MHz, CDCl₃) δ 1.43 (9H, s), 1.60 (1H, m), 2.27 (2H, m), 2.51 (1H, m), 2.62 (1H, m), 2.76 (1H, m), 3.58 (2H, s), 4.13 (1H, m), 4.89 (1H, m), 7.29 (5H, m).



15

4-((3-(R)-((1,1-Dimethylethoxycarbonyl)amino)pyrrolidin-1-yl)phenyl)nitrile (19-2)

20 A suspension of 19-1 (7.43 g, 26.9 mmol) and 10% Pd/C (2.45 g, 33% by weight) in CH₃OH (150 ml) was stirred under H₂ (g) atmosphere for 5 h. The reaction mixture was filtered through a pad of Solka Floc, and the solvent was removed. The residue was dissolved in CH₃CN (20 ml) and treated with 4-fluorobenzonitrile (16.1 g, 133 mmol) at 70°C for 18 h. The reaction mixture was then cooled to room


25 temperature and the solvent was removed. The residue was purified by

- 138 -

flash chromatography on silica gel eluting with EtOAc (1)/hexane (1) to afford 19-2 as a white solid.

R_f=0.4 (silica gel, EtOAc (2)/hexane (3)).

¹H NMR (400 MHz, CDCl₃) δ 1.45 (9H, s), 1.99 (1H, m), 2.30 (1H, m),
5 3.18 (1H, m), 3.46 (2H, m), 3.62 (1H, m), 4.36 (1H, b), 4.67 (1H, b),
6.52 (2H, d), 7.47 (2H, d).

19-3


10 Methyl 4-((3-(R)-(1,1-dimethylethoxycarbonyl)amino)pyrrolidin-1-yl)-benzoate (19-3)

A solution of 19-2 (1.48 g) in dioxane (25 ml) and H₂SO₄ (1)/H₂O (1) (25 ml) was heated at 70°C for 15 h. The reaction mixture was then concentrated to remove the dioxane, diluted with CH₃OH (100
15 ml), heated at 60°C for 2 h, and stirred at room temperature for 48 h. The reaction mixture was concentrated to remove the CH₃OH, and the residue adjusted to pH 10 with 6N NaOH and sat. NaHCO₃. The aqueous mixture was then extracted with CH₂Cl₂, and the organic
20 extracts concentrated to afford an oil. This residue was dissolved in CH₂Cl₂ (25 ml) and treated with Boc₂O (2.96 g, 13.6 mmol) and Et₃N (2.2 ml, 16 mmol). The reaction mixture was stirred at room temperature for 15 h. The solvent was then removed and the residue purified by flash chromatography on silica gel eluting with EtOAc (2)/hexane (3) to yield 19-3 as an oil.

25 R_f=0.5 (silica gel, EtOAc (2), hexane (3)).

¹H NMR (400 MHz, CDCl₃) δ 1.27 (9H, s), 1.99 (1H, m), 2.30 (1H, m),
3.22 (1H, m), 3.42 (2H, m), 3.85 (3H, s), 4.37 (1H, b), 4.69 (1H, b),
6.51 (2H, d), 7.91 (2H, d).


- 139 -



Ethyl 2-(4-((3-(R)-(1,1-dimethylethoxycarbonyl)amino)pyrrolidin-1-yl)phenylcarbonylamino)-3-methylphenoxy)acetic acid (19-4)

- 5 A solution of 19-3 (0.418 g, 1.30 mmol) in dioxane (10 ml) was treated with 1N NaOH (7.0 ml, 7.0 mmol), and the reaction mixture was stirred at room temperature for 15 h. A second portion of 1N NaOH (3.0 ml, 3.0 mmol) was then added and the reaction mixture was stirred an additional 15 h. Solvent was removed, and the residue was
- 10 taken up in H₂O, adjusted to pH 6-7 with 10% KHSO₄ and extracted with EtOAc. The combined organic extracts were dried (Na₂SO₄) and the solvent was removed. The residue was taken up in CH₂Cl₂ (7 ml) and treated with 10-4 (0.33 g, 1.3 mmol), DIPEA (0.81 mmol, 4.6 mmol) and PYCLU (Fluka, 0.53 g, 1.5 mmol). The reaction mixture
- 15 was stirred at room temperature for 48 h. The solvent was then removed and the residue was purified by flash chromatography on silica gel eluting with EtOAc (1)/hexane (1) to afford 19-4 as a white solid. R_f=0.3 (silica gel, EtOAc (1)/hexane (1)).
- ¹H NMR (400 MHz, CDCl₃) δ 1.30 (3H, t), 1.46 (9H, s), 2.04 (1H, m),
- 20 2.29 (3H, s), 2.31 (1H, m), 3.23 (1H, m), 3.45 (2H, m), 3.65 (1H, m), 4.27 (2H, q), 4.38 (1H, b), 4.60 (2H, s), 4.72 (1 H, b), 6.57 (2H, d), 6.77 (1H, d), 7.67 (1H, s), 7.41 (1H, s), 7.72 (1H, d), 7.77 (2H, d).


- 140 -







2-(4-((3(R)-amino)pyrrolidin-1-yl)phenylcarbonylamino)-3-methylphenoxy)acetic acid (19-5)

- 5 A solution of 19-4 (0.306 g, 0.615 mmol) in EtOAc (15 ml) at -78°C was treated with HCl (g) for 1.5 min. The reaction mixture was then stirred at 0°C for 1 h, and the solvent was removed. The residue was taken up in THF (1)/CH₃OH(1)/H₂O (1) (6 ml) and treated with LiOH·H₂O at room temperature for 1 h. The solvent was
- 10 removed, and the residue was purified by flash chromatography on silica gel eluting with EtOH (18)/H₂O (1)/NH₄OH (1) to give 19-5 as a white solid.
- R_f=0.4 (silica gel, EtOH (18)/H₂O (1)/NH₄OH.
- ¹H NMR (400 MHz, D₂O) δ 1.74 (1H, m), 2.10 (3H, s), 2.12 (1H, m),
- 15 3.00 (1H, m), 3.28 (1H, m), 3.39 (1H, m), 3.47 (1H, m), 3.59 (1H, m), 4.39 (2H, s), 6.61 (2H, d), 6.71 (1H, d), 6.81 (1H, s), 7.07 (1H, d), 7.79 (2H, d).


- 141 -

SCHEME 20


- 142 -

SCHEME 20 (CONT'D)20-3

- 143 -

20-14-(Piperidin-4-yl)piperidinyl carboxylic acid, acetic acid salt (20-1)

- A suspension of the lithium salt of N-(pyridin-4-yl)-4-piperidine carboxylic acid (prepared as described in *Tetrahedron*, 1988 44(23) 7095-7108, 1 g, 5.55 mmol) in 50 mL 20% HOAc/MeOH, 10 mL H₂O and 10 mL concentrated HCl was treated with PtO₂ (1.7 g) and hydrogenated at 65 psi for 24 hrs. The solution was filtered, evaporated and the residue azeotroped with heptane to yield 20-1 as a white solid.
- $R_f(9:1:1 \text{ EtOH/H}_2\text{O/NH}_4\text{OH})=0.39$.
- ¹H NMR (400 MHz, D₂O) δ 3.6-3.5 (m, 4H), 3.9 (m, 1H), 3.1-3.0 (m, 4H), 2.65 (m, 1H), 2.32 (d, 2H), 2.25 (d, 2H), 2.0-1.7 (m, 4H).


20-2

- 4-((1,1-Dimethylethoxycarbonyl)piperidin-4-yl)piperidinyl carboxylic acid (20-2)

- A solution of 20-1 (1.7 g, 5.55 mmol) in H₂O (10 mL) was treated with sufficient 1N NaOH to bring the solution to pH 11. Dioxane (20 mL) was added followed by BOC anhydride (1.33 g, 6.2 mmol) dissolved in 5 mL dioxane. After 1 hr the solvents were removed and the residue was triturated with acetonitrile and n-butanol, filtered and the filtrate concentrated. The residue was chromatographed (silica gel, 9:1:1 EtOH/H₂O/NH₄OH) to give 20-2 as a white solid.
- $R_f(9:1:1 \text{ EtOH/H}_2\text{O/NH}_4\text{OH})=0.70$

- 144 -

^1H NMR (400 MHz, D_2O) δ 4.12 (bd, 2H), 3.5 (bd, 2H), 3.32 (m, 1H), 2.95 (bt, 2H), 2.75 (bt, 2H), 2.9 (m, 1H), 2.15 (bd, 2H), 2.0 (bd, 2H), 1.7 (m, 2H), 1.55 (m, 2H), 1.35 (s, 9H).



5

Ethyl 2-(4-(4-((1,1-dimethylethoxycarbonyl)piperidin-4-yl)piperidinylcarboxamido)-3-methylphenoxy)acetic acid (20-3)

20-2 (486 mg; 1.6 mmol) and 10-4 (250 mg, 1.6 mmol) were dissolved in CH_2Cl_2 . PYCLU (1.8 mmol, 634 mg) was added, followed by diisopropylethylamine (6.4 mmol, 1.1 mL). The reaction is stirred for 2 days. The reaction mixture is diluted with EtOAc and washed with H_2O , 10% KHSO_4 , sat NaHCO_3 and brine. The organic layer is dried (MgSO_4), filtered and concentrated to yield a tan oil.

Flash chromatography (10% MeOH/ CHCl_3 sat NH_3) yielded desired product (20-3) plus bis piperidine urea by-product. This material is triturated with hexane to remove most of the by-product.


15

R_f (10% MeOH/ CHCl_3 sat. NH_3)=0.20

^1H NMR (400 MHz, CDCl_3) δ 7.55-7.57 (d, 1H), 6.88 (s, 1H), 6.74 (s, 1H) 6.71-6.72 (d, 1H), 4.6 (s, 1H), 4.27-4.29 (q, 2H), 4.23-4.25 (bs, 2H), 2.9-3.0 (d, 2H), 2.6-2.7 (t, 2H), 2.35-2.45 (t, 2H).

20

- 145 -




5 2-(4-(4-((1,1-Dimethylethoxycarbonyl)piperidin-4-yl)piperidin-4-yl)carboxamido)-3-methylphenoxy)acetic acid (20-4)

20-3 (300 mg) was dissolved in THF/H₂O/MeOH (2 mL/2 mL/2 mL). LiOH (50 mg) was added and the reaction is stirred for 2 hours. 1N HCl was added (0.50 mL) and the reaction mixture was concentrated to yield 20-4 as a tan solid.

10 R_f(9/1/1 CH₂Cl₂/MeOH/HOAc)=0.16

¹H NMR (400 MHz, CD₃OD) δ 7.06-7.08 (d, 1H), 6.81 (s, 1H), 6.75 (d, 1H), 4.88 (s, 2H), 4.12-4.15 (bd, 2H), 3.04-3.07 (bd, 2H), 2.6-2.8 (vbs, 2H), 2.25-2.45 (m, 4H), 2.17 (s, 3H), 1.46-1.56 (m, 6H), 1.45 (9H).



15

2-(4-(4-(Piperidin-4-yl)piperidin-4-yl)carboxamido)-3-methylphenoxy)acetic acid (20-5)


20-4 (0.08 mmol) is dissolved in EtOAc and cooled to -78°. HCl (g) is bubbled through until the solution is saturated. The reaction is warmed to 0°, and stirred for five minutes. The reaction mixture is concentrated to yield a tan solid. The material was purified by flash chromatography using 10/1/1 EtOH/NH₄OH/H₂O as an eluent, resulting in pure 20-5 as a white solid.

25 R_f(10/1/1 EtOH/NH₄OH/H₂O)=0.15


- 146 -

¹H NMR (400 MHz, D₂O) 7.0 (d, 1H), 6.8 (s, 1H), 6.7 (dd, 1H), 4.7 (s, 1H), 3.4 (d, 2H), 3.1 (bd, 2H), 2.9 (t, 2H), 2.8 (bt, 1H), 2.5 (bs, 3H), 2.10-2.13 (d, 2H), 2.06 (s, 3H), 1.96-1.99 (d, 2H), 1.65-1.75 (m, 4H).


- 147 -

SCHEME 21

- 148 -

SCHEME 21 (CONT'D)

- 150 -

21-34-Hydroxy-2-methyl benzoic acid (21-3)


5 21-3 was prepared in two steps from 4'-hydroxy-2'methyl-acetophenone, 21-1, (Aldrich, 18.0 g, 0.120 mol).

The first step employed the procedure found in Merck Process Patent US 852870-92031, which resulted in a 70/30 mix of 21-3 and 3-iodo-4-hydroxy-6-methyl benzoic acid (21-2)

10 For the second step, the mixture (7.0 g) of 21-2 and 21-3 was reduced in MeOH (200 mL) using 10% Pd/C (700 mg) under a hydrogen balloon. After 16 hours of stirring, the reaction mixture was filtered through celite, the celite pad was washed with MeOH and the filtrate was concentrated to yield pure 21-3 as a tan solid.

¹H NMR (400 MHz, CDCl₃) δ 7.8 (d, 1H), 6.6 (m, 2H), 2.5 (s, 3H).

15 R_f (90 % Ethyl Acetate/Hexane)=0.34

21-4Methyl 4-hydroxy-2-methylbenzoate (21-4)


20 21-3 (5.0 g, 32.9 mmol) was redissolved in MeOH (150 mL) and cooled to 0°. HCl (g) was bubbled through for a few minutes, the cooling bath was removed and the reaction was stirred at RT for 16

- 151 -

hours. The reaction mixture was then concentrated to yield pure 21-4 as a tan solid.

R_f (50% Ethyl Acetate/Hexane)=0.83

¹H NMR (400 MHz, CDCl₃) δ 7.9 (d, 1H), 6.7 (m, 2H), 3.85 (s, 3H),
5 2.57 (s, 3H).




Ethyl 2-(3-methyl-4-methoxycarbonylphenoxy)acetate (21-5)

10 21-4 (1.5 g; 9.0 mmol) was dissolved in DMF (150 mL). Ethyl bromoacetate (9.0 mmol, 1.0 mL) was added followed by Cs₂CO₃ (9.0 mmol, 2.9 g). The slurry was stirred vigorously for 16 hours. The reaction mixture was diluted with EtOAc and washed twice with water, 10% KHSO₄ and brine. The organic layer was dried (MgSO₄),
15 filtered and concentrated to yield 21-5 which will be used in the next step without any further purification.


R_f (30 % Ethyl Acetate/Hexane)=0.40

¹H NMR (400 MHz, CDCl₃) δ 7.9 (d, 1H), 6.7-6.8 (m, 2H), 4.6 (s, 2H), 4.3-4.3 (q, 2H), 3.9 (s, 3H), 2.6 (s, 3H), 1.3 (t, 3H).

- 152 -

21-6Ethyl 2-(3-bromomethyl-4-methoxycarbonylphenoxy)acetate (21-6)21-5 (2.1 g; 8.3 mmol) was dissolved in CCl₄ (40 mL).

- 5 NBS (10.3 mmol, 1.9 g) was added followed by dibenzoyl peroxide (1.66 mmol, 400 mg). The reaction mixture was heated to reflux for 16 hours. The reaction mixture was cooled and filtered through a celite pad to remove excess succinimide. The filtrate was concentrated to yield 21-6 as a tan oil, which was used in the next step without any
- 10 further purification.

R_f (30% Ethyl Acetate/Hexane)=0.5221-7

- 15 Ethyl 1-(4-(1,1-Dimethylethoxycarbonylpiperazin-1-yl)phenyl)-2-oxoisoindolin-5-oxyacetate (21-7)

21-6 (8.3 mmol) was dissolved in benzene (100 mL), followed by 14-3. The mixture was heated to reflux for 32 hours. Triethylamine (8.3 mmol) was added and the reaction was refluxed for


20 2 more days. The reaction mixture was then concentrated to yield a brown solid which was absorbed on silica and purified by flash chromatography. A small amount of the product was eluted with 50% EtOAC/Hex. Most of the material was then flushed off the column with

- 153 -

10% MeOH/CHCl₃ saturated with NH₃. These flushings yielded a brown solid which was repurified on a column of silica using 10% MeOH/CHCl₃ as a eluent to yield 21-7 as a brown solid.

R_f (50% EtOAc/Hex)=0.48

- 5 ¹H NMR (400 MHz, CDCl₃) δ 7.8 (d, 1H), 7.7 (d, 2H), 7.0 (m, 4H), 4.77 (s, 2H), 4.72 (s, 2H), 4.3 (q, 2H), 3.6 (m, 4H), 3.1 (m, 4H), 1.5 (s, 9H), 1.3 (t, 3H).



10


1-(4-(1,1-Dimethylethoxycarbonylpiperazin-1-yl)phenyl)-2-oxo-isoindolin-5-oxy)acetic acid (21-8)

- 15 21-7 (1.3 g; 2.6 mmol) was dissolved in THF/H₂O/MeOH (5 mL/5/5). LiOH (5.2 mmol, 218 mg) was added and the reaction mixture was stirred for 2 hours. 1 N HCl was added (2.6 mL), and the reaction mixture was concentrated to yield 21-8 and excess LiCl as a brown solid.

R_f(9/1/1 CH₂CH₂/MeOH/HOAc)=0.80

- 20 ¹H NMR (400 MHz, CD₃OD) δ 7.7 (m, 3H), 7.0-7.1 (m, 4H), 3.3 (bm, 4H), 3.1 (bm, 4H), 1.5 (s, 9H).

- 154 -




1-(((4-Piperazin-1-yl)phenyl)-2-oxo-isoindolin-5-yl)oxyacetic acid (21-9)

5 21-8 (2.6 mmol) was dissolved in EtOAc and cooled to -78°. HCl was bubbled through until the solution was saturated. The reaction mixture was then stirred at 0° for 10 min and concentrated to yield a brown solid. Flash chromatography (10/0.8/0.8 EtOH/NH₄OH/H₂O) yielded 21-9 as a brown solid. This material was further purified by preparative HPLC to yield pure 21-9 (TFA salt) as an off-white
10 solid.

R_f(10/1/1 EtOH/NH₄OH/H₂O)=0.72

¹H NMR (400 MHz, DMSO- d₆) δ 7.8 (d, 2H), 7.7 (d, 1H), 7.2 (s, 1H), 7.1 (d, 3H), 4.9 (s, 2H), 4.8 (s, 2H), 3.2-3.3 (bd, 8H).


- 155 -

SCHEME 22


- 156 -

SCHEME 22 (CONT'D)22-3


NaOH

22-4


HCl/n-butanol

22-5


- 157 -

SCHEME 22 (CONT'D)



- 158 -

SCHEME 22 (CONT'D)


- 159 -

SCHEME 22 (CONT'D)22-9


nBuLi/CNBr

22-10H₂/Pd/C/HOAc22-11

- 160 -


SCHEME 22 (CONT'D)

- 161 -



1-Chloro-2-(2-methyl-4-acetamidophenyl)ethanone (22-2)

- A suspension of 3-acetamido toluene (Aldrich) (33.45 g, 0.224 mole) in nitromethane (100 mL) was treated with chloracetylchloride (69.3 mL, 0.739 mole). The solution became homogenous. Aluminum trichloride (92.3 g, 0.694 mol) was added in 10 g portions over 40 minutes. The temperature rose to 50°C and the solution became dark brown. The reaction was heated to 80°C for 2 hours, then cooled to room temperature and concentrated to give a thick green oil that was added to crushed ice and stirred with a overhead stirrer. The resulting tan solid was collected in a sintered glass funnel and washed with water and dried to give 22-2 as a tan solid. R_f (40% EtOAc/Hexanes)=0.14.
- ^1H NMR (300 MHz, CDCl_3) δ 7.66 (d, 1H), 7.58 (m, 1H), 7.43 (s, 1H), 7.28 (s, 1H), 4.62 (s, 2H), 2.55 (s, 3H), 2.2 (s, 3H).



1-(1-Pyridinium)-2-(2-methyl-4-acetamidophenyl)ethanone, chloride (22-3)


A solution of 22-2 (21.8 g, 0.098 mol) in refluxing ethanol (110 mL) was treated with pyridine (28 mL). A salmon-pink precipitate formed and after 2 hours of reflux the mixture was cooled to

- 162 -

room temperature, filtered and rinsed with cold (-20°C) EtOH and dried to give 22-3 as an off-white solid.

R_f (9:1:1 EtOH/H₂O/NH₄OH) 0.12

¹H NMR (400 MHz, D₂O) δ 8.66 (d, 2H), 8.5 (m, 1H), 8.08 (d, 2H),
5 7.92 (d, 1H), 7.5 (d, 1H), 7.33 (s, 1H), 2.4 (s, 3H), 2.1 (s, 3H).

22-4


2-Methyl-4-amino-benzoic acid 22-4

10 To a 60°C solution of 22-3 (23.5 g, 0.077 mol) in H₂O (155 mL) was added 2.5 M NaOH solution (160 mL). An orange precipitate formed. The reaction was heated to reflux for 2.5 hours, then the homogenous solution was cooled to room temperature and treated with 2.5 M HCl (160 mL) and stirred overnight. The pH of the
15 solution was adjusted to pH 4-5 with NaOH solution and the yellow precipitate that formed was washed with water and dried to give 22-4 as a gummy yellow solid.

R_f(9:1:1 EtOH/H₂O/NH₄OH)=0.76.

¹H NMR (300 MHz, CD₃OD) δ 7.75 (d, 1H), 6.43 (m, 2H), 2.42 (s,
20 3H).

- 163 -




n-Butyl 2-methyl-4-amino-benzoate, hydrochloride (22-5)

5 A suspension of 22-4 (8.8 g, 58 mmol) in n-butanol (200 mL) was cooled to 0°C under argon and saturated with HCl gas. A salmon-pink precipitate formed. The solution was heated to reflux for 18 hours then evaporated. The residue was dissolved in EtOAc and saturated NaHCO₃ and the layers were separated. The aqueous layer was washed repeatedly with EtOAc, the EtOAc layers were combined, 10 dried with brine and MgSO₄, filtered and evaporated. The oily residue was dissolved in CHCl₃ and evaporated to give 22-5 as a brown solid.

R_f (20% EtOAc/Hexanes) 0.5

¹H NMR (300 MHz, CDCl₃) δ 7.83 (d, 1H), 6.48 (m, 2H), 4.23 (t, 2H), 3.9 (bs, 2H), 2.53 (s, 3H), 1.7 (m, 2H), 1.48 (m, 3H), 0.95 (t, 3H).

15




n-Butyl 2-methyl-4-piperizin-1-yl-benzoate, hydrochloride (22-6)

20 A solution of 22-5 (10.7 g, 52 mmol) in n-butanol (285 mL) was treated with bis chloroethylamine hydrochloride (9.22 g, 52 mmol) and refluxed for one week. The ethanol was removed *in vacuo* and the residue was diluted with EtOAc. A precipitate formed and was collected and washed with EtOAc and dried to give 22-6 as tan solid.

R_f (2.5% MeOH/CHCl₃ saturated with NH₃)=0.31

- 164 -

¹H NMR (400 MHz, CD₃OD) δ 7.88 (d, 1H), 6.88 (m, 2H), 4.24 (t, 2H), 3.55 (m, 4H), 3.36 (m, 4H), 2.56 (s, 3H), 1.73 (m, 2H), 1.5 (m, 2H), 1.0 (t, 3H).




5

n-Butyl 2-methyl-4-(4-(1,1-dimethylethoxycarbonylpiperizin-1-yl)-benzoate acid (22-7)

A solution of 22-6 (10.5 g, 33.3 mmol) in CH₂Cl₂ (100 mL) was cooled to 0°C and treated with triethylamine (18.8 mL, 0.133 mol) and di-tert-butylidicarbonate (14.75 g, 66 mmol). The solution was allowed to warm to room temperature and after 1 hour was washed with 10% KHSO₄, brine, dried over MgSO₄, filtered and evaporated to give 22-7 as brown oil.

R_f (5% EtOAc/Hexanes)=0.4

¹H NMR (300 MHz, CDCl₃) δ 7.9 (d, 2H), 6.68 (m, 2H), 4.23 (t, 2H), 3.55 (m, 4H), 3.38 (m, 4H), 2.6 (s, 3H), 1.75 (m, 2H), 1.5 (m, 11H), 0.95 (t, 3H).



20

2-Methyl-4-(4-(1,1-dimethylethoxycarbonylpiperizin-1-yl)benzoic acid (22-8)


A solution of 22-7 (2.55 g, 6.78 mmol) in 4:1 EtOH/H₂O (125 mL) was treated with NaOH (2.7 g, 67.8 mmol) and refluxed overnight. The solvents were removed and the residue was partitioned between EtOAc and 10% KHSO₄. The layers were separated and the aqueous layer was washed with EtOAc several times. The organic layers

- 165 -

were combined, washed with brine, dried over MgSO₄, filtered and evaporated to give 22-8 as a white solid.

¹H NMR (400 MHz, -CDCl₃) δ 8.0 (d, 1H), 6.7 (m, 2H), 3.6 (m, 4H), 3.34 (m, 4H), 2.6 (s, 3H), 1.5 (s, 9H).

5




N-(4-Benzyloxyphenyl)-2-methyl-4-(4-(1,1-dimethylethoxycarbonyl)piperidin-1-yl)benzamide (22-9)

10 A solution of 22-8 (2.06 g, 6.43 mmol) in CH₂Cl₂ (50 mL) was treated with p-benzyloxy aniline hydrochloride (Aldrich, 1.66 g, 7.08 mmol), diisopropyl amine (5.6 mL, 32 mmol) and PYCLU 93.47 g, 9.6 mmol). After stirring for 24 hours the volatile components were removed *in vacuo* and the residue was dissolved in EtOAc and washed
15 with 10% KHSO₄, water, saturated NaHCO₃, water and brine, dried over MgSO₄, filtered and evaporated. The residue was chromatographed in a gradient of 20 to 50% EtOAc/Hexanes to give 22-9 as an oil.

R_f (50% EtOAc/Hexanes)=0.57

20 ¹H NMR (400 MHz, CDCl₃) δ 7.4 (m, 8H), 7.0 (d, 2H), 6.76 (m, 2H), 4.08 (s, 2H), 3.6 (s, 4H), 3.22 (bs, 4H), 2.53 (s, 3H), 1.5 (s, 9H).

- 166 -




1-(4-Benzyloxyphenyl)-5-(4-(1,1-dimethylethoxycarbonyl)piperizin-1-yl)isoindolin-2-one (22-10)

- 5 A solution of 22-9 (0.66 g, 1.31 mmol) in THF (65 mL) was cooled to -78°C under argon. n-Butyllithium (2.2M in hexanes, 2.4 mL) was added dropwise to give a deep red solution. The reaction was stirred for 20 minutes, then rapidly transferred via wide bore cannula to a -78°C THF solution of cyanogen bromide (2.77 g, 26.2 mmol in 65 mL). The resulting colorless solution was stirred for 25 minutes, then quenched with methanol. The solution was diluted with water, the volatile solvents were removed *in vacuo* and the remaining water layer was extracted with EtOAc. The EtOAc layer was washed with brine, dried over MgSO₄, filtered and evaporated. The residue was
- 10
- 15 chromatographed in a gradient of 20 to 30% EtOAc/Hexanes to give 22-10 as an oil.

R_f (40% EtOAc/Hexanes)=0.25

- ¹H NMR (400 MHz, CDCl₃) δ 7.77 (s, 1H), 7.7 (d, 2H), 7.44 (m, 2H), 7.4 (m, 2H), 7.34 (m, 1H), 7.0 (m, 3H), 6.9 (s, 1H), 5.1 (s, 2H), 4.73 (s, 2H), 3.6 (m, 4H), 3.3 (m, 4H), 1.5 (s, 9H).
- 20

- 167 -



5 1-(4-Hydroxyphenyl)-5-(4-(1,1-dimethylethoxycarbonyl)piperizin-1-yl)isoindolin-2-one (22-11)


A solution of 22-10 (0.155 g, 0.31 mmol) in 10 mL glacial acetic acid was treated with 10% Pd/C (0.3 g) and hydrogenated at 60 psi for 5 hours. The solution was decanted from the catalyst, concentrated and the residue chromatographed using a gradient of 60 to 90% EtOAc/Hexanes to give 22-11 as an oil.

10 $R_f(50\% \text{ EtOAc/Hexanes})=0.19$

$^1\text{H NMR}$ (300 MHz, CDCl_3) δ 7.79 (d, 1H), 7.55 (d, 2H), 7.0 (m, 1H), 6.92 (bs, 1H), 6.86 (m, 2H), 4.72 (s, 2H), 3.6 (m, 4H), 3.3 (m, 4H), 1.5 (s, 9H).

15


- 168 -



Ethyl 4-(2-oxo-5-(4-(1,1-dimethylethoxycarbonyl)piperizin-1-yl)isoindolin-1-yl)phenoxyacetate (22-12)


- 5 A solution of 22-11 (0.045 g, 0.11 mmol) in DMF (5 mL) was treated with cesium carbonate (23 mg, 0.07 mmol) and ethyl bromoacetate (15 μ L, 0.011 mmol). After 3 hours the solvents were removed *in vacuo* and the residue was dissolved in EtOAc and washed with water, brine, dried over MgSO₄, filtered and evaporated. The
- 10 residue was chromatographed in a gradient of 30 to 50% EtOAc/Hexanes to give 22-12 as an oil.
R_f(40% EtOAc/Hexanes)=0.36
- 15 ¹H NMR (400 MHz, CDCl₃) δ 7.74 (m, 3H), 7.0 (m, 2H), 6.95 (m, 2H), 4.73 (s, 2H), 4.62 (s, 2H), 4.28 (q, 2H), 3.6 (m, 4H), 3.3 (m, 4H), 1.5 (s, 9H).

- 169 -



Ethyl 4-(2-oxo-5-piperizin-1-yl)isoindolin-1-yl)phenoxyacetate, hydrochloride (22-13)


- 5 A solution of 22-12 (0.04 g, 0.08 mmol) in EtOAc (10 mL) was cooled to -78°C, saturated with HCl gas, warmed to 0°C and evaporated at ambient temperature to give 22-13 as a white solid. ¹H NMR (300 MHz, D₂O) δ 7.54 (d, 1H), 7.4 (d, 2H), 7.03 (m, 3H), 6.89 (d, 2H), 4.6 (s, 2H), 4.15 (q, 2H), 3.43 (m, 4H), 3.23 (m, 4H), 1.15
- 10 (t, 3H).




4-(2-Oxo-5-piperizin-1-yl)isoindolin-1-yl)phenoxyacetic acid (22-14)

- 15 A solution of 22-13 (0.04 g, 0.08 mmol) in 1:1 THF/H₂O (6 mL) was treated with 1N NaOH solution (0.4 mL). The reaction was concentrated and the residue chromatographed in 9:1:1 EtOH/H₂O/NH₄OH to give 22-14 as a white solid. R_f(9:1:1 EtOH/H₂O/NH₄OH)=0.62
- 20 ¹H NMR (400 MHz, D₂O + deuterio trifluoroacetic acid) δ 7.49 (d, 1H), 7.44 (d, 2H), 6.95 (m, 3H), 6.74 (d, 2H), 4.33 (bs, 4H), 3.42 (bs, 4H), 3.25 (bs, 4H).




- 170 -

SCHEME 23

- 171 -

SCHEME 23 (CONT'D)


- 172 -

SCHEME 23 (CONT'D)23-223-723-8


5

10


- 173 -

23-2


1. H₂ Pd/C
2. 3-pyridylSO₂Cl

23-9


HCl / EtOAc

23-10


HCl .

H₂N-1-5


PYCLU

23-11

1. HCl/EtOAc
2. LiOH

23-12

- 174 -




2-Nitro-4-(1,1-dimethylethoxycarbonylamino)phenol (23-1)

A solution of 2-nitro-4-amino phenol (Aldrich) (20 g, 130 mmol) in THF (500 mL) was cooled to 0°C and treated with di-tertbutyldicarbonate (64 g, 293 mmol) and triethylamine (37 mL, 265 mmol). After 24 hours the solution was concentrated and the residue dissolved in EtOAc, washed with 10% KHSO₄, saturated NaHCO₃, and brine, dried over Na₂SO₄, filtered and evaporated. The crude bis-protected material (R_f (40% EtOAc/Hexanes) 0.69) was then dissolved in 400 mL 1:1 THF/H₂O and treated with LiOH·H₂O (38 g, 1.3 mol). After stirring at room temperature overnight the solvent was removed and the residue was dissolved in EtOAc and washed with brine, dried with Na₂SO₄, filtered and concentrated to give 23-1 as a reddish oily solid.

R_f(20% EtOAc/Hexanes)=0.41

¹H NMR (400 MHz, CDCl₃) δ 10.35 (s, 1H), 8.18 (s, 1H), 7.58 (d, 1H), 7.13 (d, 1H), 6.45 (bs, 1H), 1.55 (s, 9H).



Ethyl 2-(2-nitro-4-(1,1-dimethylethoxycarbonylamino)phenoxy)acetic acid (23-2)

A solution of 23-1 (5 g, 19.7 mmol) in DMF (125 mL) was treated with cesium carbonate (3.17 g, 9.73 mmol), stirred for 10


- 175 -

minutes and treated with ethyl bromoacetate (2.2 mL, 19.8 mmol) at room temperature. After 1.5 hours the solution was concentrated under high vacuum and the residue was absorbed to silica gel and chromatographed in a gradient of 20 to 30% EtOAc/Hexanes to give

5 23-2 as a bright yellow solid.

R_f(30% EtOAc/Hexanes)=0.26

¹H NMR (400 MHz, CDCl₃) δ 7.95 (s, 1H), 7.5 (d, 1H), 6.97 (d, 1H), 6.62 (bs, 1H), 4.72 (s, 2H), 4.25 (q, 2H), 1.5 (s, 9H), 1.28 (t, 3H).



10 23-4

Ethyl 2-(2-methanesulfonamido-4-aminophenoxy)acetic acid hydrochloride (23-4)


A solution of 23-2 (2 g, 5.88 mmol) in EtOAc (25 mL) was treated with 10% Pd/C (0.67 g), and hydrogenated under balloon pressure for 1.5 hours. The solution was filtered through SolkaFloc, and the cake rinsed with EtOAc. The filtrate was not concentrated but was treated directly with methanesulfonyl chloride (3.0 mL, 39 mmol) and pyridine (5.0 mL, 62 mmol) and stirred overnight. The solution was concentrated and the residue was dissolved in EtOAc and washed with 10% KHSO₄, saturated Na₂CO₃, and brine, dried with Na₂SO₄, filtered and concentrated to give a yellow oil that was chromatographed (40% EtOAc/Hexanes) to give 23-3 (R_f 30% EtOAc/Hexanes) 0.19) contaminated with 23-3a. The mixture (1.7 g) was dissolved in EtOAc (75 mL), cooled to -78°C and saturated with HCl gas, warmed to 0°C for 1 hour and concentrated. The residue was partitioned between CH₂Cl₂ and saturated NaCO₃, the layers separated and the aqueous layer extracted with CH₂Cl₂. The organic layer was dried over

- 176 -

Na₂SO₄, filtered and evaporated and the residue chromatographed (60% EtOAc/Hexanes) to give 23-4 as an off-white solid.

R_f(60% EtOAc/Hexanes) 0.3

¹H NMR (400 MHz, CDCl₃) δ 7.7 (bs, 1H), 6.95 (s, 1H), 6.74 (d, 1H),
5 6.4 (d, 1H), 4.6 (s, 2H), 4.33 (q, 2H), 2.98 (s, 3H), 1.3 (t, 3H).




10 Ethyl 2-(4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenyl-carbonylamino)-2-methanesulfonamidophenoxy)acetate (23-5)

A suspension of 23-4 (0.125 g, 0.433 mmol) and 1-5 (0.136 g, 0.444 mmol) in CH₂Cl₂ (4 mL) was treated with diisopropylamine (0.3 mL, 1.7 mmol) and PYCLU (0.173 g, 0.48 mmol) and stirred at room temperature for three days. The solution was concentrated and
15 the residue was absorbed to silica gel and chromatographed in a gradient of 20 to 60% EtOAc/Hexanes to give 23-5 as a pale yellow oil.

R_f (60% EtOAc/Hexanes)=0.27

¹H NMR (400 MHz, CDCl₃) δ 7.82 (dd, 1H), 7.79 (s, 1H), 7.77 (s, 1H),
7.54 (bs, 1H), 7.48 (s, 1H), 6.90 (m, 3H), 4.7 (s, 2H), 4.25 (q, 2H), 3.6
20 (m, 4H), 3.3 (m, 4H), 3.03 (s, 3H), 1.5 (s, 9H), 1.3 (t, 3H).

- 177 -




5 2-(4-(4-(Piperazin-1-yl)phenylcarbonylamino)-2-methane-
sulfonamidophenoxy)acetic acid (23-6)

A solution of 23-5 (0.093 g, 0.16 mmol) was dissolved in EtOAc (10 mL), cooled to -78°C and saturated with HCl gas, warmed to 0°C for 1 hour and concentrated. The resulting white solid was dissolved in 1:1:1 H₂O/THF/MeOH, treated with LiOH·H₂O (0.038 g, 10 0.9 mmol) and stirred at room temperature for 1 hour. The reaction was concentrated and chromatographed (18:1:1 EtOH/H₂O/NH₄OH) to give a yellow oil that was diluted with CH₂Cl₂ and evaporated to give 23-6 as white solid.

R_f(9:1:1 EtOH/H₂O/NH₄OH)=0.48

15 ¹H NMR (400 MHz, D₂O + NaOD) δ 7.74 (s, 1H), 7.72 (s, 1H), 7.21 (s, 1H), 7.07 (s, 1H), 7.05 (s, 1H), 6.9 (d, 1H), 6.74 (d, 1H), 4.38 (s, 2H), 3.15 (m, 4H), 2.85 (m, 7H).


- 178 -



5 Ethyl 2-(4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenylcarbonylamino)-2-nitrophenoxy)acetate (23-7)

A solution of 23-2 (0.3 g, 0.88 mmol) was dissolved in EtOAc (10 mL), cooled to -78°C and saturated with HCl gas, warmed to 0°C for 1 hour and concentrated to give Ethyl 2-(2-nitro-4-aminophenoxy)acetic acid as a white solid that was coupled immediately (0.26 g, 0.88 mmol) to 1-5 (0.29 g, 0.95 mmol) as described for 23-5 to give 23-7 as a yellow solid after chromatography in a gradient of 40 to 100% EtOAc/Hexanes.

$R_f(50\% \text{ EtOAc/Hexanes})=0.22$




15 2-(4-(4-(Piperazin-1-yl)phenylcarbonylamino)-2-nitrophenoxy)-acetic acid (23-8)

20 A solution of 23-7 (0.186 g, 0.352 mmol) in EtOAc was treated first with HCl gas then with LiOH·H₂O as described for 23-6 to give 23-8 as a yellow solid after chromatography in 18:1:1 EtOH/H₂O/NH₄OH).

$R_f(18:1:1 \text{ EtOH/H}_2\text{O/NH}_4\text{OH})=0.47$

25 ¹H NMR (400 MHz, D₂O) δ 8.0 (s, 1H), 7.68 (2s, 2H), 7.52 (d, 1H), 7.0 (m, 2H), 3.12 (bs, 4H), 2.85 (bs, 4H).

- 179 -




5 Ethyl 2-(2-(3-pyridyl)sulfonamido-4-(1,1-dimethylethoxycarbonyl)-aminophenoxy)acetate (23-9)

A solution of 23-2 (2 g, 5.88 mmol) in EtOAc (25 mL) was treated with 10% Pd/C and 3-pyridylsulfonyl chloride (*JOC*, 1989, 54, 389-393) as described for 23-3 to give 23-9 after chromatography in a gradient of 30 to 50% EtOAc/Hexanes as a white solid.

10 $R_f(40\% \text{ EtOAc/Hexanes})=0.11$

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 9.02 (s, 1H), 8.71 (d, 1H), 8.1 (m, 2H), 7.4 (s, 1H), 7.33 (m, 2H), 6.69 (d, 1H), 6.58 (s, 1H), 4.4 (s, 2H), 4.23 (q, 2H), 1.5 (s, 9H), 1.25 (t, 3H).




15

Ethyl 2-(4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenyl)carbonylamino)-2-(3-pyridylsulfonamido)phenoxy)acetate (23-11)

20 A solution of 23-9 (0.318 g, 0.704 mmol) in EtOAc (10 mL) was treated with HCl gas as described for 23-4 to give 23-10 as a white solid that was coupled directly with 1-5 as described for 23-5 to give 23-11 as a oily yellow solid after chromatography in a gradient of 20 to 40% acetone/Hexanes.

$R_f(50\% \text{ EtOAc/Hexanes})=0.41$

- 180 -

¹H NMR (400 MHz, CDCl₃) δ23-12

- 5 2-(4-(4-(Piperazin-1-yl)phenyl)carbonylamino)-2-(2-(3-pyridylsulfonamido)phenoxy)acetic acid (23-12)


A solution of 23-11 (0.047 g, 0.087 mmol) in EtOAc was treated first with HCl gas then with LiOH·H₂O as described for 23-6 to give 23-12 as a yellow solid after chromatography in 18:1:1

10 EtOH/H₂O/NH₄OH).

R_f(18:1:1 EtOH/H₂O/NH₄OH)=0.38

¹H NMR (400 MHz, D₂O + NaOD) δ 8.76 (s, 1H), 8.5 (m, 1H), 8.13 (m, 1H), 7.7 (m, 2H), 7.45 (m, 1H), 7.12 (s, 1H), 7.08 (m, 2H), 6.84 (m, 1H), 6.67 (d, 1H), 4.13 (s, 2H), 3.25 (m, 4H), 2.87 (m, 4H).

15

23-13


Ethyl 2-(2-methoxy-4-nitrophenoxy)acetic acid (23-13)

- 20 2-methoxy-4-nitro phenol (Aldrich) (1.0 g, 5.9 mmol) was treated with cesium carbonate and ethylbromoacetate as described for 23-2 to give crude 23-13 after removal of DMF. The crude material was partitioned between water and EtOAc, the organic layer was dried with brine and MgSO₄, filtered and evaporated to give 23-13 as a yellow solid.

- 181 -

R_f(50% EtOAc/Hexanes)=0.54

¹H NMR (400 MHz, CDCl₃) δ 7.8 (d, 1H), 7.76 (s, 1H), 6.75 (d, 1H), 4.71 (s, 2H), 4.2 (q, 2H), 3.9 (s, 3H), 1.21 (t, 3H).




5

23-14

Ethyl 2-(2-methoxy-4-aminophenoxy)acetic acid (23-14)

A solution of 23-13 (0.7 g, 2.7 mmol) in EtOH (10 mL) was treated with 10% Pd/C (0.14 g) and hydrogenated at balloon pressure. The solution was filtered through Solka-Floc and evaporated to give 23-14 as a tan oil.

¹H NMR (400 MHz, CDCl₃) δ 6.78 (d, 1H), 6.33 (s, 1H), 6.21 (d, 1H), 4.59 (s, 2H), 4.21 (q, 2H), 3.8 (s, 3H), 3.45 (bs, 2H), 1.28 (t, 3H).

23-15

15

Ethyl 2-(4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenyl)carbonylamino)-2-methoxyphenoxy)acetate (23-15)


Acid 1-5 and amine 23-14 were coupled as described for 23-5 to give 23-15 as brown solid after chromatography in 50% EtOAc/Hexanes.

R_f(50% EtOAc/Hexanes)=0.13

¹H NMR (400 MHz, CDCl₃) δ 7.8 (d, 2H), 7.6 (d, 1H), 6.92 (d, 2H), 6.86 (m, 2H), 4.64 (s, 2H), 4.24 (q, 2H), 3.9 (s, 3H), 3.6 (m, 4H), 3.3 (m, 4H), 1.5 (s, 9H), 1.25 (t, 3H).

25

- 182 -




2-(4-(4-(4-Piperazin-1-yl)phenyl)carbonylamino)-2-methoxy-
phenoxy)acetic acid (23-16)

5 Compound 23-15 was treated with LiOH and HCl gas as
described for 23-6 to give 23-16 as a white solid after chromatography
in 10:1:1 EtOH/H₂O/NH₄OH.


R_f (10:1:1 EtOH/H₂O/NH₄OH)=0.15

10 ¹H NMR (400 MHz, D₂O) δ 7.78 (d, 2H), 7.15 (s, 1H), 7.08 (d, 2H),
6.9 (m, 1H), 6.78 (d, 1H), 4.4 (s, 2H), 3.8 (s, 3H), 3.18 (bs, 4H), 2.88
(bs, 4H).

- 183 -

SCHEME 24

- 184 -




2-(1,1-Dimethylethoxycarbonyl)-7-bromo-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole (24-2)

5 A suspension of 24-1, prepared by the method of Rinehard *et al.* (*J. Am. Chem. Soc.*, 1987, 109, p 3378-3387) (0.366 g, 1.46 mmol) in CH₂Cl₂ (8 mL) was treated with triethylamine (0.61 mL, 4.4 mmol) followed by di-tert-butyldicarbonate (0.38 g 1.7 mmol) for 1 hour at room temperature. The solution was concentrated and the
10 residue chromatographed (20% EtOAc/Hexanes) to give 24-2 as a white solid.

R_f (20% EtOAc/Hexanes)=0.28.

¹H NMR (400 MHz, CDCl₃) δ 8.0-7.6 (m, 1H), 7.46 (s, 1H), 7.33 (d, 1H), 7.2 (d, 1H), 4.6 (bs, 2H), 3.78 (bs, 2H), 2.76 (bs, 2H), 1.5 (s, 9H).



2-(1,1-Dimethylethoxycarbonyl)-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol-7-yl carboxylic acid (24-3)


20 A solution of 24-2 (0.26 g, 0.734 mmol) in THF (10 mL) was cooled to 0°C and treated with methylmagnesium chloride (3.0 M in THF, 0.29 mL, 0.87 mmol) to give a pale yellow solution. After 15 minutes the solution was cooled to -78°C and treated with tBuLi (1.7M in pentane, 4.35 mL, 7.39 mmol) to give a bright yellow solution.
25 After 10 minutes CO₂ gas was bubbled vigorously through the solution for 10 minutes. Saturated NH₄Cl, water and enough 6N NaOH to reach

- 185 -

pH 12 were added and the solution extracted with EtOAc. The EtOAc layer was back extracted with 0.5 N NaOH and the aqueous layers combined, acidified to pH 7 and extracted with EtOAc, the EtOAc layer was dried (Na₂SO₄) filtered and concentrated to give 24-3 as an off-white solid.

R_f(75:25:1 CHCl₃/MeOH/HOAc)=0.48.

¹H NMR (400 MHz, DMSO-d₆) δ 12.0 (bs, 1H), 11.2 (s, 1H), 7.93 (s, 1H), 7.6 (d, 1H), 7.45 (d, 1H), 4.6 (s, 2H), 3.68 (m, 2H), 2.7 (m, 2H), 1.4 (s, 9H).




Ethyl 4-(2-(1,1-dimethylethoxycarbonyl)-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol-7-yl)carbonylamino-3-methylphenoxyacetate (24-4)

A solution of 24-3 (0.078 g, 0.25 mmol) and 10-4 (0.303 g, 1.23 mmol) in CH₂Cl₂ were treated with diisopropylamine and PYCLU as described for 23-5 to give 24-4 as a white solid after chromatography in a gradient of 40 to 60% EtOAc/Hexanes.

R_f (40% EtOAc/Hexanes)=0.11

¹H NMR (400 MHz, CDCl₃) δ 8.5-8.2 (m, 1H), 8.0 (s, 1H), 7.75 (d, 1H), 7.63 (s, 1H), 7.52 (s, 2H), 6.83 (s, 1H), 6.80 (d, 1H), 4.7 (bs, 2H), 4.6 (s, 2H), 4.28 (q, 2H), 3.8 (bs, 2H), 2.83 (bs, 2H), 2.82 (s, 3H), 1.5 (s, 9H), 1.3 (t, 3H).

- 186 -




5 3-Methyl-4-((1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol-7-yl)carbonylamino)phenoxyacetic acid (24-5)

A solution of 24-4 (0.082 g, 0.16 mmol) in EtOAc (10 mL) was treated first with HCl gas, then with LiOH·H₂O as described for 23-6 to give 24-5 as a white solid after chromatography in 18:1:1 EtOH/H₂O/NH₄OH.




10 R_f (18:1:1 EtOH/H₂O/NH₄OH)=0.48

¹H NMR (400 MHz, D₂O) δ 7.9 (s, 1H), 7.54 (m, 2H), 7.13 (d, 1H), 6.84 (s, 1H), 6.75 (d, 1H), 4.40 (s, 2H), 3.8 (s, 2H), 3.0 (m, 2H), 2.7 (m, 2H), 2.15 (s, 3H).


- 187 -

SCHEME 25


- 188 -

SCHEME 25 (CONT'D)

- 189 -


SCHEME 25 (CONT'D)

- 190 -



2,6-Dibromo-3-methyl-4-(1,1-dimethylethoxycarbonyl)amino-phenol (25-1)


- 5 A solution of 10-2 (1.0 g, 450 mmol) in 20 mL THF under argon was treated with N-Bromosuccinimide (1.6 g, 9 mmol) for 2 hr. The solution was concentrated and the residue was resuspended in carbontetrachloride and filtered. The filtrate was concentrated and chromatographed (15% EtOAc/Hexanes) to give 25-1 as a white solid.
- 10 R_f(20% EtOAc/Hexanes)=0.56
¹H NMR (400 MHz, CDCl₃) δ 7.79 (bs, 1H), 6.08 (bs, 1H), 5.8 (s, 1H), 2.33 (s, 3H), 1.43 (s, 9H).



15 Ethyl 2-(2,6-dibromo-3-methyl-4-(1,1-dimethylethoxycarbonyl)-aminophenoxy)acetate (25-2)

- 20 A solution of 25-1 (0.6 g, 1.57 mmol) in DMF was treated with cesium carbonate and ethyl bromo acetate as described for 10-3 to give 25-2 as a tan solid
- R_f(20% EtOAc/Hexanes)=0.56
¹H NMR (400 MHz, CDCl₃) δ 8.0 (bs, 1H), 6.21 (bs, 1H), 4.56 (s, 2H), 4.3 (q, 2H), 2.35 (s, 3H), 1.5 (s, 9H), 1.33 (t, 3H).


- 191 -



Ethyl 2-(2,6-dibromo-3-methyl-4-aminophenoxy)acetate (25-3)

5 A solution of 25-2 (0.6 g, 1.29 mmol) in EtOAc (10 mL) was treated with HCl gas as described for 16-10 to give 25-3 as a tan solid.

¹H NMR (400 MHz, DMSO) δ 7.0 (s, 1H), 4.8-4.4 (b, 2H), 4.41 (s, 2H), 4.2 (q, 2H), 2.18 (s, 3H), 1.2 (t, 3H).



10

Ethyl 2-(2,6-dibromo-3-methyl-4-(4-(N-(1,1-dimethylethoxycarbonyl)piperidin-4-yl)phenylcarboxamide)phenoxy) acetate (25-4)

15 A solution of 25-3 (0.520 g, 1.29 mmol) and 1-5 (0.395 g, 1.29 mmol) in CH₂Cl₂ was treated with chloro-N,N,N',N'-bis(pentamethylene)formamidine hexafluorophosphate (0.504 g, 0.14 mmol) and diisopropylethyl amine (0.9 mL, 5.16 mmol) and stirred at room temperature for 24 hours. The solution was diluted with EtOAc and washed with H₂O, 10% KHSO₄, saturated NaHCO₃ and brine, dried
20 over MgSO₄, filtered and evaporated. The residue was chromatographed (silica gel 30% EtOAc/Hexanes) to give a mixture of 25-4 and 25-4a.


R_f25-4a(50% EtOAc/Hexanes)=0.45.

- 192 -

^1H NMR (400 MHz, CDCl_3) δ 8.0 (m, 2H), 7.8 (d, 2H), 7.5 (s, 1H), 6.93 (d, 2H), 6.85 (d, 1H), 4.6 (s, 2H), 4.3 (q, 2H), 3.6 (bs, 8H), 3.35 (m, 8H), 2.4 (s, 3H), -1.45 (s, 9H), 1.35 (t, 3H).

R_f 25-4 (50% EtOAc/Hexanes)=0.37.

- 5 ^1H NMR (400 MHz, CDCl_3) δ 7.6 (d, 2H), 6.7 (d, 2H), 4.6 (s, 2H), 4.3 (q, 2H), 3.55 (bs, 4H), 3.3 (bs, 4H), 2.38 (s, 3H), 1.45 (s, 9H), 1.33 (t, 3H).



10

2-(2,6-Dibromo-3-methyl-4-(4-(4-(1,1-dimethylethoxycarbonyl)-piperidin-4-yl)phenylcarbamoyl)phenoxy)acetic acid (25-5)

A solution of 25-4 and 25-4a (0.3 g) in 1:1:1


THF/MeOH/H₂O was treated with LiOH (0.084 g, 2 mmol) at 60°C.

- 15 After 1 hour the reaction was diluted with EtOAc and 10% KHSO₄ and the layers were separated. The organic layer was washed with H₂O, brine, dried with MgSO₄, filtered and evaporated to give 25-5 as a clear oil after chromatography in 9:0.5:0.5 CH₂Cl₂/MeOH/HOAc.

R_f (9:0.5:0.5 CHCl₃/MeOH/HOAc)=0.6.

- 20 ^1H NMR (400 MHz, CD₃OD) δ 7.90 (d, 2H), 7.6 (s, 2H), 7.05 (d, 2H), 4.55 (s, 2H), 3.6 (bs, 4H), 3.3 (bs, 4H), 2.35 (s, 3H), 1.5 (s, 9H).

- 193 -




5 2-(2,6-Dibromo-3-methyl-4-(4-piperizin-4-yl)phenylcarbonylamino) phenoxy) acetic acid, hydrochloride (25-6)

A slurry of the intermediate acid (0.4 g, 0.6 mmol) in EtOAc was cooled to -78°C and saturated with HCl gas. The reaction was warmed to 0°C , then concentrated *in vacuo* to give 25-6 as the HCl salt.


10 $R_f(10:0.5:0.5 \text{ EtOH}/\text{H}_2\text{O}/\text{NH}_4\text{OH})$ 0.18.

^1H NMR (400 MHz, D_2O) δ 7.73 (d, 2H), 7.23 (s, 1H), 7.02 (d, 2H), 4.3 (s, 2H), 3.1 (bs, 4H), 2.82 (bs, 4H), 2.1 (s, 3H).






- 194 -

SCHEME 26


- 195 -

SCHEME 26 (CONT'D)

- 196 -


SCHEME 26 (CONT'D)

- 197 -



1-(1,1-dimethylethoxycarbonyloxy)-3-nitro-4-aminophenol (26-1)

5 A solution of 3-nitro-4-amino phenol (Aldrich) (8 g, 52.6 mmol) in THF (250 mL) was cooled to 0°C and treated with di-tertbutyldicarbonate (24 g, 110 mmol) and triethylamine (14 mL, 105 mmol). The solution was allowed to warm slowly and after 24 hours was concentrated and the residue dissolved in EtOAc, washed with 10% KHSO₄, saturated NaHCO₃, and brine, dried over Na₂SO₄, filtered and
10 evaporated to give 26-1 as a brown oil.
¹H NMR (400 MHz, CDCl₃) δ 7.94 (s, 1H), 7.21 (dd, 1H), 6.8 (d, 1H), 6.04 (bs, 2H), 1.5 (s, 9H).



15

3-Nitro-4-(1,1-dimethylethoxycarbonylamino)phenol (26-2)


A solution of 26-1 (52.6 mmol) in dichloroethane (150 mL) was added at a rapid drip to a refluxing solution of di-tert-butylidicarbonate (12 g, 52.6 mmol) in dichloroethane (100 mL) and the
20 resulting mixture was refluxed for 20 minutes, then cooled to room temperature and stirred overnight. Triethylamine (52.6 mmol) and 2,6-dimethylaminopyridine (1.3 g, 10.5 mmol) were added and the solution refluxed for 2 hours and stirred at room temperature overnight. The solvents were removed and the residue was dissolved in 240 mL 1:1:1
25 THF/MeOH/H₂O and treated with LiOH·H₂O (22 g, 526 mmol) for 48

- 198 -

hours. The solution was diluted with water, 10% KHSO₄ and EtOAc and the layers separated. The organic layer was washed with water and brine, dried over MgSO₄, filtered and evaporated. The residue was chromatographed (20% EtOAc/Hexanes) to give 26-2 as a yellow solid.

5 R_f (20% EtOAc/Hexanes)=0.26

¹H NMR (400 MHz, CDCl₃) δ 9.5 (bs, 1H), 8.35 (d, 1H), 7.61 (s, 1H), 7.13 (d, 1H), 5.33 (s, 1H), 1.55 (s, 9H).




10

Ethyl 2-(3-nitro-4-(1,1-dimethylethoxycarbonylamino)phenoxy)
acetate (26-3)

A solution of 26-2 (2 g, 7.87 mmol) in DMF (75 mL) treated with cesium carbonate (1.28 g, 3.93 mmol), stirred for 10 minutes and treated with ethyl bromoacetate (0.8 mL, 7.92 mmol) at room temperature. After 1.5 hours the solution was concentrated under high vacuum and the residue was absorbed to silica gel and chromatographed in 10% EtOAc/Hexanes to give 26-3 as a yellow solid. R_f(30% EtOAc/Hexanes) 0.18

20 ¹H NMR (400 MHz, CDCl₃) δ 9.4 (bs, 1H), 8.44 (d, 1H), 7.65 (s, 1H), 7.26 (m, 1H), 4.63 (s, 2H), 4.24 (q, 2H), 1.55 (s, 9H), 1.3 (t, 3H).


- 199 -



Ethyl 2-(3-nitro-4-aminophenoxy)acetate, hydrochloride (26-4)

A solution of 26-3 (0.5 g, 0.25 mmol) was dissolved in
 5 EtOAc (15 mL), cooled to -78°C and saturated with HCl gas, warmed to
 0°C for 1 hour and concentrated to give 26-4 as an orange solid.
 R_f (10% MeOH/CHCl₃ saturated with NH₃)=0.13
¹H NMR (400 MHz, CD₃OD) δ 7.51 (d, 1H), 7.18 (dd, 1H), 7.0 (d,
 1H), 4.68 (s, 2H), 4.24 (q, 2H), 1.15 (t, 3H).


10



Ethyl 2-(3-nitro-4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenylcarbonylamino)phenoxy)acetate (26-5)

15 A solution of 26-4 (0.65 g, 2.46 mmol) and 1-5 (1.5 g, 4.9
 mmol) were treated with PYCLU and diisopropylamine as described for
23-5 to give 26-5 and 26-5a after chromatography in 30%
 EtOAc/Hexanes.
 R_f(30% EtOAc/Hexanes)=0.16
 20 ¹H NMR 26-5 (400 MHz, CDCl₃) δ 8.95 (d, 1H), 7.9 (d, 2H), 7.75 (s,
 1H), 6.95 (d, 2H), 4.65 (s, 2H), 4.28 (q, 2H), 3.6 (m, 4H), 3.35 (m, 4H),
 1.5 (s, 9H), 1.3 (t, 3H).

- 200 -



Ethyl 2-(3-phenylsulfonamido-4-(4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenylcarbonylamino)phenoxy)acetate (26-7)

5 A solution of 26-5 (0.4 g, 0.76 mmol) in EtOH (10 mL) was treated with 10% Pd/C (0.070 g), and hydrogenated under balloon pressure for 1.5 hours. The solution was filtered through SolkaFloc, and the cake rinsed with EtOAc. The filtrate was concentrated to give 26-6.


10 R_f(10% MeOH/CHCl₃ saturated with NH₃)=0.72

 The crude amine was dissolved in pyridine (3 mL) and treated with phenylsulfonyl chloride (0.10 mL, 0.83 mmol) and stirred for four hours. The solution was diluted with EtOAc and washed with water and brine, dried with MgSO₄, filtered and concentrated to give a yellow oil that was chromatographed (gradient 30% EtOAc/Hexanes to 100% EtOAc) to give 26-7 as an oil.

(R_f 30% EtOAc/Hexanes) 0.85)

15 ¹H NMR 26-5(400 MHz, CDCl₃) δ 8.04 (s, 1H), 7.7 (d, 2H), 7.65 (d, 2H), 7.5 (s, 2H), 7.42 (d, 1H), 7.38 (m, 2H), 6.9 (m, 2H), 6.8 (d, 1H),
20 6.6 (s, 1H), 4.46 (s, 2H), 4.25 (q, 2H), 3.6 (m, 4H), 3.3 (m, 4H), 1.5 (s, 9H), 1.28 (t, 3H).

- 201 -




5 2-(3-Phenylsulfonamido-4-(4-(4-piperazin-1-yl)phenylcarbonyl-amino)phenoxy)acetic acid (26-8)


A solution of 26-7 (0.18 g, 0.28 mmol) was treated with LiOH and HCl gas as described for 23-6 to give 26-8 as a white solid after chromatography (10:0.5:0.5 EtOH/NH₄OH/H₂O) and further purification via reverse phase HPLC.

10 ¹H NMR (400 MHz, D₂O) δ 7.6 (m, 3H), 7.48 (d, 2H), 7.23 (m, 1H), 7.18 (m, 2H), 7.1 (d, 2H), 6.59 (s, 1H), 6.5 (d, 1H), 4.23 (s, 2H), 3.2 (m, 4H), 2.9 (m, 4H).

- 202 -

SCHEME 27

- 203 -

SCHEME 27 (CONT'D)

- 5 4-[4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenyl-
carbonylamino]-3-methylphenoxyacetic acid; N,N-diethylglycolamide
ester (27-2)

A solution of carboxylic acid 10-6 (500 mg, 1.07 mmol),
N,N-diethyl chloroacetamide 27-1 (0.154 mL, 1.12 mmol), NaI (5 mg,
10 0.03 mmol), Cs₂CO₃ (173 mg, 0.535 mmol) and DMF (5 mL) was
heated at 60°C for 20 h. The reaction mixture was diluted with EtOAc
and washed with water, 10% aqueous KHSO₄ and brine. Drying
(MgSO₄), filtration, removal of the solvent *in vacuo*, and
15 chromatography on silica gel using a gradient of 50 to 90% EtOAc in
hexane as eluant gave 4-[4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-
yl)phenylcarbonylamino]-3-methylphenoxyacetic acid N,N-diethyl-
glycolamide ester (27-2) as a white solid. ¹H NMR (CD₃OD): δ 1.23 (t,
J=7Hz, 6H), 1.48 (s, 9H), 2.25 (s, 3H), 3.32 (m, 8H), 3.58 (m, 2H), 4.83
(s, 2H), 4.92 (s, 2H), 6.83 (dd, J=3Hz, 9Hz, 1H), 6.90 (s, 1H), 7.03 (d,
20 J=9Hz, 2H), 7.19 (d, J=(Hz, 1H), 7.78 (d, J=9Hz, 2H).

- 204 -

4-[4-(Piperazin-1-yl)phenylcarbonylamino]-3-methylphenoxyacetic acid; N,N-diethylglycolamide ester, hydrochloride (27-3)

To a stirred solution of EtOAc (7 mL) saturated with HCl gas was added ester 27-2 (500 mg, 0.86 mmol), suspended in EtOAc (3 mL). The mixture was stirred for 1 h at ambient temperature, purged with dry argon for 30 min and concentrated *in vacuo* to give 4-[4-(piperazin-1-yl)phenylcarbonylamino]-3-methylphenoxyacetic acid N,N-diethylglycolamide ester, hydrochloride (27-3) as a white solid. ¹H NMR (D₂O): δ 1.11 (t, J=7Hz, 3H), 1.21 (t, J=7Hz, 3H), 2.23 (s, 3H), 3.37 (t, J=7Hz, 4H), 3.44 (m, 4H), 3.62 (m, 4H), 4.96 (s, 2H), 5.01 (s, 2H), 6.92 (d, J=9Hz, 1H), 7.00 (s, 1H), 7.21 (m, 3H), 7.90 (d, J=9Hz, 2H).

4-[4-(4-(1,1-Dimethylethoxycarbonyl)piperazin-1-yl)phenylcarbonylamino]-3-methylphenoxyacetic acid; N-methylglycolamide ester (27-5)

A solution of carboxylic acid 10-6 (500 mg, 1.07 mmol), N-methyl chloroacetamide 27-4 (0.121 mg, 1.12 mmol), NaI (5 mg, 0.03 mmol), Cs₂CO₃ (173 mg, 0.535 mmol) and DMF (5 mL) was heated at 60°C for 20 h. The reaction mixture was diluted with EtOAc and washed with water, 10% aqueous KHSO₄ and brine. Drying (MgSO₄), filtration, removal of the solvent *in vacuo*, and chromatography on silica gel using EtOAc as eluant gave 4-[4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenylcarbonylamino]-3-methylphenoxyacetic acid N-methylglycolamide ester (27-5) as a white solid. ¹H NMR (CD₃OD): δ 1.49 (s, 9H), 2.31 (s, 3H), 2.77 (d, J=5Hz, 3H), 3.29 (m, 4H), 3.61 (m, 4H), 4.67 (s, 2H), 4.75 (s, 2H), 5.85 (br s, 1H), 6.87 (m, 2H), 6.95 (d, J=(Hz, 2H), 7.47 (s, 1H), 7.78 (m, 1H), 7.79 (d, J=9Hz, 2H).


4-[4-(Piperazin-1-yl)phenylcarbonylamino]-3-methylphenoxyacetic acid; N-methylglycolamide ester, hydrochloride (27-6)

HCl gas was rapidly bubbled through a solution of 4-[4-(4-(1,1-dimethylethoxycarbonyl)piperazin-1-yl)phenylcarbonylamino]-3-methylphenoxyacetic acid N-methylglycolamide ester (27-5) (325 mg,


- 205 -

0.60 mmol) in EtOAc (30 mL) at 0°C for 20 min. The mixture was aged 40 min., purged with argon and concentrated *in vacuo*. The solid was triturated with EtOAc and Et₂O to give 4-[4-(piperazin-1-yl)phenylcarbonylamino]-3-methylphenoxyacetic acid N-methylglycolamide ester, hydrochloride (27-6) as a white solid. ¹H NMR (D₂O): δ 2.23 (s, 3H), 2.78 (s, 3H), 3.43 (m, 4H), 3.62 (m, 4H), 4.75 (s, 2H), 4.95 (s, 2H), 6.90 (d, J=8Hz, 1H), 6.99 (s, 1H), 7.21 (m, 3H), 7.90 (d, J=9Hz, 2H).

- 206 -

SCHEME 28

- 207 -






SCHEME 28 (CONT'D)

- 208 -


4-[4-(1-Piperazinyl)phenylcarbonylamino]-3-methoxyphenoxyacetic acid, hydrochloride (28-8)

5 Using a sequence essentially the same as described for compound 15-8, but starting with 3-methoxyphenol (28-1), 4-[4-(1-piperazinyl)phenylcarbonylamino]-3-methoxyphenoxyacetic acid, hydrochloride (28-8) as prepared. ¹H NMR (D₂O): δ 3.33 (d, J=3.9Hz, 4H), 3.51 (t, J=3.9Hz, 4H), 3.75 (s, 3H), 4.62 (s, 2H), 6.51 (d, J=8.6Hz, 1H), 6.64 (s, 1H), 7.05 (d, J=7.4Hz, 2H), 7.32 (d, J=8.6Hz, 1H), 7.75 (d, J= 7.4Hz, 2H).

- 209 -

SCHEME 2929-1 I_2 , pyridine, $100^\circ C$ 29-2 $i\text{-Pr}_2\text{NEt}$, CH_2Cl_2 29-3 $\text{BrCH}_2\text{COOBU}^t$, Cs_2CO_3 , DMF

- 210 -

SCHEME 29 (CONT'D)5 4-Hydroxy-2-methylbenzoic acid (29-2)

Following the procedure described in US 92-852870 920317, 4-hydroxy-2-methylbenzoic acid was prepared from 4-hydroxy-2-methylacetophenone 29-1. ^1H NMR (CD_3OD): δ 2.52 (s, 3H), 6.64 (m, 2H), 7.84 (d, $J=8.4$ Hz, 1H).







10

4-[4-(1-Piperazinyl)phenylaminocarbonyl]-3-methylphenoxyacetic acid, hydrochloride (29-5)



Using a sequence essentially the same as described for compound 14-6, but starting with 4-hydroxy-3-methylbenzoic acid (29-2), 4-[4-(1-piperazinyl)phenylaminocarbonyl]-3-methylphenoxyacetic acid, hydrochloride (29-5) was prepared. ^1H NMR ($\text{DMSO}-d_6$): δ 2.36 (s, 3H), 3.26 (d, $J=7.3$ Hz, 8H), 3.80 (br s, 4H), 4.73 (s, 2H), 6.81 (dd, $J=2.4, 8.4$ Hz, 2H), 6.84 (d, $J=2.4$ Hz, 1H), 6.97 (d, $J=8.7$ Hz, 2H), 7.39 (d, $J=8.4$ Hz, 1H), 7.62 (d, $J=8.7$ Hz, 2H), 8.72 (br s, 1H), 9.99 (s, 1H).

20


- 211 -

SCHEME 3030-130-230-3

- 212 -

SCHEME 30 (CONT'D)

- 213 -

SCHEME 30 (CONT'D)

5 4-(1,1-Dimethylethoxycarbonyl)amino-3-trifluoromethylphenol (30-3)

Using a method similar to that described for compound 15-3, starting with 3-trifluorophenol, 4-(1,1-dimethylethoxycarbonyl)-amino-3-trifluoromethylphenol (30-3) was prepared. ¹H NMR (CDCl₃): δ 1.55 (s, 9H), 4.12 (m, 2H), 6.72 (d, 1H), 7.12 (m, 1H), 7.26 (m, 1H).

10

- 214 -


Ethyl 4-(1,1-dimethylethoxycarbonyl amino-3-trifluoromethyl-
phenoxyacetate (30-5)

To a 200 mL round bottomed flask with a stirring bar and an argon inlet was added 4-(1,1-dimethylethoxycarbonyl)amino-3-trifluorophenol (4.80 g, 17.3 mmol), 18-crown-6 (4.63 g, 17.5 mmol), and THF (69 mL). This mixture was cooled to 0°C in an ice-water bath, then a solution of potassium hexamethyl disilylazide in toluene (34.7 mL, 17.4 mmol) was added followed by ethyl bromoacetate (1.93 mL, 17.4 mmol). This mixture was stirred under argon for 16 h, allowing the cooling bath to expire. This mixture was transferred to a separatory funnel, acidified with 10% aqueous citric acid and extracted with EtOAc. The organic layer was washed with water and brine, dried (MgSO₄), filtered and concentrated *in vacuo*. The BOC group was removed as described for 29-9. This material was chromatographed on silica gel to give ethyl 4-(1,1-dimethylethoxy-carbonyl amino-3-trifluoromethylphenoxyacetate (30-5) as an oil. ¹H NMR (CDCl₃): δ 1.58 (t, 3H), 3.93 (br s, 2H), 4.27 (q, 2H), 4.56 (s, 2H), 6.69 (d, 1H), 6.95 (dd, 1H), 7.00 (d, 1H).


4-[4-(1-Piperazinyl)phenylcarbonylamino]-3-trifluoromethylphenoxy-acetic acid (30-8)

Using a sequence similar to that described for compound 12-8 but starting with ethyl 4-(1,1-dimethylethoxycarbonyl amino-3-trifluoromethylphenoxyacetate (30-5), 4-[4-(1-piperazinyl)phenyl-carbonylamino]-3-trifluoromethylphenoxyacetic acid (30-8) was prepared. ¹H NMR (DMSO-d₆): δ 3.25 (s, 4H), 3.50 (s, 4H), 4.84 (s, 2H), 7.09 (d, J=8.0 Hz, 2H), 7.25 (m, 2H), 7.39 (d, J=8.4 Hz, 2H), 7.88 (d, J= 8.0 Hz, 2H), 8.82 (br s, 1H), 9.72 (s, 1H).

- 215 -

SCHEME 31

- 216 -

SCHEME 31 (CONT'D)

- 217 -

Ethyl 4-(4-nitrophenylcarbamate)-3-methylphenoxyacetate (31-1)

A solution of ethyl 4-amino-3-methylphenoxyacetate hydrochloride (10-4) (300 mg, 1.22 mmol) in CH₂Cl₂ (30 mL) was placed in a 50 mL flask. To this solution 4-nitrophenyl chloroformate (246 mg, 1.22 mmol) and pyridine (0.22 mL) were added at room temperature. The reaction was stirred at ambient temperature 18 h, then concentrated *in vacuo* to yield ethyl 4-(4-nitrophenylcarbamate)-3-methylphenoxyacetate (32-1). ¹H NMR (CDCl₃): δ 1.30 (t, j=7.0 Hz, 3H), 2.34 (s, 3H), 4.28 (q, j=7.0 Hz, 2H), 4.59 (s, 2H), 6.70 (dd, j=8.3, 2.0 Hz, 1H), 6.7 (d, j=2.0 Hz, 1H), 7.40 (d, j=8.3 Hz, 1H), 8.05 (d, j=7.0 Hz, 1H), 8.28 (d, j=7.0 Hz, 2H).

4-(1,1-Dimethylethoxycarbonyl)-4,4'-bipiperidine (31-3)

A solution of bipiperidine dihydrochloride (Aldrich 31-2) (25 g, 0.1 mol) in H₂O (100 mL) was placed in a 2L round bottomed flask. A solution of 6N NaOH was added dropwise to adjust the pH to 8-9. The solution was diluted with EtOH (1200 mL) and stirred vigorously at ambient temperature. The resulting mixture was treated with a solution of di-t-butyl dicarbonate (24 g, 0.11 mol) in EtOH (800 mL). Periodically, 6N NaOH was added to maintain pH 8-9. After stirring at ambient temperature 18 h, the reaction was concentrated *in vacuo*. The residue was dissolved in 1:1 ether:H₂O (1000 mL) and the pH adjusted to 12 with 6N NaOH. The aqueous phase was separated and extracted again with ether. The ether phases were combined and washed with brine, 10% citric acid, and H₂O. The citric acid and H₂O washes were combined and the pH adjusted to 12-13 with 6N NaOH, then extracted in 3 portions with ether (600 mL). The ether extract was washed (brine), dried (Na₂SO₄) and concentrated *in vacuo* to a clear oil which solidified on standing to yield 4-(1,1-dimethylethoxycarbonyl)-4,4'-bipiperidine (31-3). ¹H NMR (CDCl₃): δ 1.25 (br m, 7H), 1.45 (s, 9H), 1.66 (br d, 4H), 2.60 (dd, 4H), 3.1(d, j=12 Hz, 2H), 4.21(br s, 2H).

- 218 -

Ethyl-4-[(4-(1,1-dimethylethoxycarbonyl)-4,4'-bipiperidinyl-1-carbonyl)amino]-3-methylphenoxyacetate (31-4)

A solution of ethyl 4-(4-nitrophenylcarbamate)-3-methylphenoxyacetate (31-1), (457 mg, 1.22 mmol), 4-(1,1-dimethylethoxycarbonyl)-4,4'-bipiperidine (31-3) 327 mg, 1.22 mmol), and triethylamine (0.34 mL, 2.44 mmol) in CH₂Cl₂ (20 mL). The solution was refluxed 4 h, cooled and diluted with CH₂Cl₂ (10 mL). The reaction was extracted with H₂O (15 mL). The CH₂Cl₂ extract was washed (1% NaOH, H₂O, 10% KHSO₄, brine), dried (Na₂SO₄), filtered, then concentrated *in vacuo* to an oil. The oil was chromatographed on silica using 50% EtOAc/hexane to obtain ethyl-4-[(4-(1,1-dimethylethoxycarbonyl)-4,4'-bipiperidinyl-1-carbonyl)amino]-3-methylphenoxyacetate (31-4) ¹H NMR (CDCl₃): δ 1.27 (br m, 7H), 1.30 (t, j= 7.0 Hz, 3H), 1.46 (s, 9H), 1.68 (d, j=12 Hz, 2H), 1.75 (d, j=10 Hz, 2H), 2.22 (s, 3H), 2.65 (t, j=12 Hz, 2H), 2.83 (t, j=12 Hz, 2H), 4.08 (d, j=12 Hz, 1H), 4.25 (br s, 2H), 4.27 (q, j=7 Hz, 2H), 4.58 (s, 2H), 5.97 (s, 1H), 6.70 (dd, j=8.3, 2 Hz, 1H), 6.73 (d, j=2 Hz, 1H), 7.40 (d, j=8.3 Hz, 1H),

4-[(4-(1,1-Dimethylethoxycarbonyl)-4,4'-bipiperidinyl-1-carbonyl)amino]-3-methylphenoxyacetic acid (31-5)

In a 25 mL round bottomed flask a solution of ethyl-4-[(4-(1,1-dimethylethoxycarbonyl)-4,4'-bipiperidinyl-1-carbonyl)amino]-3-methylphenoxyacetate (31-4) (100 mg, 0.2 mmol), 1M LiOH, (0.6 mL, 0.6 mmol), H₂O (5 mL), THF (5 mL), and MeOH (5 mL) was stirred at ambient temperature 3 h. The reaction was concentrated *in vacuo*, then dissolved in CHCl₃ (20 mL). The CHCl₃ extract was washed (1N HCl, H₂O, and brine), dried (NaSO₄), filtered, and concentrated to yield 4-[(4-(1,1-dimethylethoxycarbonyl)-4,4'-bipiperidinyl-1-carbonyl)amino]-3-methylphenoxyacetic acid (31-5). ¹H NMR (CDCl₃): δ 1.22 (br m, 6H), 1.46 (s, 9H), 1.6 (br m, 4H), 2.2 (s, 3H), 2.6 (br t, 2H), 2.79 (t, j=11 Hz, 2H), 4.0 (br m, 5H), 4.58 (s, 2H), 6.1 (dd, j=9, 2 Hz, 1H), 6.75 (d, j=2 Hz, 1H), 7.21 (d, j=9Hz, 1H), 8.1 (s, 1H).

- 219 -


4-[(4-[4,4']-Bipiperidiny-1-carbonyl)amino]-3-methylphenoxyacetic
acid, hydrochloride (31-6)

In a 35 mL round bottomed flask 4-[(4-(1,1-dimethyl-ethoxycarbonyl)-4,4'-bipiperidiny-1-carbonyl)amino]-3-methylphenoxyacetic acid (31-5) (83 mg, 0.17 mmol) was dissolved in CH₂Cl₂ (10 mL) and cooled to 0°. Anhydrous HCl was bubbled through the solution for 5 min. The reaction was stirred at 0° 4 h, then concentrated *in vacuo* to yield 4-[(4-[4,4']-bipiperidiny-1-carbonyl)amino]-3-methylphenoxyacetic acid, hydrochloride (31-6). ¹H NMR (DMSO-d₆):

10 δ 1.04 (br d, j=11 Hz, 3H), 1.3 (br s, 3H), 1.62 (d, j=12 Hz, 2H), 1.79 (d, j=11 Hz, 2H), 2.07 (s, 3H), 2.67 (t, j=12 Hz, 2H), 2.74 (br m, 2H), 4.07 (d, j=12 Hz, 2H), 4.59 (s, 2H), 6.62 (dd, j=9, 2 Hz, 1H), 6.70 (d, j=2 Hz, 1H), 6.95 (d, j=9 Hz, 1H), 7.87 (s, 1H), 8.2 (br s, 1H), 8.5 (br s, 1H).

15

- 220 -

SCHEME 32

- 221 -

4-(2-(4-Dimethoxyethoxycarbonyl)-(4,4')-bipiperidinyl-1-carbonyl)phenol (32-2a)

In a 50 mL round bottomed flask a solution of 4-(1,1-dimethylethoxycarbonyl)-4,4'-bipiperidine (31-3) (400 mg, 1.49 mm), 4-hydroxybenzoic acid (206 mg, 1.49 mm), (32-1a), chloro-N,N,N',N'-bis(pentamethyl)formamidinium hexafluorophosphate (537 mg, 1.49 mm) and diisopropylethylamine (0.52 mL, 2.98 mm) in 25 mL DMF was stirred at ambient temperature 48 h. The reaction was concentrated *in vacuo*, then partitioned between EtOAc and H₂O. The EtOAc extract was washed (H₂O, sat'd NaHCO₃, H₂O, 10% KHSO₄ and brine), dried (Na₂SO₄), filtered and concentrated *in vacuo*. The resulting oil was chromatographed on silica using 5% MeOH/CHCl₃ as eluent to yield 4-(2-(4-dimethoxyethoxycarbonyl)-(4,4')-bipiperidinyl-1-carbonyl)-phenol (32-2a). ¹H NMR (CDCl₃): δ 1.2 (br m, 6H), 1.4 (s, 9H), 1.58 (br m, 4H), 4.1 (m, 2H), 4.3 (m, 1H), 6.83 (d, j=8.5 Hz, 2H), 7.31 (d, j=8.5 Hz, 2H).

4-(2-(4-Dimethoxyethoxycarbonyl)-(4,4')-bipiperidinyl-1-yl-2-oxo-ethyl)phenol (32-2b)

In a manner similar to the preparation of compound 32-2a, 4-(2-(4-dimethoxyethoxycarbonyl)-(4,4')-bipiperidinyl-1-yl-2-oxo-ethyl)-phenol (32-2b) was prepared. ¹H NMR (CDCl₃): δ 0.89 (m, 1H), 1.1 (m, 3H), 1.45 (s, 9H), 1.5 (br m, 6H) 2.49 (t, j=12 Hz, 1H), 2.62 (m, 2H), 2.91 (t, j=12 Hz, 1H), 3.64 (s, 2H), 3.90 (d, j=12 Hz, 1H), 4.1 (m, 2H), 4.68 (d, j=12 Hz, 1H), 6.12 (br m, 1H), 6.77 (d, j=8 Hz, 2H), 7.07 (d, j=8 Hz, 2H).

t-Butyl-4-(2-(4-Dimethoxyethoxycarbonyl)-(4,4')-bipiperidinyl-1-carbonyl)phenoxyacetate (32-3a)

In a 50 mL round bottomed flask a mixture of 4-(2-(4-dimethoxyethoxycarbonyl)-(4,4')-bipiperidinyl-1-carbonyl)-phenol (32-2a) (378 mg, 0.97 mm), t-butyl bromoacetate (0.16 mL, 1.067 mm) and cesium carbonate (348 mg, 1.067 mm) in 50 mL DMF was stirred at ambient temperature 18 h. The reaction was concentrated *in vacuo*,

- 222 -

then partitioned between CHCl_3 and H_2O . The CHCl_3 extract was washed (10% KHSO_4 , H_2O , NaHCO_3 and brine), dried (Na_2SO_4), filtered and concentrated *in vacuo* to yield t-butyl-4-(2-(4-dimethoxyethoxycarbonyl)-(4,4')-bipiperidinyl-1-carbonyl)-phenoxyacetate (32-3a). ^1H NMR (CDCl_3): δ 1.2 (m, 6H), 1.42 (s, 9H), 1.45 (s, 9H), 2.68 (m, 4H), 2.61 (t, 2H), 2.8 (m, 2H), 4.18 (m, 4H), 4.5 (s, 2H), 6.9 (d, $j=8$ Hz, 2H), 7.35 (d, $j=8$ Hz, 2H).

10 t-Butyl-4-(2-(4-dimethoxyethoxycarbonyl)-(4,4')-bipiperidinyl-1-yl-2-oxo-ethyl)phenoxyacetate (32-3b)

In a manner similar to the preparation of 32-3a, t-butyl-4-(2-(4-dimethoxyethoxycarbonyl)-(4,4')-bipiperidinyl-1-yl-2-oxo-ethyl)-phenoxyacetate (32-3b) was prepared. ^1H NMR (CDCl_3): δ 0.88 (m, 1H), 1.11 (m, 5H), 1.45 (s, 9H), 1.48 (s, 9H), 1.61 (m, 4H), 2.48 (t, $j=12$ Hz, 1H), 2.61 (br t, 2H), 2.88 (t, $j=13$ Hz, 1H), 3.66 (s, 2H), 3.88 (d, $j=13$ Hz, 1H), 4.1 (m, 2H), 4.49 (s, 2H), 4.68 (d, $j=13$ Hz, 1H), 6.84 (d, $j=8.8$ Hz, 2H), 7.15 (d, $j=8.8$ Hz, 2H).

20 [4-([4,4']-Bipiperidinyl-1-carbonyl)phenoxy]acetic acid (32-4a)

In a round bottomed flask, t-butyl-4-(2-(4-dimethoxyethoxycarbonyl)-(4,4')-bipiperidinyl-1-carbonyl)-phenoxyacetate (32-3a) (56 mg, 0.11 mm) was stirred with trifluoroacetic acid (2.5 mL) and CH_2Cl_2 (5 mL) at 0° 18 h. The reaction was concentrated *in vacuo* to yield [4-([4,4']-bipiperidinyl-1-carbonyl)phenoxy]-acetic acid (32-4a). ^1H NMR ($\text{DMSO}-d_6$) δ 1.11 (m, 2H), 1.32 (m, 4H), 1.78 (m, 2H), 1.80 (d, $j=12$ Hz, 2H), 2.81 (dd, $j=11$ Hz, 4H), 3.28 (d, $j=11$ Hz, 2H), 4.73 (s, 2H), 6.94 (d, $j=8.5$ Hz, 2H), 7.32, $J=8.5$, 2H), 8.16 (br s, 1H), 8.47 (br s, 1H).

30 [4-(2-[4,4']-Bipiperidinyl-1-yl-2-oxo-ethyl)phenoxy]acetic acid (32-4b)


In a manner similar to the preparation of (32-4a), 4-(2-[4,4']-bipiperidinyl-1-yl-2-oxo-ethyl)-phenoxy]-acetic acid (32-4b) was prepared. ^1H NMR (CDCl_3): δ 0.81 (m, 1H), 1.07 (m, 1H), 1.36 (br s,

- 223 -


2H), 1.62 (d, j=13 Hz, 1H), 1.74 (d, j=12 Hz, 1H), 1.87 (br s, 2H), 2.56 (t, j=11 Hz, 1H), 2.94 (m, 3H), 3.36 (d, j=12 Hz, 2H), 3.70 (m, 3H), 4.0 (d, j=13 Hz, 1H), 4.57 (d, j=13 Hz, 1H), 4.64 (s, 2H), 6.89 (d, j=8.5 Hz, 2H), 7.17 (d, j=8.5 Hz, 2H).

5


- 224 -

SCHEME 33

- 225 -


SCHEME 33 (CONT'D)

5


Ethyl 4-pyridylpiperidin-4-ylcarboxylate (33-1)

- Ethyl isonipecotate (6.0 g 38.66 mmol), 4-chloropyridine
 10 hydrochloride (5.9 g, 38.66 mmol) and N-methylmorpholine (9.3 g mL,
 85.00 mmol), were dissolved in N-methylpyrrolidine (50 mL) and the
 resulting solution was heated at 100°C for 48 h. The solution was
 concentrated *in vacuo* and the residue was dissolved in EtOAc and
 washed with water and brine (2 x 100 mL), then dried (Na₂SO₄) and
 15 evaporated. The resulting residue was purified by flash
 chromatography (5% MeOH/CHCl₃) to afford 33-1 as a crystalline
 solid. ¹H NMR (CDCl₃) δ 8.21 (d, J=6.8 Hz, 2H), 6.78 (d, J=6.8 Hz,
 2H), 4.18 (q, J=7.0 Hz, 2H), 3.85 (m, 2H), 3.10 (m, 2H), 2.61 (m, 1H),
 2.05 (m, 2H), 1.85 (m, 2H), 1.23 (t, J=7.0 Hz, 3H).

- 226 -

33-24-Pyridylpiperidin-4-ylcarboxylic acid (33-2)


A solution of 33-1 (10 g, 42.7 mmol) in THF (50 mL) was
 5 treated with 1N LiOH (47 mL, 47.0 mmol) and water (50 mL). The
 resulting solution was stirred at ambient temperature for 12 h. The
 solution was concentrated and the aqueous residue was cooled to 0°C,
 then adjusted to pH = 6 with 1N HCl. The resulting solid was collected
 by filtration and dried *in vacuo* to afford 33-2 as a white solid. ¹H
 10 NMR (D₂O) δ 7.95 (d, J=6.8 Hz, 2H), 6.73 (d, J=6.8 Hz, 2H), 3.76 (d,
 J=12.8 Hz, 2H), 2.81 (m, 2H), 2.20 (m, 1H), 1.85 (d, J=12.9 Hz, 2H),
 1.55 (m, 2H).

33-3Ethyl 4-(Pyridyl)(piperidin-4-yl)-carbonylamino-3-methylphenoxy-
acetate (33-3)

Ethyl 4-amino-3-methylphenoxyacetate hydrochloride
 (10-4) (0.35 g, 1.41 mmol), 4-(Pyridyl)(piperidin-4-yl)-carboxylic acid
 (0.30 g, 1.41 mmol), chloro-N, N, N', N'-bis(pentamethylene)form-
 20 amidinium hexafluorophosphate (0.50 g, 1.41 mmol), and
 diisopropylethylamine (0.25 mL, 1.41 mmol) were dissolved in
 dimethylformamide (15 mL). The solution was stirred at ambient
 temperature for 48 h and the solvent removed *in vacuo* to give an oil.
 This material was chromatographed on silica gel using 5:95 methanol-
 25 ammonia saturated chloroform as eluant to afford 33-3 as a beige solid.
¹H NMR (CDCl₃): δ 8.27 (d, j=5.6 Hz, 2H), 7.53 (d, j=8.8 Hz, 1H),
 7.03 (s, 1H), 6.78 (s, 1H), 6.73 (d, j=8.8 Hz, 1H), 6.68 (d, j=6.1 Hz,
 2H), 4.59 (s, 2H), 4.27 (q, j=7.1 Hz, 2H), 3.97 (d, j=13.2 Hz, 2H), 2.95

- 227 -

(t, $j=11.7$ Hz, 2H), 2.53 (m, 1H), 2.06 (d, $j=10.7$ Hz, 2H), 1.92 (m, 2H), 1.73 (s, 3H), 1.30 (t, $j=7.1$ Hz, 3H).




5


4-(Pyridyl)(piperidin-4-yl)-carbonylamino-3-methylphenoxyacetate
(33-4)

A solution of Ethyl 4-(Pyridyl)(piperidin-4-yl)-carbonyl-
amino-3-methylphenoxyacetate (33-3) (0.05 g, 0.126 mmol) in
10 tetrahydrofuran (10 mL) was treated with 1 N lithium hydroxide (0.13
mL, 0.132 mmol) and H₂O (10 mL). The resulting solution was stirred
at ambient temperature and the solvent removed *in vacuo* to give 33-4 as
a colorless glass. ¹H NMR (CD₃OD) δ 8.09 (d, $j=6.6$ Hz, 2H), 7.09 (d,
 $j=8.6$ Hz, 2H), 6.87 (d, 6.8 Hz, 1H), 6.81 (s, 1H), 6.75 (d, $j=8.6$ Hz,
15 1H), 4.34 (s, 2H), 4.10 (d, $j=13.2$ Hz, 2H), 3.02 (t, 10.0 Hz, 2H), 2.82
(m, 1H), 2.18 (s, 3H), 1.98 (d, $J=10.3$ Hz, 2H), 1.83 (m, 2H).

- 228 -

SCHEME 34

- 229 -

SCHEME 34 (CONT'D)

- 230 -

3-Chloro-4-aminophenol (34-2)

Using a procedure similar to that described for compound 12-2 but starting with 3-chlorophenol (34-1), 3-chloro-4-aminophenol (34-2) was prepared. ¹H NMR (CDCl₃): δ 6.57 (dd, J= 2.8, 8.6 Hz, 1H), 6.73 (m, 2H).

4-(1,1-Dimethylethoxycarbonyl)amino-3-chlorophenol (34-3)

To a 100 mL round bottomed flask with a stirring bar and an argon inlet was added 4-(1,1-dimethylethoxycarbonyl)amino-3-chlorophenol (1.91 g, 13.3 mmol), di-tert-butylidicarbonate (3.14 g, 14.4 mmol) and THF (50 mL). To this mixture was added triethylamine (2.23 mL, 16.0 mmol) and the mixture was stirred at room temperature for 98 h. The solvent was removed *in vacuo*. The residue was acidified with 10% aqueous citric acid and extracted with EtOAc. The EtOAc extract was washed with water and brine. Drying (MgSO₄), filtration, removal of the solvent *in vacuo* and chromatography on silica gel using EtOAc-hexane as eluant gave an oil. This material was dissolved in THF (25 mL) and MeOH (8 mL) and 1N LiOH (25 mL) were added. This solution was stirred at ambient temperature 4 h. This mixture was acidified with 10% citric acid and extracted with EtOAc. The organic layer was dried (MgSO₄), filtered and concentrated *in vacuo* to give 34-3 as an oil. ¹H NMR (CDCl₃): δ 1.53 (s, 9H), 6.69 (dd, J= 2.8, 8.9 Hz, 2H), 6.85 (d, J= 2.8 Hz, 1H), 7.80 (d, J= 8.9 Hz, 1H).

Ethyl 4-(1,1-dimethylethoxycarbonyl)amino-3-chlorophenoxyacetate (34-4)

To a 50 mL round bottomed flask with a stirring bar and an argon inlet was added 4-(1,1-dimethylethoxycarbonyl)amino-3-chlorophenol (0.831 g, 3.41 mmol) and DMF (16 mL). This mixture was cooled in an ice bath then Cs₂CO₃ (0.552 g, 1.69 mmol) and ethyl bromoacetate (0.37 mL, 3.34 mmol) were added. The resulting mixture was stirred for 6 h, during which time the cooling bath was allowed to expire. The mixture was filtered through a frit and the DMF was

- 231 -





removed *in vacuo*. The residue was dissolved in EtOAc and washed with water (12X) and brine. Drying (MgSO₄), filtration and removal of the solvent *in vacuo* gave an oil which was purified by silica gel chromatography (EtOAc-hexane) to give ethyl 4-(1,1-dimethylethoxycarbonyl)amino-3-chlorophenoxyacetate (34-4) as an oil. ¹H NMR (CDCl₃): δ 1.30 (m, 3H), 1.53 (s, 9H), 4.27 (m, 2H), 4.57 (s, 2H), 6.78 (br s, 1H), 6.83 (dd, J= 2.8, 8.8 Hz, 1H), 6.96 (d, J=2.8 Hz, 1H), 8.02 (br d, J= 8.8 Hz, 1H).

10 4-[4-(1-Piperazinyl)phenylcarbonylamino]-3-chlorophenoxyacetic acid (34-8)


Using a sequence similar to that described for compound 12-8, but starting with ethyl 4-(1,1-dimethylethoxycarbonyl)amino-3-chlorophenoxyacetate (34-4), 4-[4-(1-piperazinyl)phenylcarbonylamino]-3-chlorophenoxyacetic acid was prepared. ¹H NMR (DMSO-d₆, HCl salt): δ 3.22 (t, J= 5.0 Hz, 4H), 3.53 (t, J= 5.0 Hz, 4H), 4.75 (s, 2H), 6.94 (dd, J= 2.9, 8.8 Hz, 1H), 7.08 (d, J= 8.9 Hz, 2H), 7.11 (d, J=2.9 Hz, 1H), 7.40 (d, J=8.8 Hz, 1H), 7.91 (d, J= 8.9 Hz, 2H), 9.12 (br s, 1H), 9.69 (s, 1H).

20


- 232 -

SCHEME 35

- 233 -

SCHEME 35 (CONT'D)

- 234 -

SCHEME 35 (CONT'D)

5 1-Hydroxymethyl-4-(4-(1,1-dimethylethoxycarbonyl)piperazinyl)-
benzene (35-1)

To an oven dried 500 mL round bottomed flask with a stirring bar and an argon inlet was added acid 1-5 (5.00 g, 16.32 mmol) and distilled, dry, THF (80 mL). This solution was cooled in an ice bath and borane•THF complex (125 mL of a 1M solution in THF, 125 mmol) was added with a syringe. The resulting solution was maintained at 0°C for 3.5 h. The reaction was quenched by addition of MeOH (50 mL), slowly, with a syringe over 5 min. This mixture was stirred at ambient temperature for 18 h. The solvents were removed *in vacuo* and the residue was dissolved in EtOAc (300 mL). This solution was washed with saturated aqueous NaHCO₃ and brine. Drying (MgSO₄), filtration and removal of the solvent *in vacuo* gave 4.86 g of 1-hydroxymethyl-4-(4-(1,1-dimethylethoxycarbonyl)piperazinyl)benzene, 35-1, as a white

- 235 -

solid. ^1H NMR (CDCl_3): δ 1.48 (s, 9H), 3.11 (m, 4H), 3.59 (m, 4H), 4.61 (s, 2H), 6.91 (d, $J=7$ Hz, 2H), 7.27 (d, $J=7$ Hz, 2H).

4-(4-(1,1-Dimethylethoxycarbonyl)piperazinyl)benzaldehyde (35-2)

5 To a 50 mL round bottomed flask with a stirring bar and an argon inlet was added 1-hydroxymethyl-4-(4-(1,1-dimethylethoxycarbonyl)piperazinyl)benzene, 35-1 (2.15 g, 7.35 mmol), CHCl_3 (100 mL), and MnO_2 (12.0 g, 138 mmol). This mixture was stirred at ambient temperature for 24 h. The salts were removed by filtration and
10 the solvent was removed *in vacuo*. The residue was chromatographed on 90 g of silica gel using 30/70 EtOAc-hexane as eluant. There was obtained 4-(4-(1,1-dimethylethoxycarbonyl)piperazinyl)benzaldehyde 35-2 (2.10 g, 99%) as a crystalline solid. ^1H NMR (CDCl_3): δ 1.49 (s, 9H), 3.39 (m, 4H), 3.59 (m, 4H), 6.89 (d, $J=9$ Hz, 2H), 7.75 (d, $J=9$ Hz, 2H), 9.79 (s, 1H).
15

Ethyl 2-(4-hydroxymethylphenoxy)acetate (35-4)

To a 500 mL round bottomed flask with a stirring bar and an argon inlet was added 4-hydroxybenzyl alcohol (7.50 g, 60.42
20 mmol), Cs_2CO_3 (29.53 g, 90.63 mmol), DMF (100 mL), and ethyl bromoacetate (11.09 g, 66.46 mmol). This mixture was stirred at ambient temperature for 2 h. The mixture was filtered and the filtrate was concentrated *in vacuo*. The residue was partitioned between EtOAc and water. The layers were separated and the organic phase was washed
25 with two additional portions of water. Drying (MgSO_4), filtration and removal of the solvent *in vacuo*, gave an oil. This material was chromatographed on 250 g of silica gel using 1:1 EtOAc-hexane as eluant. There was obtained ethyl 2-(4-hydroxymethyl-phenoxy)acetate 35-4 (7.47 g, 59%) as an oil. ^1H NMR (CDCl_3): δ 1.29 (t, $J=7$ Hz, 3H), 2.07 (br s, 1H), 4.26 (q, $J=7$ Hz, 2H), 4.58 (s, 2H), 4.60 (s, 2H),
30 6.88 (d, $J=9$ Hz, 2H), 7.27 (d, $J=9$ Hz, 2H).

- 236 -

Ethyl 2-(4-bromomethylphenoxy)acetate (35-5)

To a 1L round bottomed flask with a stirring bar, addition funnel and an argon inlet was added ethyl 2-(4-hydroxymethylphenoxy)acetate 35-4 (7.47 g, 35.53 mmol), CBr₄ (13.26 g, 39.97 mmol) and dry CH₂Cl₂ (300 mL). This solution was cooled in an ice bath and a solution of triphenyl phosphine (10.48 g, 39.97 mmol) in CH₂Cl₂ (100 mL) was added dropwise over 1 h. The ice bath was allowed to expire and the mixture was stirred at ambient temperature 18 h. The solvent was removed *in vacuo* and the residue was chromatographed directly on 200 g of silica gel using 15% EtOAc-hexane as eluant. There was obtained ethyl 2-(4-bromomethylphenoxy)acetate 35-5 (7.2 g, 74%) as a low melting solid, mp.: 44-45°C. ¹H NMR (CDCl₃): δ 1.29 (t, J=7 Hz, 3H), 4.26 (q, J=7 Hz, 2H), 4.48 (s, 2H), 4.61 (s, 2H), 6.86 (d, J=9 Hz, 2H), 7.32 (d, J=9 HZ, 2H).

4-(Ethoxycarbonylmethoxy)benzyltriphenylphosphonium bromide (35-6)

To a 100 mL round bottomed flask with a stirring bar and a reflux condenser topped with an argon inlet was added ethyl 2-(4-bromomethylphenoxy)acetate 35-5 (2.73 g, 10 mmol), triphenylphosphine (2.62 g, 10 mmol) and dry benzene (50 mL). This solution was warmed to 50°C for 20 h. The mixture was cooled to room temperature and the product was collected by filtration. The white solid was washed with a little benzene and dried *in vacuo* to give 4-(ethoxycarbonylmethoxy)benzyltriphenyl-phosphonium bromide 35-6 as a white, crystalline solid (4.79 g, 89%). ¹H NMR (CDCl₃): δ 1.28 (t, J=7 Hz, 3H), 4.27 (q, J=7 Hz, 2H), 4.53 (s, 2H), 5.38 (d, J=14 Hz, 2H), 6.66 (d, J=9 Hz, 2H), 7.06 (d, J=9 Hz, 2H), 7.62 (m, 6H), 7.76 (m, 9H).

(E) Ethyl 4-(2-(4-(4-(1,1-dimethylethoxycarbonyl)piperazinyl)phenyl)-ethenyl)phenoxyacetate (35-7)

To an oven dried 100 mL round bottomed flask with a stirring bar and an argon inlet was added 4-(ethoxycarbonylmethoxy)benzyltriphenyl-phosphonium bromide (1.106 g, 2.07 mmol)

- 237 -

and dry THF (50 mL). To this well stirred mixture was added a solution of lithium hexamethyldisilylazide (2.20 mL of a 1M solution in THF). The deep red solution was stirred 1 h at ambient temperature then cooled in an ice bath to 0°C. To this mixture was added a solution of 4-(4-(1,1-dimethylethoxycarbonyl)piperazinyl)benzaldehyde (0.60 g, 2.07 mmol) in 10 mL of THF. The ice bath was removed and the solution was stirred at ambient temperature for 3 h. The reaction mixture was diluted with EtOAc and washed with water and brine. Drying (MgSO₄), filtration and removal of the solvent *in vacuo* gave 1 g of an oil. This material was chromatographed on 80 g of silica gel using 25% EtOAc-hexane as eluant. There was obtained (E)-ethyl 4-(2-(4-(4-(1,1-dimethylethoxycarbonyl)piperazinyl)phenyl)ethenyl)phenoxyacetate 35-7 as an oil. ¹H NMR (CDCl₃): δ 1.26 (t, j=7 Hz, 3H), 1.49 (s, 9H), 3.16 (m, 4H), 3.57 (m, 4H), 4.27 (q, j=7 Hz, 2H), 4.60 (s, 2H), 6.90 (m, 6H), 7.40 (m, 4H), and 175 mg of a mixture of E,Z isomers.

4-(2-(4-(1-Piperazinyl)phenyl)ethyl)phenoxyacetic acid (35-8)

To a 25 mL round bottomed flask with a stirring bar and a balloon hydrogenation adaptor was added (E,Z) ethyl 4-(2-(4-(4-(1,1-dimethylethoxycarbonyl)piperazinyl)phenyl)ethenyl)phenoxyacetate (175 mg, 0.36 mmol), absolute EtOH (10 mL) and 10% Pd-C. This mixture was hydrogenated at 1 atmosphere at ambient temperature for 18 h. The catalyst was removed by filtration and the filtrate was concentrated *in vacuo*. The residue was chromatographed on 40 g of silica gel using 20% EtOAc-hexane as eluant. The purified hydrogenation product was hydrolyzed in THF (2 mL) with 1N NaOH (1 mL) for 3 h at ambient temperature. The reaction mixture was diluted with EtOAc and washed with 10% aqueous citric acid, water, and brine. Drying (MgSO₄), filtration and removal of the solvent *in vacuo* gave the corresponding acid as a white solid. This material was dissolved in EtOAc (20 mL) and cooled to 0°C in an ice bath. The solution was saturated with dry HCl gas for 15 min. The resulting suspension was aged 30 min at 0°C, then the solvent and excess HCl


- 238 -

were removed *in vacuo*. The solid product was triturated with fresh EtOAc and collected on a frit. After drying at 60°C/0.05 torr there was obtained 103 mg of 4-(2-(4-(1-piperazinyl)phenyl)ethyl)phenoxyacetic acid 35-8 as the hydrochloride salt. mp > 250°C. ¹H NMR (DMSO-D₆): δ 2.76 (s, 4H), 3.20 (m, 4H), 3.33 (m, 4H), 4.61 (s, 2H), 6.80 (d, J=8 Hz, 2H), 6.90 (d, J=8 Hz, 2H), 7.12 (m, 4H), 9.21 (br s, 2H).


(E) 4-(2-(4-(1-Piperazinyl)phenyl)ethenyl)phenoxyacetic acid (35-9)

To a 25 mL round bottomed flask with a stirring bar and an argon inlet was added (E) ethyl 4-(2-(4-(4-(1,1-dimethylethoxycarbonyl)piperazinyl)phenyl)ethenyl)phenoxyacetate (57 mg, 0.12 mmol), THF (2.0 mL) and 1N NaOH (1.00 mL). This mixture was stirred at ambient temperature 18 h. The reaction was neutralized with 1N HCl (1.00 mL) and extracted with several portions of EtOAc. The combined EtOAc extracts were washed with water and brine. Drying (MgSO₄), filtration and removal of the solvent *in vacuo* gave 45 mg of a solid. This solid was dissolved in 4N HCl-1,4-dioxane. The mixture was stirred 18 h at ambient temperature. The milky suspension was concentrated *in vacuo*. The crude product was triturated with a little EtOAc and collected on a frit. This material was dried *in vacuo* to provide 24 mg of (E) 4-(2-(4-(1-piperazinyl)phenyl)ethenyl)phenoxyacetic acid 35-9 as the hydrochloride salt, mp > 250°C. ¹H NMR (DMSO-D₆): δ 3.2 (m, 4H), 3.45 (m, 4H), 4.69 (s, 2H), 6.89 (d, J=9 Hz, 2H), 6.98 (d, J=9 Hz, 2H), 7.02 (s, 2H), 7.48 (m, 4H), 9.15 (br s, 2H), 13.02 (br s, 1H).


- 239 -

SCHEME 36

- 240 -


SCHEME 36 (CONT'D)

- 241 -



5-Nitrothiophene-2-carboxylic acid (36-2)

- To a 500 mL round bottomed flask with a stirring bar, was added 5-nitrothiophene-2-carboxaldehyde (7.86 g, 50.00 mmol) in CH₃CN (50 mL), NaH₂PO₄ (1.86 g, 13.50 mmol) in water (20 mL), and 30% H₂O₂ (aq) (6 mL). To this mixture, cooled in an ice bath, was added NaClO₂ (8 g, 70.80 mmol) in water (70 mL) dropwise over a period of an hour. The reaction was stirred at room temperature for 5 hours. It was worked up by addition of Na₂SO₃ (500 mg), acidified with 1M HCl, and then extracted with ethyl acetate (3X). The combined organic layers were washed with water (1X), and brine (1X). Drying (MgSO₄), filtration and removal of the solvents *in vacuo* yielded 5-Nitrothiophene-2-carboxylic acid as a yellow powder.
- ¹H NMR (300 MHz, CDCl₃) δ 7.91(d, J= 4.4 Hz, 1H), 7.80(d, J= 4.4 Hz, 1H)




Methyl 5-nitrothiophene-2-carboxylate (36-3)

- To a 500 mL round bottomed flask with a stirring bar, was added 5-nitrothiophene-2-carboxylic acid (4.62 g, 26.68 mmol) and MeOH (100 mL). This solution was cooled in an ice bath and dry HCl gas was bubbled through the solution till saturated. The reaction was equipped with a condensor and a drying tube and refluxed overnight. The solvent was then removed *in vacuo* to a yellow solid, which was

- 242 -

then dissolved in EtOAc. This solution was washed with NaHCO₃ (sat, aq) (3X), and brine (2X), dried (MgSO₄), and filtered. Removal of the solvents *in vacuo* and drying of the product *in vacuo* yielded methyl 5-nitrothiophene-2-carboxylate as a tan solid.


5 ¹H NMR (300 MHz, CDCl₃) δ 7.88(d, J= 4.4 Hz, 1H), 7.70(d, J= 4.4 Hz, 1H), 3.96(s, 3H)

36-4

10 Methyl 5-aminothiophene-2-carboxylate (36-4)

To a Parr flask was added methyl 5-nitrothiophene-2-carboxylate (5.00 g, 26.71 mmol) and MeOH (100 mL). The solution was purged with a stream of Ar, and 5% platinum on sulfide carbon (2.00 g) was added. The mixture was hydrogenated on a Parr apparatus set at 50 psi for 6.5 hours. The reaction was then filtered through celite and the solvents removed *in vacuo* to yield methyl 5-aminothiophene-2-carboxylate as an olive green oil.

15 ¹H NMR (300 MHz, CDCl₃) δ 7.45(d, J= 4.0 Hz, 1H), 6.09(d, J= 4.0 Hz, 1H), 4.31(br s, 2H), 3.81(s, 3H)

36-5


20 5-(4-(1,1-Dimethylethoxycarbonyl)-piperazin-1-yl)-thiophene-2-carboxylate, (36-5)

25 To a 500 mL round bottomed flask equipped with a condenser, stirring bar, and argon inlet was added methyl 5-aminothiophene-2-carboxylate (4.27 g, 27.16 mmol), bis(2-

- 243 -

chloroethyl)amine, hydrochloride (5.82 g, 32.59 mmol) and n-BuOH (90 mL, previously purged with Ar). This solution was relaxed for 7 days under Ar, and the reaction was followed by HPLC. The solvents were then removed *in vacuo*, and the residue partitioned between EtOAc and NaHCO₃ (aq). Extracted aqueous with EtOAc (3X), and then washed the combined organics with brine (1X), dried (Na₂SO₄), filtered, and concentrated *in vacuo*. The residue was azeotroped with toluene (3X), and dried *in vacuo* overnight.

The dried product was dissolved in CH₂Cl₂ (80 mL), and triethylamine (4.2 mL, 30.13 mmol), di-*tert*-butylpyrocarbonate (6.53 g, 29.90 mmol), and CH₂Cl₂ (20 mL) were added and the reaction was stirred at room temperature for 2 hours. The reaction was then concentrated *in vacuo*. This yielded 490 mg of n-butyl 5-(4-(1,1-dimethylethoxycarbonyl)-piperazin-1-yl)-thiophene-2-carboxylate and 700 mg of 5-(4-(1,1-dimethylethoxycarbonyl)-piperazin-1-yl)-thiophene-2-carboxylate as a mixture of the methyl and n-butyl esters. ¹H NMR of n-butyl ester (300 MHz, CDCl₃) δ 7.55(d, J= 4.4 Hz, 1H), 6.06(d, J= 4.4 Hz, 1H), 4.24(t, 2H), 3.58(t, 4H), 3.22(t, 4H), 1.69(m, 2H), 1.48(s, 9H), 1.42(m, 2H), 0.95(t, 3H)



5-(4-(1,1-Dimethylethoxycarbonyl)-piperazin-1-yl)-thiophene-2-carboxylic acid, (36-6)


To a 50 ml round bottomed flask with a stirring bar was added n-butyl 5-(4-(1,1-dimethylethoxycarbonyl)-piperazin-1-yl)-thiophene-2-carboxylate (490 mg, 1.33 mmol) and 4.2 mL of a 2.5M NaOH solution in 3:1 MeOH/H₂O. THF (2 mL) was added to keep the reaction homogeneous. The reaction was stirred at room temperature and followed by HPLC. After 2 days, the reaction was concentrated *in*

- 244 -

vacuo, acidified with 10% citric acid and extracted with EtOAc (3X). The combined organics were washed with water (1X), brine (1X), dried (Na₂SO₄), filtered, and the solvents removed *in vacuo*. The product was azeotroped with benzene (3X) and dried *in vacuo* over 2 days to

5 yield 5-(4-(1,1-dimethylethoxycarbonyl)-piperazin-1-yl)-thiophene-2-carboxylic acid as a dark green solid.

¹H NMR (300 MHz, CD₃OD) δ 7.51(d, J= 4.4 Hz, 1H), 6.19(d, J= 4.4 Hz, 1H), 3.57(t, 4H), 3.24(t, 4H), 1.47(s, 9H)



10

36-7

Ethyl 2-(4-(5-(4-(1,1-dimethylethoxycarbonyl)-piperazin-1-yl)-2-thienylcarbonylamino)-3-methylphenoxy)-acetate (36-7)


To a 100 ml round bottomed flask with a stirring bar and an argon inlet was added 5-(4-(1,1-dimethylethoxycarbonyl)-piperazin-1-yl)-thiophene-2-carboxylic acid (428 mg, 1.370 mmol), anhydrous CH₂Cl₂ (10 mL), DMF (.05 mL), and distilled oxalyl chloride (.180 mL, 2.06 mmol). It was stirred 1.5 hours at room temperature. The acid chloride was concentrated *in vacuo*, azeotroped with benzene (3X), and stored under a blanket of Ar.

To another 100 mL round bottomed flask with a stirring bar and an argon inlet was added ethyl 4-amino-3-methylphenoxyacetate hydrochloride, anhydrous pyridine (7 mL), and dimethylaminopyridine (34 mg, 0.278 mmol).

25 Cooled in an ice bath. A solution of the acid chloride in pyridine (3 mL) was added. The ice bath was removed and the reaction was stirred at 80°C overnight.

- 245 -

The reaction was concentrated *in vacuo*, dissolved in EtOAc, washed with aq. KHSO₄ (3X), aq. NaHCO₃ (2X), brine (1X), dried (Na₂SO₄), filtered, and the solvents removed *in vacuo*. This material was chromatographed on silica gel in 18% EtOAc-hexane as eluant yielding ethyl 2-(4-(5-(4-(1,1-dimethylethoxycarbonyl)-piperazin-1-yl)-2-thienylcarbonylamino)-3-methylphenoxy)-acetate. ¹H NMR (300 MHz, DMSO-d₆) δ 9.42(s, 1H), 7.67(d, J= 4.3 Hz, 1H), 7.13(d, J= 8.8 Hz, 1H), 6.83(d, J=2.7 Hz, 1H), 6.74(dd, J= 8.8, 2.7 Hz, 1H), 6.24(d, J= 4.3 Hz, 1H), 4.76(s, 2H), 4.17(q, J= 7.1, 2H), 3.47(t, 4H), 3.16(t, 4H), 2.15(s, 3H), 1.42(s, 9H), 1.22(t, J= 7.1 Hz, 3H)

36-8

2-(4-(5-(4-(1,1-Dimethylethoxycarbonyl)-piperazin-1-yl)-2-thienylcarbonylamino)-3-methylphenoxy)-acetic acid (36-8)

To a 100 mL round bottomed flask with a stirring bar was added ethyl 2-(4-(5-(4-(1,1-dimethylethoxycarbonyl)-piperazin-1-yl)-2-thienylcarbonylamino)-3-methylphenoxy)-acetate (250mg, 0.496 mmol), MeOH (8 mL), and 1M NaOH (1 mL). The reaction was stirred overnight at room temperature.

The reaction was concentrated *in vacuo*, acidified with aq. KHSO₄ and extracted with EtOAc (2X). The organic extracts were washed with brine (1X), dried (Na₂SO₄), filtered, and the solvents removed *in vacuo*.

This product was dissolved in CH₂Cl₂ (8 mL), and trifluoroacetic acid (2 mL) was added. The reaction was stirred for 2 hours at room temperature and then concentrated *in vacuo*. The residue was subjected to HPLC on a C-18 reverse-phase column eluting with

- 246 -

100% H₂O -50% H₂O/CH₃CN (with 0.1% TFA) over 40 minutes.

Collection and lyophilization of the appropriate fractions yielded 2-(4-(5-(4-(1,1-Dimethylethoxycarbonyl)-piperazin-1-yl)-2-

5 thienylcarbonylamino)-3-methylphenoxy)-acetic acid as a white fluffy solid.

¹H NMR (300 MHz, CD₃OD) δ 7.62(d, J= 4.1 Hz, 1H), 7.16(d, J= 8.5 Hz, 1H), 6.86(d, J=2.7 Hz, 1H), 6.79(dd, J= 8.5, 2.7 Hz, 1H), 6.34(d, J= 4.1 Hz, 1H), 4.65(s, 2H), 3.50(m, 4H), 3.40(m, 4H), 2.24(s, 3H)

10

EXAMPLE 37

Tablet Preparation

15 Tablets containing 25.0, 50.0, and 100.0 mg., respectively, of the active compound 3-(4-(4-piperazin-1-ylphenylcarbonylamino)-phenyl)-propanoic acid are prepared as illustrated below:

TABLE FOR DOSES CONTAINING
FROM 25-100MG OF THE ACTIVE COMPOUND

20

		<u>Amount-mg</u>	
Active Compound	25.0	50.0	100.0
Microcrystalline cellulose	37.25	100.0	200.0
Modified food corn starch	37.25	4.25	8.5
Magnesium stearate	0.50	0.75	1.5

25 All of the active compound, cellulose, and a portion of the corn starch are mixed and granulated to 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 25.0, 50.0, and 100.0 mg, respectively, of active ingredient per tablet.

- 247 -

EXAMPLE 38Intravenous formulations

- 5 An intravenous dosage form of the above-indicated active compound is prepared as follows:

Active Compound	0.5-10.0mg
Sodium Citrate	5-50mg
Citric Acid	1-15mg
Sodium Chloride	1-8mg
Water for Injection (USP)	q.s. to 1 L

- 10 Utilizing the above quantities, the active compound is dissolved at room temperature in a previously prepared solution of sodium chloride, citric acid, and sodium citrate in Water for Injection (USP, see page 1636 of United States Pharmacopeia/National Formulary for 1995, published by United States Pharmacopeial Convention, Inc., Rockville, Maryland, copyright 1994.

15

EXAMPLE 39Intravenous formulation

- 20 A pharmaceutical composition was prepared at room temperature using 3-(4-(4-piperazin-1-ylphenylcarbonylamino)phenyl) propanoic acid, a citrate buffer, and sodium chloride, to obtain a concentration of of 0.25 mg/ml.

- 25 800 grams of water was introduced into a standard pharmaceutical mixing vessel. 0.25 grams of 4-(N-piperazine)benzoyl-N-(aminophen-4-yl)propionic acid was dissolved in the water. 2.7 grams sodium citrate and 0.16 grams citric acid were added to obtain a finished citrate concentration of 10 mM. 8 grams of sodium chloride was added. 200 grams of water was then added to achieve the desired

- 248 -

final concentrations of ingredients. The resulting aqueous formulation had the following concentrations:

	<u>Ingredient</u>	<u>Amount</u>
5	3-(4-(4-piperazin-1-ylphenylcarbonylamino)phenyl)propanoic acid	0.25 mg/ml
	citrate buffer	10 mM
10	sodium chloride	8 mg/ml

The finished concentrated formulation is stored in a standard USP Type I borosilicate glass container at 30-40 degrees C. Prior to compound administration, the concentrated formulation is
15 diluted in a 4:1 ratio resulting in a finished concentration of 0.05 mg/ml and transferred to an infusion bag.

Therapeutic Treatment

Compounds of the invention may be administered to
20 patients where inhibition of human or mammalian platelet aggregation or adhesion is desired.

Compounds of the invention are useful in inhibiting platelet aggregation and thus, they may find utility in surgery on peripheral arteries (arterial grafts, carotid endarterectomy) and in cardiovascular
25 surgery where manipulation of arteries and organs, and/or the interaction of platelets with artificial surfaces, leads to platelet aggregation and consumption. The aggregated platelets may form thrombi and thromboemboli. Compounds of the invention may be administered to these surgical patients to prevent the formation of thrombi and
30 thromboemboli.

- 249 -

WHAT IS CLAIMED IS:

1. A-compound of the formula

5

X-Y-Z-A-B

and pharmaceutically acceptable salts,

wherein

10

X is

15 a 5, 6 or 7 membered aromatic or nonaromatic ring, having 1, 2 or 3 heteroatoms selected from N, O, and S, and either unsubstituted or monosubstituted on the carbon and nitrogen atoms with R¹, or disubstituted on the carbon and nitrogen atoms with R¹ and R², where R¹ and R² are independently selected from the group consisting of

hydrogen,
halogen,
20 C₁-10 alkyl,
C₃-8 cycloalkyl,
aryl,
aryl C₁-8 alkyl,
amino,
25 amino C₁-8 alkyl,
C₁-3 acylamino,
C₁-3 acylamino C₁-8 alkyl,
C₁-6 alkylamino C₁-8 alkyl,
C₁-6 alkylamino,
30 C₁-6 dialkylamino C₁-8 alkyl,
C₁-6 alkoxy,
C₁-6 alkoxy C₁-6 alkyl,
aryl C₁-6 alkyloxy,
aryl C₁-6 alkyloxy C₁-6 alkyl,

- 250 -

- 5 carboxy,
carboxy C₁-6 alkyl,
C₁-3 alkoxycarbonyl,
C₁-3 alkoxycarbonyl C₁-6 alkyl,
carboxy C₁-6 alkyloxy,
hydroxy, and
hydroxy C₁-6 alkyl, or
- 10 a 9 or 10 membered fused aromatic or nonaromatic ring, having
1, 2 or 3 heteroatoms selected from N, O, and S, and either
unsubstituted or monosubstituted on the carbon and nitrogen
atoms with R¹, or disubstituted on the carbon and nitrogen atoms
with R¹ and R², where R¹ and R² are independently selected
from the group consisting of
- 15 hydrogen,
halogen,
C₁-10 alkyl,
C₃-8 cycloalkyl,
aryl,
- 20 aryl C₁-8 alkyl,
amino,
amino C₁-8 alkyl,
C₁-3 acylamino,
C₁-3 acylamino C₁-8 alkyl,
- 25 C₁-6 alkylamino C₁-8 alkyl,
C₁-6 alkylamino,
C₁-6 dialkylamino C₁-8 alkyl,
C₁-6 alkoxy,
C₁-6 alkoxy C₁-6 alkyl,
- 30 aryl C₁-6 alkyloxy,
aryl C₁-6 alkyloxy C₁-6 alkyl,
carboxy,
carboxy C₁-6 alkyl,
C₁-3 alkoxycarbonyl,

- 251 -

C₁-3 alkoxycarbonyl C₁-6 alkyl,
carboxy C₁-6 alkyloxy,
hydroxy, and
hydroxy C₁-6 alkyl;

5

Y is

a 5 or 6 membered aromatic ring or non-aromatic ring, having 0,
1, 2 or 3 heteroatoms selected from N, O, and S, and either
unsubstituted or substituted on the carbons and nitrogens with R³
selected from the group consisting of

hydrogen,
halogen,
C₁-10 alkyl,
C₃-8 cycloalkyl,
aryl,
aryl C₁-8 alkyl,
amino,
amino C₁-8 alkyl,
C₁-3 acylamino,
C₁-3 acylamino C₁-8 alkyl,
C₁-6 alkylamino,
C₁-6 alkylamino C₁-8 alkyl,
C₁-6 dialkylamino,
C₁-6 dialkylamino C₁-8 alkyl,
C₁-6 alkoxy,
C₁-6 alkoxy C₁-6 alkyl,
aryl C₁-6 alkyloxy,
aryl C₁-6 alkyloxy C₁-6 alkyl,
carboxy,
carboxy C₁-6 alkyl,
C₁-3 alkoxycarbonyl,
C₁-3 alkoxycarbonyl C₁-6 alkyl,
carboxy C₁-6 alkyloxy,
hydroxy, and

10

15

20



25

30

- 252 -





hydroxy C₁-6 alkyl;

X and Y combined together form the structures







5

Z is



10

- 253 -



Z represents a bond;

5 R⁴ is

hydrogen,
C₁₋₄ alkyl, or
C₃₋₆ cycloalkyl;

A is

10 a 5 or 6 membered aromatic ring, having 0, 1, 2 or 3 heteroatoms
selected from N, O, and S, and either unsubstituted or
monosubstituted on the carbons or nitrogen with R⁵, disubstituted
with R⁵ and R⁶, or trisubstituted with R⁵, R⁶ and R⁷, where R⁵,
15 R⁶ and R⁷ are independently selected from the group consisting
of

hydrogen,
halogen,
C₁₋₁₀ alkyl,
C₃₋₈ cycloalkyl,
20 aryl,



- 254 -

- 5 aryl C₁-8 alkyl,
 arylsulfonylamino,
 amino, -
 amino C₁-8 alkyl,
 nitro,
 C₁-3 acylamino,
 C₁-3 acylamino C₁-8 alkyl,
 C₁-6 alkylamino,
 10 C₁-3 alkylsulfonylamino,
 C₁-6 alkylamino C₁-8 alkyl,
 C₁-6 dialkylamino,
 C₁-6 dialkylamino C₁-8 alkyl,
 C₁-6 alkoxy,
 C₁-6 alkoxy C₁-6 alkyl,
 15 trihaloalkyl,
 aryl C₁-6 alkyloxy,
 aryl C₁-6 alkyloxy C₁-6 alkyl,
 carboxy,
 carboxy C₁-6 alkyl,
 20 C₁-3 alkoxycarbonyl,
 C₁-3 alkoxycarbonyl C₁-6 alkyl,
 carboxy C₁-6 alkyloxy,
 hydroxy, and
 hydroxy C₁-6 alkyl, or
 25
- 30 a 9 or 10 membered fused aromatic ring, having 0, 1, 2 or 3
 heteroatoms selected from N, O, and S, and either unsubstituted
 or monosubstituted on the carbons or nitrogen with R⁵,
 disubstituted with R⁵ and R⁶, or trisubstituted with R⁵, R⁶ and
 R⁷, where R⁵, R⁶ and R⁷ are independently selected from the
 group consisting of
 hydrogen,
 halogen,
 C₁-10 alkyl,

- 255 -

C3-8 cycloalkyl,
 aryl,
 aryl C1-8 alkyl,
 amino,
 5 amino C1-8 alkyl,
 C1-3 acylamino,
 C1-3 acylamino C1-8 alkyl,
 C1-6 alkylamino,
 C1-6 alkylamino C1-8 alkyl,
 10 C1-6 dialkylamino,
 C1-6 dialkylamino C1-8 alkyl,
 C1-6 alkoxy,
 C1-6 alkoxy C1-6 alkyl,
 aryl C1-6 alkyloxy,
 15 aryl C1-6 alkyloxy C1-6 alkyl,
 carboxy,
 carboxy C1-6 alkyl,
 C1-3 alkoxycarbonyl,
 C1-3 alkoxycarbonyl C1-6 alkyl,
 20 carboxy C1-6 alkyloxy,
 hydroxy, and
 hydroxy C1-6 alkyl;

25 B is



wherein

m is 1, 2, or 3,

- 256 -

n is 0, 1, 2, or 3, and
p is 0, 1, 2, or 3;

- R⁸ is selected from the group consisting of
- 5 hydrogen,
 - C₁-10 alkyl,
 - C₃-8 cycloalkyl,
 - aryl,
 - aryl C₁-8 alkyl,
 - 10 amino,
 - amino C₁-8 alkyl,
 - C₁-3 acylamino,
 - C₁-3 acylamino C₁-8 alkyl,
 - C₁-6 alkylamino,
 - 15 C₁-6 alkylamino C₁-8 alkyl,
 - C₁-6 dialkylamino,
 - C₁-6 dialkylamino C₁-8 alkyl,
 - C₁-6 alkoxy,
 - C₁-6 alkoxy C₁-6 alkyl,
 - 20 aryl C₁-6 alkyloxy,
 - aryl C₁-6 alkyloxy C₁-6 alkyl,
 - carboxy,
 - carboxy C₁-6 alkyl,
 - C₁-3 alkoxycarbonyl,
 - 25 C₁-3 alkoxycarbonyl C₁-6 alkyl,
 - carboxy C₁-6 alkyloxy,
 - hydroxy,
 - hydroxy C₁-6 alkyl; and
- 30 R⁹ is
- hydrogen,
 - C₁-8 alkyl,
 - aryl,
 - aryl C₁-6 alkyl,

- 257 -

C₁-8 alkylcarbonyloxy C₁-6 alkyl
 aryl carbonyloxy C₁-6 alkyl,
 aryl C₁-6 alkylcarbonyloxy C₁-6 alkyl,
 C₁-8 alkylaminocarbonyl C₁-6 alkyl, or
 5 C₁-8 dialkylamino carbonyl C₁-6 alkyl.

2. A compound of claim 1 having the formula

X-Y-Z-A-B

10





and pharmaceutically acceptable salts,

wherein

15 X is a 5, 6 or 7 membered aromatic or nonaromatic ring having 1, 2 or 3 nitrogen atoms and unsubstituted or substituted with NH₂;

20 Y is a 5 or 6 membered aromatic or nonaromatic ring having 0, 1, 2 or 3 nitrogen atoms and unsubstituted or substituted with C₁-3alkyl;


or X and Y together form the fused ring systems:



25

- 258 -

Z is



Z represents a bond;

- 5 A is a 5 or 6 membered aromatic ring, having 0, 1, 2, or 3
 nitrogen atoms and unsubstituted or monosubstituted on
 the carbons or nitrogen with R⁵, disubstituted with R⁵ and
 R⁶, same or different, or trisubstituted with R⁵, R⁶ and
 10 R⁷, same or different, wherein R⁵, R⁶ and R⁷ are selected
 from the group consisting of
 arylsulfonylamino,
 C₁-3 alkylsulfonylamino,
 C₁-3 alkyl,
 -CF₃,
 15 C₁-3alkyloxy,
 halogen,
 nitro,
- or
- 20 A is a 9 membered fused aromatic ring system having 0, 1, 2 or
 3 nitrogen atoms,
- or
- A is isoindolinone or indolinone;
- 25 B is -OCH(R⁸)(CH₂)_pCO₂R⁹,
 (CH₂)_nCO₂R⁹,

- 259 -

n = 0, 1, 2, 3,

p = 0, 1, 2, 3,

wherein-

R⁸ is hydrogen or C₁₋₃alkyl and

5

R⁹ is hydrogen or -(CH₂)₁₋₃C(O)NH(CH₂)₀₋₂CH₃or -(CH₂)₁₋₃ C(O)N((CH₂)₀₋₂CH₃)₂.

3. A compound of claim 2 having the formula

10

X-Y-Z-A-B





and pharmaceutically acceptable salts,

wherein

15



X is a 5 or 6 membered aromatic or nonaromatic ring having 1 or 2 nitrogen atoms and unsubstituted or substituted with NH₂;20 Y is a 6 membered aromatic or nonaromatic ring having 0 or 1 nitrogen atoms and unsubstituted or substituted with CH₃;

or X and Y form the fused ring systems:



- 260 -

Z is




Z represents a bond;


- 5 A is phenyl unsubstituted, monosubstituted with R⁵,
disubstituted with R⁵ and R⁶, or trisubstituted with R⁵, R⁶,
or R⁷, where R⁵, R⁶, or R⁷ are selected from



10



15



or

20

A is

a 9 membered fused aromatic ring system having 1
nitrogen atom,

or

A is


isoindolinone or indolinone;

25

B is



- 261 -




wherein $n = 1$ or 2

R^8 is hydrogen or C_{1-3} alkyl and

5 R^9 is hydrogen, $-(\text{CH}_2)_{1-3}\text{C}(\text{O})\text{NH}(\text{CH}_2)_{0-2}\text{CH}_3$, or $-(\text{CH}_2)_{1-3}\text{C}(\text{O})\text{N}((\text{CH}_2)_{0-2}\text{CH}_3)_2$.

4. A compound of claim 3 having the formula




10


and pharmaceutically acceptable salts,

wherein

15 X is






Y is




- 262 -

or X and Y form the fused ring systems:




5 Z is



Z represents a bond;

- 263 -

A is



and

5

B is

10

$-\text{OCH}_2\text{CO}_2\text{H}$,
 $-\text{OCH}_2\text{CO}_2\text{CH}_2\text{C}(\text{O})\text{NHCH}_3$,
 $-\text{OCH}_2\text{CO}_2\text{CH}_2\text{C}(\text{O})\text{N}(\text{CH}_2\text{CH}_3)_2$,
 $-\text{OCH}_2\text{CO}_2\text{CH}_2\text{CH}_3$,
 $-\text{CH}_2\text{CH}_2\text{CO}_2\text{H}$,

- 264 -

-CH₂COOH,
-OCH(CH₃)CO₂H, or
-OCH(CH₃)CO₂CH₂CH₃.

- 5 5. A compound of claim 4 selected from the group
consisting of
- 3-(4-(4-piperazin-1-ylphenylcarbonylamino)phenyl)
propanoic acid,
10 2-(4-(4-Piperazinyl-1-yl)phenylcarbonylamino)phenoxy)
acetic acid,
Ethyl 2-(4-(4-(1-piperazinyl)phenylcarbonylamino)phenoxy)acetate,
15 hydrochloride,
2-(5-(4-(1-Piperazinyl)phenylcarbonylamino)indol-1-yl)
acetic acid,
20 3-(3-(4-Piperazin-1-ylphenyl)carbonylamino)phenyl)
propanoic acid,
Ethyl 2-(4-(4-(piperazin-1-yl)phenylcarbonylamino)
phenoxy)propanoate
25 2-(4-(4-(Piperazin-1-yl)phenylcarbonylamino)phenoxy)
propionic acid,
2-(4-(((2-Piperazin-1-yl)pyridin-5-yl)carbonylamino)phenoxy)acetic
30 acid,
3-Methyl-4-((1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol-7-
yl)carbonylamino)phenoxyacetic acid,

- 265 -

2-(4-(5-(4-(1,1-Dimethylethoxycarbonyl)-piperazin-1-yl)-2-thienylcarbonylamino)-3-methylphenoxy)-acetic acid,

4-(2-(1,1-dimethylethoxycarbonyl)-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]benzofuran-7-yl)carbonylamino)-3-methylphenoxy acetic acid,

4-((2,3,4,5-tetrahydropyrazino-[1,2-a]indole-8-yl)carbonylamino)-3-methylphenoxyacetic acid, and

(+ /-) 4-((3-(1,1-Dimethylethoxycarbonyl)-1,1a,2,3,4,5-hexahydropyrazino-[1,2-a]indole-8-yl)carbonylamino)-3-methylphenoxyacetic acid,

and pharmaceutically acceptable salts thereof.

15

6. A compound of Claim 1 for use in inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus formation or embolus formation, or preventing thrombus or embolus formation in a mammal.

20

7. A composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

8. A method for inhibiting the binding of fibrinogen to blood platelets in a mammal, comprising treating the mammal with a composition of Claim 7.

25

9. A method for inhibiting the aggregation of blood platelets in a mammal, by blocking fibrinogen from acting at its receptor site, comprising treating the mammal with a composition of Claim 7.

30

10. A composition for inhibiting the aggregation of blood platelets in a mammal, comprising an efficacious amount of a

- 266 -

compound of Claim 1 in combination with one or more agents selected from a thrombolytic agent, an anticoagulant agent, and an antiplatelet agent and a pharmaceutically acceptable carrier.

5 11. A method for inhibiting the aggregation of blood platelets in a mammal, by blocking fibrinogen from acting at its receptor site, comprising treating the mammal with a composition of Claim 10.

10 12. A method for inhibiting the binding of fibrinogen to blood platelets in a mammal, by blocking fibrinogen from acting at its receptor site, comprising treating the mammal with a composition of Claim 10.

15 13. A method for inhibiting osteoclast mediated bone resorption, comprising treating the mammal with a composition of Claim 7.

20 14. A method for inhibiting angiogenesis in a mammal comprising treating the mammal with a composition of Claim 7.

 15. A method for inhibiting tumor growth in a mammal comprising treating the mammal with a composition of Claim 7.

25 16. The use of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting the aggregation of blood platelets, preventing platelet thrombosis, preventing thromboembolism or preventing reocclusion, in a mammal.

30

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/11133

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/241, 242, 255, 292, 318, 334, 357, 429; 544/180, 182, 215, 346, 400; 546/87, 194, 262, 340; 548/577

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	EP 0659743 A1 (HOECHST AKTIENGESELLSCHAFT) 28 June 1995, pages 7-8.	1-4, 6-17 ----- 5
X -- Y	EP 0718287 A2 (PIEPER ET AL) 26 June 1996, pages 2-3; page 27, examples 3, 4.	1-3, 6-17 ----- 4, 5
X -- Y	DE 4446301 A1 (PIEPER ET AL) 27 June 1996, pages 2-3; page 25, example 3.	1-3, 6-17 ----- 4, 5
X -- Y	WO 94/22834 (ZENECA LIMITED) 13 October 1994, pages 1-6; pages 86-98, examples 96-113.	1-4, 6-17 ----- 5



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

&

document member of the same patent family

Date of the actual completion of the international search

22 AUGUST 1997

Date of mailing of the international search report

15 SEP 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

EVELYN HUANG

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/11133

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6):

A61K 31/41, 31/44, 31/53, 31/445, 31/495; C07D 207/04, 211/32, 213/44, 213/46, 241/04, 251/04, 471/04, 491/048

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

514/241, 242, 255, 292, 318, 334, 357, 429; 544/180, 182, 215, 346, 400; 546/87, 194, 262, 340; 548/577